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Abstract 
Varicose veins are a common problem affecting approximately 30% of the Western population. The 
majority of patients present to secondary care complaining of a number of commonly experienced 
symptoms, however, some present with severe complications of venous disease including venous 
ulceration. For hundreds of years varicose veins have been treated with compression and surgery. In 
the last decade, technological advances have lead to the introduction of minimally invasive therapies 
for varicose veins, with the aim of providing rapid treatment with minimum discomfort to the 
patient at acceptable cost to the healthcare provider.  
This study examined the current use of endovenous ablation procedures in the United Kingdom 
amongst consultant vascular surgeons using an online questionnaire and also explored the patient’s 
views regarding treatment of varicose veins and potential therapeutic options. Prior to conducting a 
randomised clinical trial comparing early outcomes following laser and radiofrequency ablation in 
patients with primary varicose veins, an observational pilot study was carried out in the department. 
In parallel, the use of disease specific quality of life tools were compared to clinical, anatomical and 
haemodynamic outcome measures in this cohort of patients. 
The findings of the study have shown that although endovenous ablation procedures appear to be 
increasing in popularity, traditional surgery remains the most frequently performed procedure. 
Overall, patients overall have little knowledge of potential treatment options and the majority would 
be in favour of a single treatment under a local anaesthetic. However, most would be strongly 
influenced by the advice and opinion of the surgeon to whom they were referred.  
Results from the pilot study and a randomised clinical trial showed that radiofrequency ablation is 
significantly less painful than laser ablation for up to 10 days post procedure. Clinical improvements 
and gains in quality of life were significantly improved at 6 weeks and 6 months post intervention 
compared with baseline scores and were comparable between the groups. No significant difference 
was observed in anatomical outcomes between the two treatments.  
Although radiofrequency may be less painful than laser ablation, both endovenous thermal ablation 
treatments result in significant improvements in quality of life and are likely to become increasingly 
popular in the future. 
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1.1 Introduction to Varicose Veins 
 
The term “Varicose Vein” is defined as a dilated and tortuous vein and most frequently refers to the 
superficial veins in the leg.  They are common and affect 15-40% of the adult population in the 
United Kingdom (Callam 1994; Evans, Fowkes et al. 1999). Varicose veins have affected mankind for 
thousands of years and there is documentation of their existence from as early as 3500 BCE (van den 
Bremer et al. 2010). A variety of methods are now available to treat varicose veins and it is 
estimated that approximately 40, 000 procedures are performed annually to treat varicose veins in 
the UK in the National Health Service (NHS). The number of procedures performed for varicose veins 
in the UK is available from the Hospital Episode Statistics website (http://www.hesonline.nhs.uk) 
and a summary of recent data is shown in Table 1. Although the numbers have fallen in recent years, 
the cost to the NHS remains considerable. Costs include not only those incurred for the treatment of 
varicose veins, but the management of chronic venous disorders including venous leg ulceration, 
which is estimated at approximately £600 million per annum in the UK, and hence an important 
clinical problem.  
Year Surgery Radiofrequency Laser Foam Sclerotherapy Total 
Procedures 
 Number of 
procedures 
% Number of 
procedures 
% Number of 
procedures 
% Number of 
procedures 
%  
2004-
2005 
36207 96 unknown 
 
unknown 
 
1689 4 37896 
2005-
2006 
34318 92 unknown 
 
unknown 
 
2819 8 37137 
2006-
2007 
30482 84 unknown 
 
2104 6 3824 10 36410 
2007-
2008 
26969 73 454 1 3986 11 5495 11 36904 
2008-
2009 
23863 65 1589 4 5163 14 6235 17 36850 
 
Table 1. Procedures performed for varicose veins in the UK 2004-2009 
 
The majority of patients with varicose veins have incompetence of the saphenofemoral junction 
(SFJ), resulting in reflux of blood from the deep venous system into the superficial great saphenous 
vein (GSV)(Labropoulos et al. 1994). In addition they will frequently have tributary vessels arising 
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from the incompetent SFJ or GSV resulting in additional varicosities.  Reflux may also involve the 
small saphenous vein (SSV), usually as a result of incompetence at the sapheno-popliteal junction 
(SPJ), and may also occur in perforator veins joining the deep and superficial venous system. For 
many years, the gold standard treatment was junctional ligation, disconnection and stripping of the 
great saphenous vein. In the last decade the introduction of minimally invasive endovenous 
treatments for varicose veins has meant that a wide variety of treatment options now exist from 
which surgeons can choose. Consequently the treatment of varicose veins is moving away from 
being performed under general anaesthesia in the operating theatre to treatment in an outpatient 
setting under local or tumescent anaesthesia.  
1.1.1 Aetiology and Pathogenesis of Varicose Veins 
 
Despite the high prevalence, the aetiology and pathogenesis of varicose veins remains poorly 
understood. There is currently much interest in the pathogenesis of varicose veins and research 
suggests several plausible theories exist (Raffetto and Khalil 2008; Lim and Davies 2009). It is known 
that the valves in the superficial venous system and possibly perforator valves become incompetent, 
allowing blood from the higher pressure deep venous system to reflux into the superficial veins 
giving rise to the characteristic dilated and tortuous vessels. It is thought that in individuals 
predisposed to the development of varicose veins, increased venous hydrostatic pressure causing 
increased wall tension and endothelial injury leads to changes in the extracellular matrix, venous 
smooth muscle and endothelium causing vein wall dilatation and valvular dysfunction (Raffetto et al. 
2008). It is not known whether the primary pathology is valvular dysfunction or vein wall dilatation, 
and there is evidence to suggest that both processes may be involved (Raffetto et al. 2008). It has 
been suggested that pathological changes occur in the connective tissues, extra cellular matrix, 
elastin and smooth muscle cells in the walls of these varicose veins (Rose et al. 1986; Mashiah et al. 
1991; Borden et al. 1997; Gomez et al. 1997; Nagase 1997). Matrix metalloproteinases (MMPs) and 
tissue inhibitors of MMPs (TIMPs), are endopeptidase enzymes involved in the degradation of the 
extracellular matrix and are known to be involved in some of these changes. They have been shown 
to cause alterations to the vascular endothelium and smooth muscle in early venous disease and the 
activity of MMPs correlates with the severity of skin changes in later disease with associated 
leukocyte interactions and inflammatory processes (Raffetto et al. 2008a; Raffetto et al. 2008b). 
MMPs 1, 2, 3, 7 and 9 and TIMP 1 and 3 are up-regulated in varicose veins and TIMP 2 appears to be 
decreased (Lim et al. 2009). Smooth muscle cell apoptosis, hypoxia and endothelial cell dysfunction 
are also thought to be involved in the pathogenesis of varicose veins and have been showed to lead 
to venous relaxation in vitro (Lim et al. 2010). Hypoxia Inducible Factor (HIF) is an upstream regulator 
The Role of Endovenous Thermal Ablation in the Treatment of Varicose Veins 
 
21 
 
of many cellular processes including MMPs and has been shown to be increased in varicose veins 
(Lim et al unpublished data). These findings have implications for the development of medications 
and the future treatment of venous disease, with many of these molecules and signalling pathways 
being considered as therapeutic drug targets (Naoum et al. 2007; Lim et al. 2010).  
1.1.2 Risk Factors for the Development of Varicose Veins 
 
Predisposing factors for the development of varicose veins include increasing age (Evans et al. 1999; 
Maurins et al. 2008; Robertson et al. 2008) and increases in pressure exerted on the venous system 
due to obesity, intra-abdominal pathology or pregnancy (Laurikka et al. 2002; Maurins et al. 2008). 
Hypertension has been shown to contribute to chronic venous disease (Maurins et al. 2008) and 
poor mobility, previous injury and phlebitis have also been shown to induce varicose veins. Recent 
evidence suggests that both smoking and alcohol may lead to an increased risk of developing 
varicose veins, particularly in women (Ahti et al. 2010). Although no specific gene abnormality has 
been discovered, there is also a strong familial tendency (Scott et al. 1995; Carpentier et al. 2004) 
and varicose veins are also associated with a number of rare genetic disorders.   
1.1.3 Epidemiology of Varicose Veins 
 
The prevalence of varicose veins varies throughout populations and increases with age (Callam 1994; 
Evans et al. 1999; Maurins et al. 2008). The Edinburgh Vein Study found the prevalence of venous 
disorders was 32% in women and 40% in men (Evans et al. 1998; Evans et al. 1999). Similarly, the 
Bonn Vein Study conducted in Germany found 35.3% of the population had pathological reflux of 
greater than 0.5 seconds (Maurins et al. 2008) and the overall prevalence is thought to be between 
15 and 40% of the western population (Callam 1994; Lee et al. 2003). Females have been shown to 
present more frequently than males (Lee et al. 2003). The prevalence may be higher in males, 
although discrepancies exist between studies (Callam 1994; Evans et al. 1998). The prevalence of 
deep venous insufficiency in patients presenting with apparently superficial venous incompetence 
has been shown to be approximately 20% (Labropoulos et al. 2000; Maurins et al. 2008), with the 
majority of patients demonstrating small sections of deep venous incompetence which frequently 
improve following intervention (Labropoulos et al. 2000).  
1.1.4 Symptoms of Varicose Veins 
 
The symptoms caused by varicose veins have been notoriously difficult to determine accurately, as 
many patients with varicose veins report a number of non-specific symptoms such as aching, 
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heaviness, itching and swelling which occur frequently in the absence of venous disease. Symptoms 
are more likely to be attributed to venous disease if they occur when the legs are in a dependent 
position and worsen in hot weather, although proving a causal relationship is very difficult (Campbell 
et al. 2007). The most frequently reported symptoms include: ache; heaviness/ tension in the legs; 
swelling; restless legs; cramps; itching and tingling (Bradbury et al. 1999). Evidence suggests that 
commonly reported symptoms are likely to be related to the presence of venous insufficiency rather 
than varicose veins per se (Kurz et al. 2001) which are often asymptomatic. The Edinburgh Vein 
Study found only a weak association between discomfort and truncal reflux(Bradbury et al. 1999) 
and Labroupoulos et al found that only 70% of those with GSV reflux reported symptoms 
(Labropoulos et al. 1994). The overall poor correlation of symptoms with venous insufficiency has 
meant that there is insufficient evidence to attribute the majority of symptoms to a venous cause 
(Bradbury et al. 1999; Campbell et al. 2007). Indeed, many patients presenting with varicose veins 
have been found to have a wide variety of additional concerns relating both to potential venous 
complications and general concerns about the future (Campbell et al. 2006).  
 
1.2 Natural History of Disease Progression of Varicose Veins 
 
The aetiology of chronic venous disease is classified as either primary venous disease, with no 
identifiable cause for the presence of valvular dysfunction, or secondary venous disease, following a 
precipitating event. A large number of cases are idiopathic, however, a significant proportion arise 
following deep venous thrombosis, causing deep venous obstruction and subsequent deep venous 
reflux in many patients. Both reflux and obstruction contribute to venous hypertension, and the 
majority of treatments are thought to improve symptoms by reducing venous hypertension.  
To date, the natural history of the progression of primary venous disease is poorly understood. 
Current information is based on patients self-reporting their symptoms, many of whom 
subsequently undergo treatment, and the natural history of the condition is infrequently 
documented. In a small study (56 limbs) of uncomplicated varicose veins, where superficial venous 
surgery was delayed by a median of 20 months, 2% of limbs developed lipodermatosclerosis and 
none developed ulceration (Sarin et al. 1993). In a larger study of over 300 patients on an NHS 
waiting list for varicose vein surgery, 22% of patients with previously uncomplicated disease 
developed skin changes over a median of 4 years and 4% developed ulceration, although the degree 
of clinical severity at baseline in those who developed ulceration was not reported (Brewster et al. 
1991). The number of patients with superficial reflux who are likely to progress to oedema, skin 
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changes and ulceration is unknown, however, the overall incidence of oedema and skin changes in 
the general UK population is thought to be around 1% per year (Tran et al. 2002) . 
In patients with secondary venous disease following acute deep venous thrombosis, the natural 
history of the  disease is better understood, and approximately 30% will go on to develop post-
thrombotic syndrome, with 3-6% developing venous ulceration (Prandoni et al. 1996).  
In summary, the natural progression of mild venous disease to lipodermatosclerosis and venous 
ulceration is poorly understood, with few studies in the published literature. However, it is known 
that disease progression is related to the severity of venous reflux and duration of disease (Tran et 
al. 2002). The most recent evidence from the Bonn Vein Study II, surveyed over 1978 patients in 
Germany and reported that progression of C2 disease to higher C classes (see section 1.3) was 31.8% 
in patients with saphenous reflux and 19.8% in patients with non-saphenous reflux over  6.6 years 
(Rabe et al. 2010). The sensation of leg swelling in otherwise mild disease was found to be an 
indicator of likely disease progression and a poorer prognosis. Other factors such as obesity, 
prolonged standing, and non-compliance with compression hosiery have also been shown to 
increase the progression of chronic venous disease (Kostas et al. 2010). Deep venous incompetence, 
skin changes including eczema and lipodermatosclerosis, a raised BMI and popliteal vein reflux are 
independently associated with the risk of developing venous ulceration in patients with varicose 
veins (Robertson et al. 2009), and the majority of those presenting with venous ulceration have had 
venous disease for more than 20 years (Hoare et al. 1982; Brewster et al. 1991).  
1.2.1 Complications of Venous Disease 
 
Although a large number of patients with venous insufficiency remain asymptomatic (Lee et al. 
2003), and the majority of those presenting report mild to moderate symptoms, a proportion of 
patients progress to developing skin changes, lipodermatosclerosis and venous ulceration. Although 
venous ulceration was initially attributed to deep venous incompetence, the majority of patients 
with venous leg ulcers have only superficial truncal incompetence (Gohel et al. 2007b).  
 
1.3 Classification of Venous Disease 
 
Until the 1990s there was no uniformally accepted way of classifying varicose veins. The First 
classification was proposed by Heyerdale and Stalker in 1941 which classified varicosities into 3 
groups: Group I spider veins and telangiectatic veins; group II mild to moderate varicosities in 
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patients with no demonstrable incompetence of the great or small saphenous veins and group III 
mild, moderate or marked varicosities with incompetence of the great or small saphenous vein 
(Heyerdale et al. 1941). This was not solely a clinical classification, but relied on the confirmed 
presence of anatomical reflux.  The classification written by Widmer et al in 1978 was used in the 
Basle study (Biland et al. 1988) and later in the Edinburgh Vein Study. Patients were classified as 
either having no venous disease, hyphen webs, reticular veins, trunk varices or chronic venous 
disease with I) corona phlebectatica, II) hyperpigmented or depigmented areas and III) open or 
healed ulceration. Since then other classifications by Duffy in 1988 and Weiss in 1993 have been 
published but neither were widely used. The original reporting standards in venous disease of the Ad 
Hoc Committee of the Society for Vascular Surgery and International Society for Cardiovascular 
Surgery published in 1988 suggested a classification for Chronic Venous Insufficiency according to 
clinical symptoms graded from 0-3 [asymptomatic, mild, moderate or severe (ulceration)], 
anatomical location graded from 0-7 [Unknown(0), superficial veins(1), perforator veins(2) , deep 
calf(3) , deep thigh(4), deep ilio-femoral (5), deep caval (6), or combination of 2-5(7)] and disease 
origin was classified as unknown, congenital or post thrombotic (Ad Hoc Committee on Reporting 
Standards 1988).  None of the previous classifications described were widely used or considered 
sufficiently adequate, and for these reasons an International Ad Hoc committee of the American 
Venous Forum produced a consensus document for the Clinical Etiologic Anatomic Pathophysiologic 
(CEAP) classification of chronic venous disease in 1995 (Porter et al. 1995). This was objectively 
tested in 102 patients and found to accurately identify categories of venous disease (Kistner et al. 
1996). Details of the CEAP classification are shown in Figure 1. 
1.3.1 CEAP Classification 
 
The CEAP classification is now well established and widely used in the reporting of venous disease.  It 
provides a static description of the severity of venous disease and attributes a grade for each of the 
4 domains; Clinical severity, Aetiology, Anatomical distribution of the veins and the Pathological 
process involved, thus forming a basis on which decisions regarding treatment can be made.  
Although 4 domains exist, the clinical component graded C0-C6 is the most frequently used.  
Rapid developments in varicose vein therapies lead to the need for revision of the original CEAP 
classification. Details of the revised CEAP classification were published in a consensus statement 
from the American Venous Forum in 2004 (Eklof et al. 2004). The original structure of the 
classification was maintained, however, additions and refinements were made to definitions and a 
“basic“ and “advanced ” CEAP were introduced. The C4 clinical category was sub-divided into (a) and 
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(b)  as described in Figure 1 and a category of “no venous cause identified” denoted “n” was 
introduced to categories E, A and P. Different levels of investigation were described from I-III, level I 
being office based assessment including clinical examination and hand held Doppler, level II included 
non-invasive investigations, including duplex scanning and plethysmography and level III included 
invasive or complex imaging such as venography, CT or MRI scanning.  Basic CEAP involves the 
description of all of the above categories and uses the single highest descriptor for the clinical 
classification. Advanced CEAP incorporates all elements of basic CEAP, plus the full clinical 
description, and it identifies 18 venous segments that can be used to locate venous pathology (Eklof 
et al. 2004) (Figure 2). 
Clinical Signs-C 
C0 No visible signs of venous disease 
C1 Telangiectasia or reticular veins 
C2 Varicose Veins > 3mm 
C3 Oedema 
C4 Skin changes including: a) pigmentation or eczema 
                                         b) lipodermatosclerosis or atrophie blanche 
C5 Healed venous ulcer 
C6 Active venous ulcer 
Aetiology-E 
Congenital Ec-  
Primary Ep- unknown cause 
Secondary Es (known cause- post thrombotic/ obstructive /other) 
No venous cause identified En 
Anatomy-A 
Superficial As 
Deep Ad 
Perforator Ap 
No venous cause identified An 
Pathophysiology-P 
Reflux PR 
Obstruction Po 
Reflux and obstruction PRO 
No venous cause identified Pn 
Patients are classed as symptomatic or asymptomatic 
Figure 1. CEAP classification 
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Superficial Veins  Deep Veins  Perforating Veins 
1 Telangiectasia or reticular veins  6 IVC  17 Thigh 
2 GSV above knee  7 Common iliac  18 Calf 
3 GSV below knee  8 Internal iliac    
4 SSV  9 External iliac    
5 Non saphenous vein  10 Pelvic, gonadal, broad 
ligament 
   
   11 Common femoral vein    
   12 Deep femoral vein    
   13 Femoral vein    
   14 Popliteal vein    
   15 Crural (anterior tibial, 
posterior tibial and 
peroneal) 
   
   16 Muscular- gastronemial, 
soleal, other 
   
 
Figure 2. Venous segments used in advanced CEAP 
    
1.3.2 Venous Severity Scoring 
 
Although a useful descriptive tool, the CEAP classification is not appropriate for the assessment of 
outcomes following intervention. A new clinical outcome assessment score, the Venous Severity 
Score (VSS) was proposed by the American Venous Forum Ad Hoc Committee in 2000 (Rutherford et 
al. 2000) to enable quantification and comparison of changes following interventions. This consisted 
of 3 components: 1) the Venous Clinical Severity Score (VCSS) 2) the Venous Segmental Disease 
Score (VSDS) and 3) the Venous Disability Score (VDS).  
1.3.2.1 Venous Clinical Severity Score 
 
The VCSS is a scoring system of 10 domains based on the original CEAP classification which provides 
a score out of 30 based on the presence or absence of symptoms and signs, such as pain, swelling, 
the presence of skin changes, ulceration and the use of compression (Figure 3). 
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 Absent Mild Moderate Severe 
Pain None Occasional, non 
restricting/ no analgesia 
With moderate activity, 
occasional analgesia 
Daily, severe limitations, 
regular analgesia 
Varicose 
veins>4mm 
None Few Multiple GSV Extensive GSV and LSV 
Venous oedema None Evening/ankle Afternoon/ above knee Morning/requiring 
elevation 
Skin pigmentation None Limited and old/brown Diffuse lower third/ 
purple 
Wide/ purple 
Inflammation None Mild cellulitis in marginal 
area 
Moderate involving 
most of gaiter area 
Severe cellulitis or 
significant eczema 
Induration None Focal <5cm Medial or lateral less 
than lower 1/3 
1/3 of lower leg or more 
Number of active 
ulcers 
0 1 2 3 
Active ulcer 
duration 
None <3 months >3 and <12 months >12 months 
Active ulcer 
diameter(cm) 
None <2 2-6 >6 
Compression Not used or   
non-
compliant 
Intermittent use Stockings worn most 
days 
Stockings worn daily 
 
Figure 3. Venous Clinical Severity Score 
 
1.3.2.2 Venous Segmental Disease Score 
 
The Venous Segmental disease Score (VSDS) combines the anatomical and pathological components 
of the CEAP score. Each leg is given a reflux and obstructive component score, both out of a possible 
maximum score of 10 as detailed in Figure 4. 
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Anatomical Segment  Reflux score Obstruction Score 
Small saphenous vein 0.5 - 
Great saphenous vein 1 1 
Thigh perforator 0.5 - 
Calf perforator 1 - 
Calf veins multiple 
                 or 
Posterior tibial alone 
2 
or 
1 
1 
 
 
Popliteal vein 2 2 
Superficial femoral vein 1 1 
Profunda femoris 1 1 
Common femoral vein 1 2 
Iliac vein - 1 
Inferior vena Cava - 1 
 
Figure 4. Venous Segmental Disease Score 
 
1.3.2.3  Venous Disability Score 
 
The VDS grades patients from 0-3 based on their degree of symptoms and reliance on compression. 
(Figure 5) 
 
Figure 5.Venous Disability Score 
 
The VCSS and VDS have been shown to correlate with CEAP scores pre-operatively and have been 
shown to be valid for differentiating between patients with normal venous anatomy and those with 
venous disease, and to correlate with the severity of venous disease (Meissner et al. 2002; Ricci et al. 
Score Definition 
0 Asymptomatic 
1 Symptomatic, but able to carry out usual activities without compression therapy 
2 Able to carry out usual activities only with compressive therapy and/or limb elevation 
3 Unable to carry out usual activities even with compression and/or elevation 
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2003). They are also sensitive to change following therapy (Kakkos et al. 2003) and have been 
advocated as complementary tools to the CEAP classification. Although initially designed to be used 
as a complementary tool, the VSDS is time consuming to calculate and is reliant on an accurate 
duplex scan. In general the VSDS and VDS are infrequently used in routine clinical practice. The VCSS 
is straightforward to use and has become increasingly popular, however, it is currently under 
revision. The revised VCSS aims to modify the language in certain categories to make it easily 
applicable to patients, without affecting the sensitivity, and, therefore, making it an easier tool for 
clinicians to utilise as part of their routine practice as well as in clinical research (Vasquez et al. 
2008).  
 
1.4 Investigation and Outcome Assessment in Venous Disease 
 
The severity of venous disease varies widely, as demonstrated by the wide range of clinical signs and 
patient reported symptoms. Investigation and confirmation of venous disease is frequently made 
using colour duplex scanning and haemodynamic measurements of venous function, but the clinical 
severity of venous disease and its functional impact is more difficult to evaluate. Patients with 
moderate and severe venous disease (skin changes and venous ulceration), present less frequently 
compared with those who report clinical symptoms in the absence of measurable signs. The 
assessment of disease severity and outcomes following intervention in these patients is 
consequently more difficult.  The introduction of endovenous therapies for the treatment of varicose 
veins has lead to a greater interest in the evaluation of outcomes and the reliable assessment of 
disease severity in order to draw meaningful comparisons between studies, to evaluate the efficacy 
of different treatment modalities and to assess improvements in individual patients.  
A variety of different outcome measures exist which can be broadly classified as anatomical, 
haemodynamic, clinical and functional as illustrated below (Figure 6).  
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Figure 6. Outcome Assessment in Venous Disease
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1.4.1 The use of Colour Duplex in the Management of Varicose Veins 
 
Duplex ultrasonography was introduced into UK clinical practice in the 1980s and in the last 20 years 
its use has shifted from being only available for selected patients in certain hospitals in the mid 
1990s (Campbell et al. 1996),  to replacing venography as the current gold standard investigation in 
the assessment of venous disease (Vasdekis et al. 1989; Baker et al. 1993).  It uses a combination of 
B mode ultrasound and colour Doppler to provide a detailed anatomical assessment and 
haemodynamic measurements of the venous system. The accuracy of the scan is operator 
dependent and reliably reproducible images can be achieved with a qualified Vascular Scientist or 
experienced Vascular Surgeon. Prior to the widespread use of duplex, the hand held Doppler (HHD) 
was frequently used in the outpatient setting to detect reflux at the SFJ, SPJ or in the great and small 
saphenous veins, to plan operative management in the context of clinical examination. However, it 
has been shown that relying on clinical expertise and examination with a HHD can be unreliable even 
in experienced hands, with specialists missing 3% -11% of GSV and 4%-11% of SSV reflux (Campbell 
et al. 1997; Campbell et al. 2005). The presence of deep venous incompetence was also frequently 
miss-diagnosed in patients with symptomatic superficial reflux (Makris et al. 2006). For this reason it 
is recommended that all patients, even those with primary varicose veins should undergo duplex 
imaging prior to intervention (Mercer et al. 1998). In one randomised trial pre-operative duplex did 
not appear to improve early quality of life outcomes or recurrence rates up to 12 months (Smith et 
al. 2002), but it has been shown to reduce recurrence rates and re-operation rates at 2 years in a 
randomised clinical trial of patients undergoing surgery (Blomgren et al. 2006). 
The introduction of endovenous ablation procedures has resulted in a huge increase in the use of 
duplex ultrasonography, not only in the assessment of the suitability of patients for the procedure, 
but in the delivery of tumescent anaesthesia and the cannulation of the saphenous vein. Based on 
current evidence (Makris et al. 2006) all patients presenting with symptomatic venous disease 
should undergo a full colour duplex scan prior to intervention.  
 
1.4.2 Venous Haemodynamics and Digital Photoplethysmography 
 
Venous haemodynamic assessment involves measuring the changes in venous pressure in the lower 
leg.  Haemodynamic factors have been shown to correlate with physical changes associated with 
venous insufficiency and to improve following superficial venous surgery.  The gold standard for 
venous haemodynamic assessment is invasive measurement of ambulatory venous pressure by 
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cannulating a vein in the foot and measuring pressure changes using a transducer. Digital 
photoplethysmography (PPG) is a non-invasive and validated alternative to invasive measurements.  
It uses light rheography to measure venous refill time (VRT) by measuring the light reflected from 
the blood in skin capillaries in the dermis. An initial reading is taken and then the patient performs 
10 foot dorsiflexions in order to empty blood pooled in the calf veins using the muscle pump (Figure 
7). The change in infrared absorption in the skin is then measured, and the time taken for this to 
return to 90% of the baseline value is calculated as the VRT. A recordable trace is produced as shown 
in Figure 8. 
  
Figure 7. Digital PPG machine  
 
 
Figure 8. Venous refill time trace produced by digital PPG 
 
 Improvements in VRTs following superficial venous surgery correlate with reduced venous ulcer 
recurrence (Gohel et al. 2007a). It has been suggested that digital PPG may be useful in order to 
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differentiate patients with cosmetic varicose veins, from those with genuine haemodynamic 
dysfunction (Beraldo et al. 2007), although there has been little investigation into the relationship of 
VRTs with functional outcomes. Both anatomical reflux and haemodynamic function are surrogate 
measures of the impact of venous disease and, although pre-operative VRTs have been shown to  
correlate significantly with clinical CEAP and validated disease specific quality of life outcomes 
(Aberdeen Varicose Vein Questionnaire- see section 1.4.4.2.1) there was no correlation with scores 
following foam sclerotherapy, or between the changes in disease specific quality of life and VRT 
(Darvall et al. 2010a).  
Unlike invasive ambulatory venous pressure, digital PPG readings are subject to a number of patient 
related factors including the technique of ankle dorsiflexions, the patient’s body habitus, the 
presence of significant subcutaneous oedema and skin changes including haemosiderin deposition 
and lipodermatosclerosis which can affect the absorption of the infra red wavelength. Therefore, 
digital PPG is not appropriate for use in all patients.  
 
1.4.3 Clinical Severity 
 
 A detailed description of clinical classifications used as outcome measures are described in section 
1.3. 
 
1.4.4 Quality of Life 
 
In 1997 a panel of experts from the World Health Organisation agreed upon the concept of Quality 
of Life (QoL) and defined it as “ Individuals’ perception of their position in life in the context of 
culture and value systems in which they live and in relation to their goals, expectations, standards 
and concerns. It is a broad ranging concept affected in a complex way by the person’s physical 
health, psychological state, level of independence, social relationships and their relationship to 
salient features in their environment” (Saxena et al. 1997).  It is closely related to an individual’s 
“health” defined as “a state of complete physical, mental and social well being and not merely the 
absence of disease or infirmity” (http://www.who.int/hac/about/definitions/en). Measuring the 
state of health with the aim of improving quality of life is of major importance throughout all 
branches of medicine.  
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 Many patients with venous disease report a huge range of symptoms of varying severity, despite 
the absence of clinical signs (Campbell et al. 2007). These symptoms frequently impact on their daily 
activities, ability to work and social lives, and, therefore, have a functional impact on their quality of 
life to a varying degree.  In order to investigate this impact, quality of life can be evaluate using 
questionnaires. In 1997 Beattie et al (Beattie et al. 1997) suggested that the ideal quality of life 
measure should be: 
 Equally applicable to any disease process or outcome. 
 Equally applicable across all levels of illness and degrees of invalidity. 
 Of proven validity, with a high level of convergence within patient groups, when applied 
across geographic, linguistic and cultural boundaries. 
A number of questionnaires evaluate quality of life and can be broadly classified into 2 categories: 
Generic (applicable to the population in general, frequently assessing physical and mental 
components of health) or System/disease specific (designed to assess quality of life in patients with a 
particular condition or disease process).  
 
1.4.4.1 Generic Quality of Life Assessment Tools 
 
Generic health questionnaires such as the Short form 36 (SF36) and Short form 12 (SF12) have been 
shown to be reliable for the assessment of generic quality of life in patients with a variety of health 
problems including varicose veins (Smith et al. 1999; Michaels et al. 2006). Patients with 
symptomatic varicose veins have been shown to have poorer quality of life scores when compared 
with the general population (Smith et al. 1999) and surgical treatment can improve quality of life in 
comparison to conservative treatment (Michaels et al. 2006).  The Nottingham health profile (Franks 
et al. 2001) and the EuroQol (EQ-5D) are also effective at assessing generic quality of life and have 
been used in studies of patients with varicose veins and venous leg ulceration (Iglesias et al. 2005; 
Michaels et al. 2009b). Generic quality of life changes are helpful in evaluating the impact of a 
condition on quality of life in general and can be used to compare the impact of different disease 
processes in different populations where normal values for age and sex matched populations are 
available for comparison. This allows health economic analysis to be carried out in order to compare 
the cost effectiveness of different treatments. Although important in allowing the evaluation of 
quality of life between different disease processes and allowing economic evaluation, they may lack 
the sensitivity to detect subtle but important differences in quality of life related to a specific 
disorder.  
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1.4.4.2 Disease Specific Quality of Life Tools 
 
Disease specific questionnaires were designed in order to detect subtle changes in health related 
quality of life specific to a particular disease process and, therefore, be responsive to changes 
following intervention. The views of the patient and the impact of symptoms on their quality of life is 
considered important in all disease processes, but particularly in the management of venous disease 
where clinical, anatomical and haemodynamic measurements do not always fully evaluate the 
impact of the disorder. A variety of questionnaires now exist and are detailed below.  
1.4.4.2.1 Aberdeen Varicose Vein Questionnaire 
 
The Aberdeen Varicose Vein Questionnaire (AVVQ) designed by Garratt et al was the first disease 
specific questionnaire validated for use in patients with varicose veins (Garratt et al. 1993). It was 
designed with the aim of creating  “a valid and reliable measure of patient outcome” that would  “1) 
be sensitive to small yet clinically significant changes in health status; 2) have greater power to 
discriminate between patients who’s health is only mildly affected by their varicose veins; 3) contain 
questions that clinicians ask routinely when taking a clinical history” and 4) contain questions that 
would be “familiar to patients“ (Garratt et al. 1993).  It attributes a score based on the clinical 
severity of the disease, symptoms experienced and their impact on quality of life. The questionnaire 
was based on questions commonly asked to assess patients presenting with varicose veins. Two 
consultants independently allocated scores to responses based on their perceived contribution of 
the response to disease severity. Scores were averaged and scaled from 0 (no disease) to 100 
(severe disease). Question comprehensibility was assessed by interviewing in a small group of 
patients. The original questionnaire consisted of 15 questions and was completed by 281 patients 
with varicose veins. It showed good internal consistency and validity as confirmed by a strong 
correlation with all aspects of the SF36 (Garratt et al. 1993). Two questions did not appear to 
represent any clinically distinct health factor and were subsequently removed from the 
questionnaire. The study also confirmed that patients with varicose veins had a poorer perceived 
health than the general population when matched for age and sex (Garratt et al. 1993). Since its 
initial publication, the AVVQ consisting of 13 questions has been shown to be responsive to changes 
following intervention and to correlate significantly with clinical scoring systems, generic quality of 
life and improvements in quality of life following surgery, particularly for patients with significant 
clinical disease (Smith et al. 1999). It has also been shown to be more responsive to changes 
following surgery than generic quality of life questionnaires (Garratt et al. 1996). It remains the most 
frequently used and well validated of the disease specific questionnaires and has been used in 
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numerous clinical trials to evaluate outcomes (Garratt et al. 1993; Smith et al. 1999; Rasmussen et 
al. 2007; Darwood et al. 2008).  
1.4.4.2.2 Chronic Venous Insufficiency Questionnaire (CIVIQ) 
 
The original version of the CIVIQ was developed from a cross sectional observational study in over 
2000 patients, of which over 50% had venous insufficiency as diagnosed on clinical signs and 
reported symptoms. The CIVIQ 2 was devised following a second analysis using a questionnaire of 20 
equally weighted questions in 1001 patients with venous disease based on 4 criteria including 
physical, psychological, social and pain as parameters. The CIVIQ 2 questionnaire has been shown to 
be appropriate, specific and reliable for the assessment of chronic lower limb venous insufficiency 
(Launois et al. 1996). Since its development in 1996, it has been shown to be reliable and responsive 
in the assessment of patients with chronic venous insufficiency following venous outflow stenting 
and has also been used successfully to evaluate improvements following endovenous thermal 
ablation procedures in a number of clinical trials (Lurie et al. 2003; Almeida et al. 2009b).  
1.4.4.2.3 Venous Insufficiency Epidemiologic and Economic Study (VEINES) 
Questionnaire 
 
In 2003, Lamping et al published the Venous Insufficiency Epidemiologic and Economic Study 
(VEINES-QOL/Sym) questionnaire (Lamping et al. 2003). Previous disease specific tools were thought 
to have been insufficiently validated in English (Launois et al. 1996) or designed specifically to 
evaluate a small part of the spectrum of venous disorders (either venous ulceration or varicose veins 
(Garratt et al. 1993)). The VEINES questionnaire was, therefore, designed as an effective tool for 
assessing disease specific quality of life across all degrees of chronic venous disease and has been 
validated in French and English in 5 countries as part of the VEINES study in 1531 patients (Lamping 
et al. 2003). It consists of 35 items split into a symptom questionnaire (10 items) and the QoL 
questionnaire (25 items). Criticisms of the study include the fact that there was no anatomical 
confirmation of the venous insufficiency, which was diagnosed solely on clinical grounds and that 
statistically significant correlations observed may not necessarily translate into clinically meaningful 
results (Padberg 2003).  
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1.4.4.2.4 Specific Quality of life and Outcome Response –Venous Questionnaire 
 
The latest patient reported outcome questionnaire was designed by JJ Guex et al (Guex et al. 2007) 
entitled the SQOR-V questionnaire (Specific Quality of life and Outcome Response –Venous). It was 
felt that previously designed questionnaires may not be sufficiently sensitive to evaluate symptoms 
and their impact on activities and quality of life in patients who may not have obvious clinical signs 
of venous insufficiency, i.e. patients with C0-C3/mild-moderate venous disease. A Total of 46 
questions were carefully composed in order to evaluate symptoms, with a rating scale of 1-5 instead 
of yes/no answers in order to improve accuracy and sensitivity. Questions were divided into 5 
domains, relating to physical discomfort, appearance, restriction in movement, risk or perceived risk 
and threat to health and emotional consequences. Each domain was moderated to a possible score 
of 4-20, giving a possible range of total scores from 20 (no disease) to 100 (severe disease).  
Although developed in English, it was originally validated in  French, with the SF12 and a Centre for 
Epidemiologic Studies-Depression scale (CES-D) in a group of 202 patients (Guex et al. 2007). It has 
been shown to have internal consistency, reproducibility, structural validity, convergent validity and 
clinical validity (Guex et al. 2007) and has now been validated in several other languages including 
English and Spanish (Guex et al. 2009).   
1.4.4.2.5 The Charing Cross Venous Ulceration Questionnaire (CXVUQ) 
 
The Charing Cross Venous ulceration questionnaire was designed to assess quality of life in patients 
with venous leg ulceration. An ulcer specific questionnaire was designed with questions relating to 
physical discomfort, the effects on daily activities and social activities, emotional consequences, 
perspectives regarding dressings and patient’s mobility. It was validated with the SF36 in a group of 
98 patients and has been found to be reliable and responsive to treatment in patients with venous 
leg ulcers (Smith et al. 2000). 
In summary, there are validated disease specific and generic health questionnaires that can be used 
in combination with clinical scoring systems to assess the impact of varicose veins on the quality of 
life of patients and to evaluate improvements following treatment.  A number of patient, surgical 
and operative factors have been shown to have a significant influence on the impact of superficial 
venous surgery on disease specific quality of life (Mackenzie et al. 2002). Patients with recurrent 
disease (Beresford et al. 2003a) and those with more severe disease at baseline are likely to 
continue to have a worse quality of life, but the degree of improvement seen after intervention 
appears to correlate with increasing severity of disease (Mackenzie et al. 2002). Those with more 
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advanced disease who require more complicated procedures are also likely to have a worse quality 
of life at 2 years (Mackenzie et al. 2002).   
There are enthusiastic advocates for the use of physician and patient reported outcome measures 
(Vasquez et al. 2007) and controversy exists as to which is the most useful (Guex 2008). Few studies 
have compared the efficacy of objective clinical scoring systems with disease specific quality of life 
tools (Beresford et al. 2003b), and no advantage of one scoring system over another has been 
conclusively demonstrated.  There is a current trend for the assessment of patient reported 
outcome measures (PROMs) in the United Kingdom which is likely to continue.  
 
1.4.4.3 Patient Reported Outcome Measures (PROMs) 
 
Patient reported outcome measures (PROMs) are “measures of a patient's health status or health-
related quality of life 
(http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance). 
In 2009 patient reported outcome measures were introduced in the UK to evaluate health 
improvements after surgical procedures including hip and knee replacements, hernia operations and 
varicose vein therapies. Patients undergoing varicose vein procedures from April 2009 onwards were 
asked to complete questionnaires composed of questions from validated generic (EQ-5D visual 
analogue score and profile) and disease specific (Aberdeen Varicose Vein) questionnaires pre-
operatively and were sent a postal questionnaire at 3 months.  Data from PROMs may be used “To 
evaluate the relative clinical quality of providers of elective procedures and benchmark performance 
and to help patients and GPs exercise choice”. They may also be used in research to “evaluate the 
efficiency and cost-effectiveness of different technical approaches to care” and for the assessment 
of the appropriateness of referrals to secondary care, to reduce inequality and “establish the quality 
of services PCT commissioners are contracting with providers”  
(http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance).  
The first PROMs data from April- November 2009 were published on the Hospital Episode statistics 
website in April 2010 (http://www.hesonline.nhs.uk). Only pre-operative data are currently 
available, and to date 10,533 questionnaires have been received out of a possible 25,963 episodes 
(40.6%) of which 79.7% have been linked to treatment episodes. Although the largest data set to 
date, problems include the fact that the overall response rate is at present poor, with only 40% of 
potential data being captured. In addition, it has not been possible to link all data with treatment 
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episodes, and, therefore, data should be interpreted with caution. Post-operative data is likely to be 
available in 2010, but is likely to be of poor quality. The co-operation of both patients and hospital 
staff in the recording of patient reported outcomes will have to be addressed in order that clinically 
useful data can be obtained for the purposes for which it was originally designed.  
 
1.4.5 Measuring the Burden of Venous Disease and Cost Effectiveness of Treatments 
 
At present no single method of investigation allows a full evaluation of the extent of venous disease. 
Because life threatening and severe events are rare, not all patients require an intervention and no 
simple investigation exists to evaluate disease progression or improvements after intervention. The 
evaluation of the true cost of venous disorders to a state based healthcare system is unknown and at 
present sub-optimally managed (Barnes et al. 2010). At present the societal costs and cost 
effectiveness of treatments in the UK is calculated in quality of adjusted life years (QALYs). A year in 
perfect health is equal to 1.0 QALY, and years of ill health are given reduced scores in proportion to 
the severity. QALYs form the basis of health economic analysis, where the cost effectiveness of a 
particular intervention is frequently judged by its incremental cost effectiveness ratio (ICER). This is 
the ratio of the difference in cost between two interventions divided by the change in effect. 
Treatments with an ICER of <£20,000 per QALY are usually deemed cost effective to the NHS, and 
those > £30,000 per QALY are usually not funded.  However, it has been argued that generic 
questionnaires may not be sufficiently sensitive to evaluate improvements for certain disease 
processes.  In the case of other chronic disorders the “disease burden”  has been calculated and 
takes into account the cost of patients living with chronic conditions such as osteoarthritis as well as 
the costs of treatments (Bitton 2009). This allows the targeted use of healthcare resources for 
prevention and treatment of early disease. At present it is proposed that the burden of venous 
disease should be calculated in a similar way to that of patients with osteoarthritis, in order to 
convince international organisations that better management of chronic venous disease is necessary 
and cost effective to society.  
The allocation of scarce healthcare resources to the management of venous disorders is in constant 
flux and under continuous review. Many patients with varicose veins have mild symptoms and are 
often concerned with cosmesis. This has lead to the rationing of varicose vein treatments by the 
majority of healthcare regulators in the UK, with referral to secondary care for treatment restricted 
to those with late clinical signs or very severe symptoms, although it is highly variable throughout 
the country (Lindsey et al. 2006; Nasr et al. 2008). The introduction of outpatient based vein 
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treatments potentially allows the treatment of a greater number of patients, saving money by 
reducing the need for an operating theatre, overnight stay or an anaesthetist.  Recently the cost 
effectiveness of radiofrequency has been compared with traditional surgery and it is proposed that 
the increased cost of the equipment is offset by the quicker return to work and normal activities 
(Rautio et al. 2002; Subramonia et al. 2009a). To date, few comparative cost analysis studies have 
been performed. However, using a Markov model based on published randomised studies, NHS HRG 
tariffs and device manufacturers costs, foam sclerotherapy was most likely to provide the cheapest 
option, even taking into account the cost of further treatments at 5 years. However, EVLA, RFA or 
surgery performed as day case procedures in an outpatient or office based setting with sequential 
treatment of varicosities if necessary, are also likely to be cost effective treatment strategies (Gohel 
et al. 2010) (Gohel et al. 2008). A current multicentre trial in progress (CLASS Trial- Comparing LAser 
Surgery and Sclerotherapy in the treatment of varicose veins) aims to make a detailed analysis of the 
costs of the treatments as part of the secondary analysis.  
 
1.5 Evidence Supporting the Treatment of Venous Disease 
 
The term venous disease encompasses a wide spectrum of conditions with varying degrees of 
severity. Many patients with  mild or moderate venous disease may be asymptomatic (Bradbury et 
al. 1999). Patients with severe venous disease including those with significant skin changes or 
ulceration are usually evaluated using objective clinical signs of ulcer healing or recurrence. 
However, venous disease at both ends of the spectrum has an impact on quality of life, the evidence 
for the treatment of venous disease is discussed below. 
1.5.1 Uncomplicated Venous Disease 
 
Although the benefits of intervention are clear for patients with venous ulceration, the treatment of 
uncomplicated varicose veins remains controversial and varies widely throughout the UK (Nasr et al. 
2008). The National Institute of Clinical Excellence published guidelines in 2001 to advise primary 
care practitioners when to refer to secondary care. They advise that “most varicose veins require no 
treatment” (National Institute for Clinical Excellence Issued 20 December 2001) and primary care 
physicians are encouraged to educate patients about exercise, leg elevation and weight reduction 
and to oversee the use of compression hosiery and compression bandaging when appropriate.  
Referral priorities from NICE are summarised in Table 2. 
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Referral Priority Symptoms and Signs 
Patient should be seen immediately 
(within 1 day) 
Bleeding from a varicosity that has eroded the skin 
Patient should be seen urgently (within 
a maximum of 2 weeks) 
Previous bleeding from a varicosity and at risk of further bleeding 
Patient should be seen soon 
(will depend on local waiting times) 
A leg ulcer which is progressive and/or painful despite treatment 
Patient should have a routine 
appointment 
(will depend on local waiting times) 
 An active or healed ulcer and/or progressive skin changes that 
may benefit from surgery 
 
 Recurrent superficial thrombophlebitis 
 “Troublesome symptoms attributable to their varicose veins, 
and/or they and their GP feel that the extent, site and size of 
the varicosities are having a severe impact on quality of life” 
 
 
Table 2. Summary of NICE referral priorities to secondary care for varicose veins by primary care physicians 
 
Until recently, success after varicose vein treatment was frequently judged on recurrence rates and 
haemodynamic assessment. Surgery has been shown to reduce the overall patient reported 
symptoms frequently attributable to venous disease (Campbell et al. 2007), however, the accurate 
measurement of functional improvement is complex. The introduction of validated generic and 
disease specific quality of life questionnaires have provided an objective assessment tool to evaluate 
improvement and provide credible evidence for the treatment of superficial reflux.  
Patients with chronic venous disease have been shown to have significantly worse generic quality of 
life scores than the general population, with quality of life impairment being proportional to the 
severity of the disease (Kaplan et al. 2003). 
Since the publication of the recommendations from NICE in 2001, evidence from a number of 
studies has shown that superficial venous surgery results in improvements in generic (Sam et al. 
2004) and disease specific quality of life (Smith et al. 1999), and evidence from a randomised trial by 
Michaels et al 2006 confirmed that patients with uncomplicated varicose veins gained significant 
improvements in quality of life following surgery compared with conservative management, 
assessed using validated quality of life questionnaires (Michaels et al. 2006). Treatment was also 
shown to be cost effective  at £4682  per QALY, well below the £20,000 per QALY threshold 
recommended as cost effective by NICE (Ratcliffe et al. 2006). 
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Other studies have shown that improvements in generic quality of life using the Short Form 12 
questionnaire following varicose vein treatments are comparable to those achieved after 
laparoscopic cholecystectomy in patients with C2-C4 disease (Sam et al. 2006). 
1.5.2 Ulcer Healing 
 
Rates of ulcer healing may be affected by a number of different factors. Increasing age, ulcer 
chronicity (Gohel et al. 2005b) and deep venous incompetence have been associated with 
significantly slower rates of healing (Moffatt et al. 2010), and significant seasonal variations have 
been observed, with ulcers appearing in the Spring or Autumn healing more rapidly that those 
appearing in the Summer or Winter (Simka 2010). Compression bandaging has been shown to be the 
most effective technique for healing leg ulcers, with the type of dressing used including the presence 
or absence of silver or other antimicrobial dressings being relatively unimportant (Michaels et al. 
2009a). Many researchers have hypothesised that the treatment of superficial venous reflux can 
increase rates of ulcer healing, although evidence supporting this is lacking. Smaller studies have 
suggested that treating superficial reflux with foam sclerotherapy in patients with recalcitrant ulcers 
may increase ulcer healing (Cabrera et al. 2004), however, this has not been replicated in 
randomised clinical trials (RCTs). To date the ESCHAR trial is the largest randomised study of ulcer 
healing and recurrence but failed to show significantly improved healing in the surgery group 
(Barwell et al. 2004). Other studies including a randomised trial (van Gent et al. 2006) have also 
shown superficial venous surgery to reduce ulcer recurrence but failed to show any benefit in rates 
of ulcer healing (Barwell et al. 2000; Zamboni et al. 2003; Barwell et al. 2004). 
1.5.3 Ulcer Recurrence 
 
Published evidence confirms that patients with venous ulceration have a significantly worse quality 
of life compared with the general population (Kurz et al. 2001). Until recently, the advantages of 
treating superficial reflux were believed by many, however, high quality evidence supporting the 
treatment of superficial reflux in patients with venous ulceration, and those with co-existing deep 
venous incompetence was scarce.  The ESCHAR Trial published in 2004 and 2007 randomised 500 
patients with venous ulcers to superficial venous surgery and compression versus compression alone 
and showed a clear benefit of reduced ulcer recurrence in patients randomised to the surgical 
treatment group (12% ulcer recurrence) in comparison with those randomised to compression alone 
(28% ulcer recurrence)(Barwell et al. 2004). However, healing rates at 24 weeks were 65% in both 
groups based on an intention to treat analysis. Although a small study into the use of foam 
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sclerotherapy in patients with venous ulceration suggested that treatment was likely to reduce ulcer 
recurrence (Darvall et al. 2010a), a randomised trial comparing foam sclerotherapy with 
compression to compression alone failed to show an advantage of foam sclerotherapy. However, a 
formal comparison was not performed as insufficient numbers of patients were recruited (O'Hare et 
al. 2010a). It is likely that abolition of superficial truncal reflux by any modality will result in a 
significant reduction in leg ulcer recurrence in patients with isolated superficial and co-existing deep 
venous insufficiency. In addition, the treatment of superficial reflux has been shown to lead to the 
correction of deep venous reflux in some cases, which is likely to aid further clinical improvements 
(Walsh et al. 1994; Barwell et al. 2004; Gohel et al. 2005a). 
 
1.6 Treatment Goals 
 
The treatment of venous diseases consumes approximately 1% of hospital in patient costs in many 
European countries. Although the evidence to support the treatment of complicated venous disease 
is unequivocal, the treatment of symptomatic varicose veins in the absence of skin changes remains 
controversial, with many NHS Healthcare Trusts refusing to fund treatment (Lindsey et al. 2006). It 
has, however, been shown that the treatment of uncomplicated varicose veins results in significant 
improvements in the quality of life, the cost of which is below the threshold recommended by NICE 
(O'Hare et al. 2007).  Despite this, the number of varicose vein treatments in recent years has 
significantly declined (http://hesonline.nhs.uk).  
Litigation claims for varicose vein surgery were previously the most frequently occurring claims of all 
vascular surgical, including arterial procedures (Campbell et al. 2002). Nerve damage was the 
commonest reason for complaint, followed by major vascular injury and deep venous thrombosis 
(Scurr et al. 2007).  Even in the absence of permanent or serious complications, a number of patients 
will remain dissatisfied with the results  of their treatment (Davies et al. 1995). This has lead to much 
interest in the development of alternative treatments for varicose veins.  
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Attributes of an ideal treatment should include: 
 A minimally invasive therapy  
 Ability to be performed as an outpatient procedure 
 Minimal discomfort to the patient intra and post-operatively 
 Rapid to perform  
 Provided in a single visit 
 Minimal reliance on complex or expensive imaging or that requiring radiation 
 No follow up required 
 Durable long term results 
 Minimal complications, risks or side effects 
 Cost effective 
The treatment is likely to require the abolition of truncal reflux and the removal of visible varicosities 
in order that symptoms and cosmetic concerns are addressed, and the risk of developing further 
complications of venous disease are reduced.  
 
1.7 Treatment Options 
 
Many patients with varicose veins will require no treatment for their condition but in those who 
present with complications or significant symptoms, a variety of different treatment options exist. 
The current treatment options for varicose veins are discussed below. 
1.7.1 Compression Hosiery 
 
Compression of the superficial venous system reduces venous pooling in the legs and assists the calf 
muscle pump, alleviating symptoms such as swelling and aching. Graduated compression stockings 
deliver a specific pressure at the ankle and are graded from I to III. In the UK grade I compression 
and grade II compression are the most frequently prescribed level of compression for patients with 
superficial venous incompetence. The grading systems for different degrees of compression vary 
between the UK, Europe and the United States which can cause considerable confusion. A table 
detailing the different grades of compression is presented below (Table 3). 
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Grade UK Europe USA 
I 14-17mmHg 18-21mmHg 20-30mmHg 
II 18-24 mmHg 21-32mmHg 30-40mmHg 
III 25-35mmHg 32-46mmHg 40-50 mmHg 
 
Table 3. Classification of compression hosiery in the UK, Europe and USA 
 
 A Cochrane review has confirmed that compression improves ulcer healing and reduces the 
recurrence of venous leg ulcers (O'Meara et al. 2009). A systematic review of randomised clinical 
trials confirmed that compression of 10-20 mmHg improved venous haemodynamics, reduced 
venous reflux and venous oedema and lead to a reduction in symptoms such as pain and discomfort 
(Amsler et al. 2008). However, a recent systematic review evaluating its role in uncomplicated 
varicose veins found the evidence for its use was equivocal in this patient group (Palfreyman et al. 
2009). Disadvantages of compression hosiery include discomfort to patients, especially in hot 
weather, difficulty donning stockings, especially for patients with co-existing musculoskeletal 
pathology, particularly those affecting the hands, hips or knees and cosmetic concerns.  Studies have 
shown that in many patients, compliance with compression hosiery is poor (Raju et al. 2007). 
Compression hosiery is also frequently used following varicose vein treatments. Perceived 
advantages include reduced bruising and thrombophlebitis, however, evidence from RCTs do not 
support the prolonged use of compression either following surgery (Houtermans-Auckel et al. 2009) 
or endovenous ablation (Hamel-Desnos et al. 2010; O'Hare et al. 2010b). 
 
1.7.2 Pharmacological Management of Varicose Veins 
 
Although the management of venous disease in the UK predominantly consists of compression 
therapy or ablation of truncal reflux, a number of pharmacological therapies currently exist and are 
frequently used to alleviate venous symptoms and reduce sequaelae of chronic venous disease. In 
Europe they are frequently used in combination with compression or abolition of truncal reflux, but 
at present few are licensed in the UK. Pharmacological agents are frequently classified as either 
venoactive/ phlebotrophic (drugs acting on the venous tone or capillary permeability) or non-
venoactive and consist of naturally occurring or synthetic drugs.  Of the venoactive drugs that have 
been available for many years, the most widely known is Micronized Purified Flavinoid Fraction 
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(MPFF) or Daflon (Servier France).  This has been shown to improve venous tone and decrease 
venous pressure. Although the exact mechanism of action is not completely understood, it is 
thought to inhibit noradrenaline degradation, leukocyte adhesion and activation, reduce 
inflammation, inhibit platelet function and improve lymphatic drainage (Gohel et al. 2009a). A meta-
analysis supported the use of Daflon to improve healing in patients with venous ulcers and Daflon 
has also been reported to reduce pain, oedema and leg cramps (Jantet 2002; Smith 2005). However, 
large prospective randomised trials supporting the use of many of the available drugs are lacking.  
Similar pharmacological agents to Daflon include Oxerutins and Rutosides, which are thought to act 
on capillary permeability and have been shown to reduce swelling and improve haemodynamic 
function (Petruzzellis et al. 2002). Some have been compared favourably with Daflon in prospective 
studies (Cesarone et al. 2006). Side effects are rare with venoactive drugs, but can include nausea, 
vomiting and abdominal pain (Guilhou et al. 1997).  
Non-venoactive drugs such as pentoxifyline, ergotamine and aspirin are thought to affect the 
inflammatory response associated with venous disease. Actions include reduced white cell 
activation, fibrinolysis and platelet inhibition and these drugs may provide some benefit in patients 
with venous ulceration. Some studies suggest that venous ulcer healing is improved with 
pentoxyphyline although evidence from different studies is conflicting and, therefore, inconclusive, 
with good quality evidence being scarce (Jull et al. 2002).  
Although medical treatment for venous disease is a desirable notion, and a number of drugs have 
been shown to significantly improve symptoms and ulcer healing, the majority of studies have been 
small and non-randomised.  To date few medications are readily available in the UK and they remain 
adjuncts to endovenous and surgical options, which are considered more definitive treatments. 
 
1.7.3 Traditional Surgery 
 
The first recorded treatments for varicose veins were found in the Ebers papyrus in ancient Egypt 
over 3500 years ago. It is thought that initial attempts at surgery lead to fatal haemorrhage and 
were, therefore, not advised. Detailed descriptions of varicose veins can be found in the writings of 
Hippocrates in the Hippocratic Treatises in 460 BCE. He describes applying compression following 
multiple puncture sites and also describes cautery (van den Bremer et al. 2010). Further descriptions 
of varicose vein surgery were detailed by the Romans; Celcus and Galen describe the technique of 
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phlebectomy which remains similar to that used today. The first recorded surgical procedures 
involving ligation of the great saphenous vein were from Paulus Aegineta (CE 607-690) in ancient 
Greece. He describes placing a tourniquet onto the thigh and asking the patient to walk, the dilated 
veins were then marked with ink to determine the site for the incision and the vein was ligated in 
the thigh, divided and bandaged. Removal of the GSV through multiple incision sites along the vein 
was described in the surgical text books written by the Arabian surgeon Al-Zahrawi around 960 CE, 
and the technique remained relatively unchanged until the 17th century. Advances in venous 
anatomy, physiology, anaesthetics and antisepsis meant that during the 19th century significant 
advances in the treatment of varicose veins were made. In the 1800s Friedrich Trendelenburg 
published the technique of ligation of the GSV in the mid and lower thigh (Trendelenburg 1980).This 
became a popular treatment with reported recurrence rates of 22% at 4 years, however, it was his 
student Perthes who recognised the importance of saphenofemoral ligation and groin dissection 
which did not become established until the early 1900s. The 20th century saw the introduction of 
stripping of the GSV. Mayo described an extraluminal stripper and Babcock and Keller(Keller 1905) 
described internal strippers similar to the perforation invagination(PIN) strippers used today. In 1916 
John Homans (Homans 1917) was credited with the first description of crossectomy and recognised 
the importance of preventing new vessel formation by careful dissection of tributary vessels in the 
groin, he also described performing the procedure under local anaesthetic. In the 1930s, Linton 
described the association of leg oedema with GSV incompetence and also with perforator 
incompetence (Linton 1938) and subsequently described subfascial division of perforating veins, 
although the necessity of treating them remains controversial to date.  Stripping of the GSV became 
increasingly popular from the 1950s, when evidence of its superiority over crossectomy alone was 
published (Lofgren et al. 1958). 
Since the early descriptions of varicose vein surgery, treatments have been modified, but the 
principle has remained similar for hundreds of years. Until the last decade, the gold standard for the 
treatment of varicose veins due to GSV reflux was saphenofemoral disconnection, stripping of the 
great saphenous vein and phlebectomies for superficial varicosities as shown in Figure 9. The 
treatment of short saphenous vein (SSV) reflux involves ligation of the saphenopopliteal junction, 
but frequently does not involve stripping of the SSV due to the risk of neurological injury.   
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a. Groin dissection    b. Saphenofemoral disconnection 
 
 
c. Stripping of the Great saphenous vein d. Great saphenous vein and stripper 
 
 
e. Phlebectomy using an Oesh hook 
Figure 9. Stripping of the great saphenous vein and phlebectomies 
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1.7.3.1 Complications Associated with Traditional Surgery 
 
Traditional surgery is associated with a number of adverse events, with approximately 20% of 
patients experiencing some degree of complication (Critchley et al. 1997). Bruising, post-procedural 
discomfort and phlebitis are frequently experienced following surgery with many patients requiring 
several weeks off work and up to 40% experiencing temporary sensory abnormalities (Subramonia et 
al. 2005). Skin infections and haematomas are thought to occur in 3-10% of patients (Critchley et al. 
1997). 
For many years the GSV was stripped as far as the knee only, as rates of permanent saphenous nerve 
paraesthesia were reported to be lower if the veins was stripped to the knee (7%) compared with 
those stripped to the ankle (39%)(Holme et al. 1990). However, a recent case series reported 
permanent paraesthesia rates of only 2% when the GSV was stripped to the ankle (Uncu 2009), 
perhaps reflecting the advantages of performing procedures under ultrasound guidance. Sural nerve 
injury has been reported to occur in up to 20% of small saphenous vein operations (Perkins 2009) 
and peroneal nerve injury has also been reported following varicose veins surgery but is extremely 
rare (Herman et al. 2009; Perkins 2009). 
Deep Vein Thrombosis (DVT) has been shown to occur in up to 5% of cases following surgery (van Rij 
et al. 2004), although other vascular injuries are rare and occur in less than 1% of cases. The most 
frequent vascular complications include injury to the common femoral vein, and partial stripping of 
the femoral vein and femoral artery, which have been reported with poor outcomes (Perkins 2009).  
Recurrence after traditional surgery remains a significant problem and a recent meta-analysis 
suggested that success rates are around 75% at 5 years (Van den Bos et al. 2009a). Recurrence rates 
increase with time and have been reported to be as high as 62% at 11 years (Winterborn et al. 2004).  
Unsurprisingly, surgery has been associated with a significant degree of patient dissatisfaction 
(Davies et al. 1995).  In recent years there has been much interest in the development of new, 
minimally invasive techniques for the treatment of varicose veins in order to reduce the morbidity, 
complications and recurrence associated with traditional surgery. 
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1.7.4 Conservatrice et Hemodynamique de l’insuffisance Veineuse en Ambulatoire 
(CHIVA) 
 
CHIVA is a minimally invasive surgical technique based on the principle of interruption of venous 
reflux with preservation of the truncal vein in order to improve haemodynamic function. It was 
originally described in the 1980s and is frequently performed in many European countries (Mowatt-
Larssen et al. 2010), however, it is practiced infrequently in the UK. Treatment relies on an accurate 
venous duplex scan in order to identify abnormal blood flow between venous compartments, which 
leads to the formation of re-entry flow loops of blood. Flush ligation at the proximal origin of the 
abnormal flow interrupts the recirculation and encourages drainage into the deep system via 
perforator veins. This, in combination with disconnection of tributary veins, aims to correct 
haemodynamic abnormalities, thereby reducing venous hypertension and alleviating symptoms. 
90% of patients have reflux according to one of two types of shunts described below (Zamboni et al. 
2003). The first shunt arises from the saphenofemoral junction and blood drains into the deep 
system via a perforating vein, usually in the calf, with tributaries arising from the segment of 
incompetent GSV. Correction involves disconnection of the saphenofemoral junction, encouraging 
blood to drain into the deep system via distal perforators, and disconnection of tributaries arising 
from the great saphenous vein. Alternatively the commonest shunt pattern observed arises from 
incompetence at the saphenofemoral junction, with blood draining back into the deep system via 
tributary veins. Correction involves flush ligation of the tributaries with phlebectomy of proximal 
tributaries and may also required saphenofemoral ligation in those patients with an incompetent 
terminal valve in the GSV (Zamboni et al. 2003). The advantages of this technique compared with 
traditional surgery are that it is minimally invasive, can be performed easily under local anaesthesia 
and may reduce rates of saphenous nerve paraesthesia (Mowatt-Larssen et al. 2010). Data from 2 
randomised clinical trials comparing CHIVA to traditional stripping of the GSV suggest that 
recurrence rates are lower following CHIVA, possibly due to the haemodynamic advantages of 
preservation of the GSV (Carandina et al. 2008; Pares et al. 2010). Good results including low 
recurrence rates and high levels of patient satisfaction following CHIVA are also reported from large 
case series (Maeso et al. 2001; Zamboni et al. 2001; Escribano et al. 2003) and CHIVA has also been 
shown to reduce rates of venous leg ulcer recurrence (Zamboni et al. 2003). Disadvantages include 
the fact that it is heavily reliant on accurate duplex scanning. In addition, patients may require 
multiple or staged procedures, particularly if they have significant incompetence of the terminal GSV 
value, and the appearance of tributary veins frequently takes longer to improve compared with 
patients who have undergone extensive phlebectomy (Mowatt-Larssen et al. 2010). To date there 
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are no randomised trials or observational studies comparing CHIVA to endovenous ablation 
therapies, although endovenous thermal ablation may be used in conjunction with the CHIVA 
technique to treat short segments of vein instead of ligation or phlebectomy (Mowatt-Larssen et al. 
2010).  
1.7.5 Ambulatory Selective Varices Ablation under Local Anaesthetic (ASVAL) 
 
ASVAL is an alternative minimally invasive surgical treatment option for varicose veins. It is based on 
an alternative hypothesis to the theory that venous reflux originates from the SFJ, resulting in 
descending truncal reflux affecting the GSV and the subsequent development of tributary varices. 
ASVAL is based on a newer concept that reflux can originate from multifocal sites in the superficial 
venous network and then ascend to the SFJ, and, therefore, the treatment of this superficial varicose 
reservoir can lead to the improvement or elimination of saphenous reflux. Careful duplex 
ultrasonography of the limb maps tributary varicosities into 32 different zones of the leg based on 
anterior, posterior, medial and lateral views, each with 8 segments. Treatment involves phlebectomy 
of varicosities in patients with out deep venous reflux with preservation of the GSV. The technique 
has been shown to lead to reductions in GSV diameter and a reduction in patient symptoms in 
prospective studies (Pittaluga et al. 2010). A retrospective study of 811 limbs treated with ASVAL 
reported that 88.5% of patients were free from recurrent varices at 4 years, resulting in a significant 
improvement in symptoms and elimination of truncal reflux in some cases (Pittaluga et al. 2009). The 
technique is more successful in patients with fewer zones requiring treatment and appears to be 
successful for the treatment of mild and moderate disease (Pittaluga et al. 2009). 
It shares some similarities with CHIVA, in that the GSV is preserved, however, it significantly differs 
from CHIVA because it does not rely on the identification of perforator vessels and does not involve 
the disconnection of tributary vessels or the selective ligation of the SFJ. Unlike CHIVA there are no 
randomised trials of ASVAL and alternative treatment strategies, and further evidence to support its 
effectiveness will be required before it can be recommended for widespread use.  
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1.7.6 Sclerotherapy 
 
1.7.6.1 History of Sclerotherapy 
 
Sclerotherapy of varicose veins involves the injection of a sclerosant substance into the vein lumen, 
which induces an inflammatory reaction in the vein intima, leading to fibrosis and obliteration of the 
vein. The first reported attempts at treating varicose veins with the injection of sclerosants are 
recorded in the 17th century but were largely unsuccessful. In the 1850s Cassaignac, Debout and 
Panus, injected perchloride of iron into varicose veins with some success (Yao 1997), however, 
complications such as phlebitis and infections were common, leading in some cases to gangrene. 
Other sclerosants such as carbonic acid were tried in the 1800s, but at a surgical congress in Lyon in 
1894, it was decided that the technique should be abandoned due to the frequent complications. 
The technique of injecting liquid sclerosants resurfaced in the 1920s but was still associated with 
considerable side effects.  The first recorded descriptions of foam sclerotherapy were by McAusland 
in 1939 who described shaking sodium morrhuate in a vial with air to create a froth to treat 
telangiectasia (Wollmann 2004). The invention of foam sclerotherapy for the treatment of larger 
veins is frequently credited to Orbach, who in 1944 described a technique of injecting air prior to 
liquid sodium tetradecyl sulphate (STD), in order to improve contact between the vein wall and 
sclerosant. He later published a description of producing a foam mixture by shaking  STD with air 
prior to injection (Orbach et al. 1950). Between 1940 and 1970, numerous descriptions of a variety 
of techniques to create foam used successfully to treat varicose veins were published (Wollmann 
2004), however, liquid sclerosants were still used in the majority of treatments at the time.  
1.7.6.2 Liquid Sclerotherapy 
 
Sclerotherapy liquid STD became increasingly popular in the 1960s as a minimally invasive  
alternative to traditional surgery to treat the GSV and tributaries (Fegan 1963). Unfortunately for 
many, results were disappointing, with high recurrence rates. In the 1970s and 80s Hobbs published 
initial and 10 year data from a randomised trial comparing surgery to liquid sclerotherapy. Results 
suggested that surgery produced significantly better results in comparison with Sclerotherapy 
(Hobbs 1974). Around the same time Beresford et al  published results from a 5 year randomised 
clinical trial, reporting that patients were significantly more likely to require further treatment 
following sclerotherapy in comparison with traditional surgery (Beresford et al. 1978). The use of 
liquid sclerosants for the treatment of truncal veins subsequently declined and were predominantly 
reserved for the treatment of tributaries.   
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1.7.6.3 Foam Sclerotherapy 
 
Despite its decline during the 1980s and 1990s, sclerotherapy became increasingly popular following 
the publication of studies by Cabrera et el, who reported that larger veins could be successfully 
treated with the injection of a foam sclerosant. The proposed mechanism was that the foam 
displaced blood from the vessel, allowing increased contact between the sclerosant and the vein 
wall, with substantial increase in efficacy (Cabrera et al. 1997). Although sclerotherapy had existed 
for decades, the introduction of simple techniques to create large volumes of foam of consistent 
quality, such as that described by Tessari (Tessari 2000) lead to a rapid increase in the popularity of 
foam sclerotherapy. Foam sclerotherapy was shown to be more effective at eliminating truncal 
reflux than liquid sclerosants (Hamel-Desnos et al. 2003; Yamaki et al. 2004) and has been used 
successfully to treat truncal reflux with few side effects (Belcaro et al. 2003; Jia et al. 2007). 
However, despite its success in comparison to liquid sclerosants, a recent meta-analysis reported 
truncal occlusion rates of 81% at 12 months and 74% at 5 years (Jia et al. 2007; Van den Bos et al. 
2009a), with as many as a third requiring further treatments (O'Hare et al. 2007). Because of this, 
ultrasound guided foam sclerotherapy (UGFS) is still considered by many to be inferior to traditional 
surgery or endothermal ablation. Disadvantages include poorer cosmetic outcomes with skin 
pigmentation and phlebitis occuring in up to a fifth of cases (Jia et al. 2007). There have also been 
recent concerns over safety following reported visual disturbances and cerebrovascular events, 
although these are extremely rare (Coleridge Smith 2009) and STD remains licensed for use in the 
UK.  A postal survey published in 2007 investigated the use of foam sclerotherapy amongst members 
of the Vascular Society of Great Britain and Ireland. Of 281 respondents a quarter regularly used 
foam Sclerotherapy, in the majority of cases this was for recurrent varicose veins, for elderly patients 
and for tributary varicosities (O'Hare et al. 2007). Recently a large cohort study reported significant 
improvements in disease specific quality of life following foam sclerotherapy treatment for GSV 
reflux. Results were comparable to those reported following endovenous thermal ablation in other 
studies (Darvall et al. 2010b). UGFS has also been shown to be effective in patients with SSV 
insufficiency (Darvall et al. 2009c). In addition UGFS offers a minimally invasive treatment to those 
unfit for general anaesthesia, or those with veins too tortuous for endothermal ablation. Moreover, 
UGFS results in significantly reduced discomfort and a quicker return to normal activities compared 
with traditional surgery (Darvall et al. 2009a). Results following UGFS are frequently reported to 
meet or exceed patient expectations, and are satisfactory for the majority of patients (Darvall et al. 
2009b). Foam sclerotherapy certainly appears to be significantly less expensive than endovenous 
thermal ablation procedures at least in the short term, however, when multiple treatment episodes 
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are taken into account, it may not be significantly more cost effective than endovenous thermal 
ablation treatments. At present it certainly appears the cheapest option (Gohel et al. 2008) and, 
therefore, has significant potential for widespread use in the future.  
 
1.7.7 Endovenous Thermal Ablation Procedures 
 
1.7.7.1 Endovenous Laser Ablation (EVLA): Development and Efficacy 
 
EVLA was first described by Boné in 1999 (Boné 1999) and has been used in the UK since 2001.  The 
procedure involves the introduction of an endovenous catheter into the great saphenous vein using 
the seldinger technique, under ultrasound guidance.  The catheter tip is positioned 2cm from the SFJ 
and the activated laser is withdrawn along the course of the vein.  During this process heat from the 
laser probe results in the formation of steam bubbles in the blood causing damage to the 
endothelium by coagulative necrosis (Proebstle et al. 2002a; Proebstle et al. 2002b).  This causes 
thrombus and occlusion of the vein lumen which involutes over approximately 6 weeks until it is no 
longer visible. In addition, contact between the vein wall and the laser probe also contributes to the 
heating effect. The first endovenous laser to be developed and used to treat GSV reflux had a 
wavelength of 810 nm (Min et al. 2001; Navarro et al. 2001) which is specific for haemoglobin, 
however, other wavelengths rapidly became available including 940nm, 980nm 1320nm and 
1470nm. The shorter wavelengths target haemoglobin and the longer wavelengths (1320nm and 
1470nm) target water. Since its introduction, numerous studies have been published supporting the 
efficacy of endovenous laser ablation of various wavelengths, although to date there is no conclusive 
evidence that one wavelength is superior to the others (Van den Bos et al. 2009a). It has been 
suggested that the longer wavelengths targeting the water molecules lead to a more uniform 
heating effect with reduced post-operative pain and bruising in comparison to the 810, 940 and 
980nm wavelengths (Proebstle et al. 2005; Kabnick 2006; Van den Bos et al. 2008). Indeed the 
980nm laser has been shown to result in less pain than the 810nm with no decrease in 
efficacy(Kabnick 2006) and the 1320nm laser has been shown to be less painful than the 940nm 
laser and cause less bruising (Proebstle et al. 2005).  
Since its introduction, EVLA has become increasingly popular and has been compared with 
traditional surgery in a number of clinical trials. Outcomes have been variable and although some 
have shown EVLA to be less painful than surgery (Rasmussen et al. 2007), and others have shown an 
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earlier return to normal activities (Darwood et al. 2008), results have been conflicting. Nevertheless, 
a recent meta-analysis of the outcomes after 5 years found EVLA to be superior to all other 
treatments, with success rates of 93% at 12 months and 95% at 5 years(Van den Bos et al. 2009a). 
Despite the excellent success of EVLA in terms of the abolition of reflux, post-procedural pain and 
bruising are important side effects. This has been attributed to areas of direct contact between the 
laser catheter and the vein wall causing vein wall perforations and extravasation of blood. Early laser 
fibres used a pulsed waveform and continuous external pressure was applied over the vein segment 
being treated. Extrinsic compression has since been shown to be unnecessary for successful 
occlusion and resulted in increased pain, so current lasers use a continuous waveform. 
Linear Endovenous Energy Density (LEED) has been shown to be related to outcome success and 
complications. It is believed that a LEED of >60j/cm of vein wall is required for successful abolition of 
the vein (Theivacumar et al. 2008a). Very high LEEDs >100j/cm are thought to cause more vein wall 
perforations and increased pain (Timperman et al. 2004; Timperman 2005; Pannier et al. 2009). 
Using the laser setting at a higher power (watts) has also been shown to increase side effects in 
some studies(Proebstle et al. 2006; Theivacumar et al. 2008a), however, another study used 
energies of up to 160 j/cm with no significant increase in complications (Carradice et al. 2010). 
In addition to the LEED, the diameter of the treated vein is thought to be important. Studies have 
suggested that the Endovenous Fluence Equivalent (EFE) in j/cm2, taking into account vein diameter 
and not only power and withdrawal speed, is likely to predict successful closure. Proebstle et al  
suggested the need for adjusting the dose depending on the vein diameter (Proebstle et al. 2006). 
Although appropriate threshold EFE values have been suggested, vein diameter is subject to 
positional and physiological variation, and robust data supporting the success rates of the treatment 
of large veins of >2cm with endovenous thermal ablation are still awaited. 
1.7.7.2 Endovenous Laser: Coated Fibres 
 
Preventing contact between the laser fibre and the vein wall has been suggested as a mechanism to 
reduce side effects. In one study, centring the catheter and preventing vein wall contact with a tulip 
shaped 980nm laser reduced contact with the vein wall and resulted in less post-procedural pain and 
ulceration (Vuylsteke et al. 2009). 
Based on a similar mechanism, coated laser fibres have recently been introduced in order to try and 
reduce post-procedural pain by preventing contact with the vein wall and thus reducing vein wall 
perforations. The coat consists of either a metallic (gold) or ceramic material around the energy 
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emitting area of the laser fibre. Preliminary data have shown reduced post-procedural pain scores 
with the gold coated 600um fibre in comparison to a 980nm bare tip laser and scores were similar to 
those following segmental RFA (Kabnick 2009; Kabnick 2010). The manufacturers suggest that the 
coating of the fibre introduces a divergent angle, indirectly increasing the diameter of the fibre. This 
reduces the power density by up to 56%, resulting in coagulation, rather than a cutting mechanism, 
thus reducing the pain experienced. Results of a pilot study of 20 patients suggested that pain 
following ablation with the gold coated 980nm laser from AngioDynamics resulted in significantly 
less pain (rated a mean average of 0.96 out of 10) compared with a 980nm bare laser fibre (on 
average 1.87 out of 10) at 72 hours post procedure (Kabnick 2009). Results from larger, independent 
studies are awaited and the devices are not currently in widespread use in the UK.  
1.7.7.3 Endovenous Laser: Radial Fibres 
 
Early lasers consisted of forward firing laser beams, however, the 1470nm ELVeS® Radial laser from 
Biolitec emits a beam radially and is thought to have a more uniform heating effect on the vein 
wall. It is proposed that this leads to fewer vein wall perforations and results in less post-operative 
pain and bruising and would, therefore, provide superior treatment to traditional forward firing laser 
fibres (Almeida et al. 2009a). It is proposed that the unique delivery of the energy will allow closure 
of veins at significantly lower LEEDs and, therefore, reduce complications such as post-procedural 
pain, bruising and paraesthesia and potentially negate the need for tumescent anaesthesia.  To date 
there are few published studies. In 2009 Almeida et al found the 1470nm radial firing laser to result 
in reduced pain in comparison with historical controls treated with a 980nm  bare fibre laser 
(Almeida et al. 2009a). In addition the mechanical effects of the tumescent anaesthesia are 
proposed to have resulted in a reduction in the vein diameter and, therefore, more efficient delivery 
of energy to the vein, which resulted in 100% primary occlusion rates at 3 months, in comparison to 
87% in those who had no tumescent anaesthesia. The authors concluded that using an energy 
delivery of 30j/cm at a power of 5 watts with tumescent anaesthesia yielded excellent occlusion 
rates with minimal side effects (Almeida et al. 2009a). The only published RCT comparing the 980nm 
bare fibre laser with the 1470 nm radial laser found significant reductions in post-procedural pain 
and improvements in the VCSS scores at 1 month in the patients treated with the 1470nm radial 
laser (Doganci et al. 2010). Reductions in post-procedural pain and bruising are advantages of using a 
longer wavelength. However, a further non-randomised study comparing a 1470nm bare fibre to the 
1470nm radial fibre reported significant reductions in post-procedural pain and ecchymosis with the 
radial fibre with no difference in closure rates (Schwarz et al. 2010), providing evidence that the 
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radial beam is likely to be superior to forward firing lasers.  Currently there is no data available about 
long term outcomes and because the precise mechanism of heat transfer is incompletely 
understood, the necessary degree of destruction of the outer layers of the vein wall is unknown. 
Further large studies are required to support the efficacy of the 1470nm radial laser over forward 
firing lasers in the future.  
1.7.7.4 VNUS Closure FASTTM Radiofrequency Ablation 
 
The initial technique using radiofrequency ablation was described by Goldman in 2000 (Goldman 
2000).  The original VNUS ClosureTM radiofrequency catheter consisted of electrodes that remained 
in contact with the vein wall. The heating effect was achieved secondary to resistance of the tissues 
in the vein wall which allowed the flow of current in order to reach a target temperature of 85oC. 
The ClosurePLUSTM device resulted in successful vein occlusion with a favourable side effect profile, 
but the long procedure times meant that it was less appealing than laser catheters. This was 
addressed by the development of the VNUS ClosureFASTTM segmental ablation catheter. The 
technique involves the insertion of a 7cm radiofrequency heating element into the GSV using the 
seldinger technique under ultrasound guidance.  The probe is positioned 2cm from the SFJ and the 
GSV is segmentally ablated with the catheter withdrawn by 6.5 cm after each treatment to allow a 
0.5cm overlap. The temperature is maintained at 120o and controlled by a feedback system 
measuring venous wall temperature and impedance. The radiofrequency probe powered by a 
bipolar generator heats the vein wall directly, resulting in damage to the endothelium and 
obliteration of the vein. Results following VNUS ClosureFASTTM are excellent, with a series of 252 
veins treated with 50% of patients returning to normal activity the same day and occlusion rates at 6 
months of 99.6% (Proebstle et al. 2008). Initial results of the early ClosurePLUSTM device which 
operated at 85oC showed higher re-canalisation and re-treatment rates compared with laser 
treatment, suggesting that injury to the intima and media alone may be insufficient for long term 
success (Luebke et al. 2008). Initial results from the ClosureFASTTM appear promising, but longer 
term follow-up data are still awaited. The technique of endovenous ablation with the VNUS 
ClosureFASTTM catheter is illustrated in Figure 10. 
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a. Identification of GSV    b. Cannulation of GSV    c.  Insertion of sheath and catheter 
 
 
                 
f.Tumescent anaesthesia e.  Extrinsic compression to GSV on activation of RFA device 
 
Figure 10. Endovenous thermal ablation 
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1.7.7.5 Radiofrequency Induced ThermoTherapy (RFiTT) 
 
The Radiofrequency Induced Thermotherapy (RFiTT) device produced by Olympus (RFiTT, Celon, AG, 
Berlin) is an alternative radiofrequency device to the VNUS® ClosureFASTTM segmental ablation 
catheter. RFiTT consists of a bipolar catheter with two cylindrical electrodes arranged in an in-line 
configuration, separated by an insulator. In a similar fashion to the original VNUS Closure device, 
RFiTT relies on the resistance of the vein wall to produce thermal energy.  The catheter heats the 
vein wall to 85-95oC using a high frequency current (470kHz) at 18-20 watts when activated and 
venous impedance is continually monitored. This is interpreted by the operator by means of an 
acoustic signal and the energy delivered to the vein wall is dependent on the pull back speed. The 
advantages of the RFiTT device include being able to instantly stop heating, preventing further pain 
and injury to the patient if tumescent anaesthesia is inadequate. In addition the device immediately 
cuts out when contact with the vein wall is lost, meaning that it is impossible to treat if the catheter 
is misplaced outside the vein, or if the catheter is in the sheath. This feature also reduces the risk of 
overtreatment and skin burns.  A multicentre study of 462 patients (672 limbs) reported occlusion 
rates of 98.4% at 6 months and a comparable side effects profile to other laser and radiofrequency 
devices (Braithwaite 2010). Although tumescent anaesthesia is not essential when using RFiTT, the 
incidence of saphenous neuralgia is increased in the absence of tumescence (Braithwaite 2010). A 
randomised trial compared RFiTT with a 980nm endovenous laser. The trial had 2 separate arms for 
patients with bilateral and unilateral disease. In patients with bilateral GSV incompetence there was 
less post-operative pain and bruising in the leg treated with RFiTT compared with the leg treated 
with laser therapy (BLARA trial)(Goode et al. 2010). However, no significant differences were seen in 
patients undergoing unilateral varicose vein treatment (ULARA trial)(Goode et al. 2010). Although 
the popularity of this new device is increasing, follow up data are limited (Braithwaite et al. 2007; 
Hnatek et al. 2007; Goode et al. 2010).   
1.7.7.6 Steam 
 
In 2009 Steam was proposed as a new endovenous thermal ablation treatment for varicose veins. 
The device from GUTMANN MD GmbH (Gutman Medical Devices (GutmannMDGmbH) 2010) 
involves the injection of pressurised water into a 0.1mm tube. This is heated using an electrical 
current to produce bursts of steam at 150oC, which are delivered to the intima of the vein via a 
catheter, with each pulse thought to deliver approximately 65 joules of energy. Proposed 
advantages include the rapid production of steam leading to faster treatment times, on contact with 
the vein wall steam rapidly condenses to water, reducing the potential for side effects and 
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complications and steam can also be used to treat superficial veins and tortuous veins that would be 
unsuitable for treatment with laser or radiofrequency. A pilot study of 20 limbs in 19 patients found 
that 13 veins were completely occluded at 6 months and 7 veins had very small segments of re-
canalization (Van den Bos et al. 2010). There are no published clinical trials using the device to date, 
however, an ongoing randomised clinical trial in France is reported to have promising results at 6 
months in comparison with those of laser ablation.  
1.7.7.7 Outcomes Following Endovenous Thermal Ablation Procedures 
 
Recently published trials comparing traditional surgery and EVLA by Rasmussen et al and Darwood et 
al (Rasmussen et al. 2007; Darwood et al. 2008) showed that EVLA treatments lead to significant 
improvements in quality of life post-operatively compared with baseline scores, that were 
comparable to those achieved with traditional surgery.  However, patients reported less post-
operative pain (Rasmussen et al. 2007) and were able to return to work earlier following EVLA 
(Darwood et al. 2008). Despite perceived advantages in early outcomes with EVLA, data from 
randomised trials comparing EVLA with surgery have been variable, and unable to demonstrate any 
superiority in clinical improvements and quality of life scores at 1 or 2 years post-intervention with 
EVLA compared to surgery (Christenson et al. 2010; Rasmussen et al. 2010). Clinical trials comparing 
the original VNUS ClosurePLUS device with traditional surgery have reported favourable outcomes of 
minimal pain and a more rapid return to work with RFA compared with surgery (Lurie et al. 2003; 
Subramonia et al. 2009b). Medium term data at 2 years have found similar recurrence rates 
compared with traditional surgery (Lurie et al. 2005; Elkaffas et al. 2010), although improvements in 
quality of life scores favoured the RFA group (Lurie et al. 2005).  Outcome data following truncal vein 
ablation with the VNUS ClosureFAST devices is scarce to date. In 2008, Proebstle et al reported 
occlusion rates of 99.6% at 12 months using VNUSClosureFASTTM with 70% of patients experiencing 
little or no post-operative pain and over 50% returning to work the following day (Proebstle et al. 
2008).  Several non-randomised studies and retrospective analyses comparing EVLA and RFA have 
been published.  Almeida et al reported marginally superior primary occlusion rates with EVLA 
compared with RFA (98% vs 94% respectively) (Almeida et al. 2006).  A non-randomised trial 
published by Puggoni et al showed initial occlusion rates of 94% and 91% for EVLA and RFA 
respectively at 1 month, with no significant differences in complication rates (Puggioni et al. 2005). 
Randomised trials comparing the older 810nm laser and VNUS ClosurePLUS reported that bruising 
and VCSS scores were lower with RFA compared with EVLA, however no differences were observed 
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at 1 month. However, at 1 year, significantly higher rates of re-canalization were observed in the RFA 
group (Roddy 2010).  
To date the only randomised trial comparing laser with VNUSClosureFASTTM radiofrequency is the 
RECOVERY Trial sponsored by VNUS Medical Technologies. VNUSClosureFASTTM has been shown to 
result in significantly less post-operative discomfort and bruising at 48 hrs, 1 week and 2 weeks 
compared with 980nm laser in 68 patients, but there were no differences at 1 month and longer 
term outcomes were not investigated (Almeida et al. 2009b). Both EVLA and RFA treatments have 
been shown to significantly improve disease specific quality of life as well as clinical disease severity 
scores following treatment (Lurie et al. 2003; Mekako et al. 2006; Rasmussen et al. 2007; Darwood 
et al. 2008). Improvements in quality of life following endovenous ablation were greater than those 
following traditional surgery in some studies (Lurie et al. 2003; Mekako et al. 2006). Although both 
endovenous techniques are safe and effective, the lack of data from randomised clinical trials 
directly comparing EVLA and RFA means that choosing between treatments on the basis of clinical 
success, patient satisfaction and cost effectiveness is extremely difficult.  At present, decisions are 
made on clinician preference and local availability and resources.  Data suggested that RFA may lead 
to less post-operative pain and quicker recovery times than EVLA as the lower temperatures and the 
pull back method used lead to fewer vein wall perforations and subsequently less pain and bruising 
(Proebstle et al. 2002a; Proebstle et al. 2004; Kabnick 2006; Roth 2007). However, studies have been 
insufficiently powered and subject to significant conflicts of interest.    
1.7.7.8 Complications following Endovenous Thermal Ablation Procedures 
 
Complications following EVLA and RFA occur infrequently. Three systematic reviews of endovenous 
laser treatment have been published (Mundy et al. 2005; Darwood et al. 2009; Van den Bos et al. 
2009b) detailing frequently occurring complications encountered, the commonest being superficial 
thrombophlebitis occurring in up to 25% of cases. Temporary paraesthesia occurs in approximately 
4-11% of patients in the majority of studies but has been reported to be as high as 22% (Van den Bos 
et al. 2009b). The use of adequate tumescent anaesthesia has been shown to result in lower 
incidences of saphenous nerve paraesthesia. DVT, skin burns  and other neurological injuries are rare 
and occur in approximately 1% of patients(Van den Bos et al. 2009b). Unusual cases of arteriovenous 
fistulae following laser ablation, and device related complications where parts of laser catheters 
have been left inside patients have been reported but are extremely uncommon(Van den Bos et al. 
2009b). Hyperpigmentation as a result of thermal damage to the skin can lead to undesirable 
cosmetic outcomes, but can be greatly reduced with appropriate tumescent anaesthesia and most 
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manufacturers advise not to treat veins within 1cm of the skin due to the increased risk of 
pigmentation and skin burns.  
There are few reported studies detailing complications following VNUS ClosureFASTTM, and the 
majority of evidence in the published literature relates to the Closure PLUS device. Complications are 
infrequent and similar to those experienced with EVLA, however, the incidence of thrombophlebitis 
is reportedly lower on average than that experienced following EVLA, (approx 2.9%)(Gohel et al. 
2009b). Skin burns and DVT remain low (<1%) and comparable to laser ablation.  
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1.8 Aims of the Thesis 
 
In the last decade the introduction of minimally invasive endovenous therapies has changed the 
management of varicose veins. In particular, the use of endovenous thermal ablation is increasing in 
popularity. In view of the current published literature, a number of questions remain unanswered 
regarding the current role of endovenous thermal ablation treatments. The current use of these new 
procedures amongst surgeons in the UK is unknown, in addition, patient preference regarding 
endovenous treatment modalities for varicose veins has not been investigated. To date, limited 
evidence is available regarding patient reported outcomes following endovenous ablation 
modalities, particularly with regard to direct comparisons between laser and radiofrequency 
ablation and indeed, the choice of outcome measures for use in venous disease is a contentious 
issue.  
Based on the current literature the following aims and objectives have been identified and will be 
addressed in this thesis. 
 Investigate of the current use of endovenous thermal ablation amongst consultant Vascular 
Surgeons in the United Kingdom using an online web based questionnaire of current 
practice. 
 
 Evaluation of patient knowledge and opinions of varicose vein treatments and their 
preferences regarding different therapies by means of an anonymous questionnaire in a 
vascular outpatient clinic at Charing Cross Hospital. 
 
 Perform a comparison of RFA and EVLA, by designing, setting up, and conducting a 
randomised clinical trial concentrating on the investigation of early patient reported 
outcome measures, including post-procedural pain and quality of life. Prior to this conduct a 
pilot study to investigate post-procedural pain following RFA and EVLA. 
 
 Evaluate the commonly used outcome measures currently available for the assessment of 
venous disease including the use of Venous Severity Scoring, digital photoplethysmography 
to measure venous refill times, and generic and disease specific quality of life 
questionnaires. 
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2 Chapter 2. The Use of Endovenous Thermal 
Ablation Procedures in the United Kingdom: A 
Consultant Survey 
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2.1 Introduction and Review of the Literature 
 
Recent technological advances in the treatment of varicose veins have meant that specialists are 
faced with an ever increasing choice of treatment modalities for varicose veins. Until the last decade 
surgical treatment consisting of saphenofemoral disconnection and stripping of the great or small 
saphenous vein with phlebectomies to treat varicosities was the gold standard of treatment. 
Although a relatively effective treatment, problems included wound complications, high recurrence 
rates (Tenbrook et al. 2004; Winterborn et al. 2004; Allegra et al. 2007) and significant patient 
dissatisfaction (Davies et al. 1995; Campbell et al. 2003).  A survey of members of the Vascular 
Society conducted in 1999 showed that traditional surgery was the most popular treatment for 
primary and recurrent great and small saphenous vein reflux, although sclerotherapy was used 
selectively by 60% of surgeons (Lees et al. 1999). In recent years, minimally invasive endovenous 
techniques have become increasingly popular in the United Kingdom as an alternative to traditional 
surgery. Postal surveys conducted in 2005 showed that endovenous treatments, including laser and 
radiofrequency ablation were used by around 30% of surgeons in the UK (Lindsey et al. 2006). 
Interestingly, over 50% of surgeons reported that local referral guidelines restricted the treatment of 
varicose veins and in the majority of cases, the use of endovenous techniques was restricted to 
private practice (Lindsey et al. 2006; Winterborn et al. 2008). Foam sclerotherapy was reported to 
have been used by 20-42% of surgeons in postal surveys conducted in 2006 and 2007(Lindsey et al. 
2006; O'Hare et al. 2007; Winterborn et al. 2008). 
More recent surveys have suggested an increase in the use of endovenous thermal ablation 
therapies, particularly in the private sector (Edwards et al. 2009), however, traditional surgery 
remained the most frequently performed procedure.  
In this chapter the use of endovenous therapies for varicose veins by consultant vascular surgeons in 
the UK was evaluated by means of an online questionnaire survey in order to establish trends in 
current practice. 
 
2.2 Methods 
 
A questionnaire consisting of 16 multiple choice questions was designed and an online survey was 
created using the academic online survey website Bristol Online Surveys (BOS) 
(www.survey.bis.ac.uk). Consultant members of the Vascular Society of Great Britain and Ireland 
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(VSGBI) with published email addresses in the Vascular Society handbook 2008 were invited to 
participate by email. The questions related to: routine treatments offered to patients with varicose 
veins; use of venous duplex scanning; indications for re-intervention; anaesthesia and the location in 
which the treatment was performed; factors influencing the decision regarding treatment; the use of 
post-operative compression and thromboprophylaxis, restrictions imposed by primary care trusts 
regarding treatment of varicose veins and the nature of treatments offered in the private sector (see 
Appendix 1). All responses were anonymous and all participants were sent one reminder email in an 
attempt to maximise responses. Where responses were incomplete, the number of responses 
received for that particular question is given as the denominator. 
 
2.3 Results 
 
A total of 352 Consultant members of the VSGBI were invited to complete the survey. There were 
108 responses, of which 80 were complete (31% response).  
2.3.1 Current Use of Endovenous Treatments 
 
In patients deemed suitable for all treatment modalities 60/108 (55.6%) of surgeons would perform 
traditional surgery, whereas 24/108 (22.2%) preferred EVLA. Radiofrequency ablation (6/108) and 
foam sclerotherapy (11/108) were used relatively less frequently (5.5% and 10.2% respectively). Of 
the surgeons offering endovenous treatment, half performed concomitant phlebectomies for 
varicosities and half performed subsequent phlebectomy or sclerotherapy for varicosities, if 
required. Surgeons were also asked specifically about the treatments they would routinely offer for 
primary great and small saphenous vein reflux. 
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Values in parentheses are raw data 
Figure 11.  First line treatment of primary great saphenous vein reflux 
 
 
 
Values in parentheses are raw data 
Figure 12. First line treatment of primary small saphenous vein reflux. 
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Traditional surgery remained the commonest treatment for primary GSV (Figure 11) and SSV (Figure 
12) reflux. Interestingly, although 77/108 (71.3%) of surgeons stated that patient preference was the 
most important factor when deciding which treatment to offer, (more important than time taken for 
the procedure, cost or space considerations), it is unclear how many surgeons informed patients of 
all potential treatment options and the risks and benefits of individual treatment modalities.  
2.3.2 Anaesthesia 
 
Local/ tumescent anaesthesia alone was used by 36/51 (70.6%) of surgeons performing endovenous 
thermal ablation treatments, whereas 1 surgeon used regional anaesthesia and the remaining 14/51 
(27.5%) preferred general anaesthesia. Almost half of respondents reported performing concomitant 
phlebectomy with endothermal treatments (25/51, 49.0%) with the intention of completing 
treatment in a single hospital visit (Figure 13). 
 
Values in parentheses are raw data 
Figure 13. Anaesthesia used for endovenous thermal ablation procedures 
 
2.3.3 Treatment Location 
 
Endothermal treatments were performed in an operating theatre by 30/51 (58.8%) of surgeons, and 
the remainder conducted treatments in an adapted outpatient clinic or outpatient theatre. 
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2.3.4 Thromboprophylaxis 
 
A Total of 66/98 (67%) of respondents prescribed subcutaneous heparin or low molecular weight 
heparin and 42/98 (43%) advised Thrombo-embolic deterrent stockings (TEDS). Of those prescribing 
subcutaneous heparin, 42/66 (64%) would use a single dose only, 18/66 (27%) would prescribe it for 
the duration of their inpatient stay and two surgeons would routinely advise it for 1 week. Two 
surgeons prescribed subcutaneous heparin for bilateral or recurrent varicose veins only and many 
commented that they may alter thromboprophylaxis based on the individual risk of the patient. Four 
surgeons stated they would not use pharmacoprophylaxis for patients undergoing foam 
sclerotherapy, but would for endovenous thermal ablation or traditional surgery. A total of 16/98 
(16%) did not routinely prescribe any form of thromboprophylaxis, of these 6/16 (38%) were 
performing surgery and foam sclerotherapy only, 6/16 (38%) were performing all treatments, one 
was performing EVLA and foam sclerotherapy and 3/16 (19%) were performing surgery only.  
2.3.5 Compression 
 
Post-intervention compression was most frequently recommended for 7-14 days by 37% of surgeons 
(Figure 14), although 17% of surgeons continued to use compression for 6 weeks.  
 
Figure 14. Duration of compression following treatment 
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Over half of the surgeons 54/101 (53.4%) applied compression bandaging immediately following the 
procedure, which was replaced with TED stockings (<18mmHg) prior to discharge (usually within 24 
hours), whereas 6/101 (5.9%) replaced the bandaging with TEDS after 24 hours. Some surgeons 
14/101 (13.8%) did not use elastic compression hosiery and preferred bandaging, usually crepe, 
Pannelast® (Vernon Carus, Preston) or Coban™ (3M™, Berkshire). There was considerable variation 
in regimens and duration of compression as illustrated in Figure 15. 
 
 
Values in parentheses are raw data 
Figure 15. Type of compression used following treatment 
 
2.3.6 Post-Procedural Management 
 
Following traditional surgery, only 2/108 (1.9%) surgeons would routinely perform colour duplex, 
whereas 30/48 (62.5%) would investigate patients with colour duplex after EVLT or RFA and 33/71 
(46.5%) would do so following foam sclerotherapy. The commonest stated reason for post-operative 
duplex was to ensure successful ablation of the treated vein 29/38 (76.3%) following EVLA, 17/21 
(81.0%) following RFA and 29/44 (65.9%) following foam sclerotherapy. Of the surgeons who 
performed colour duplex following treatment, 10/51 (19.6%) would re-intervene following 
endothermal treatments and 14/68 (20.6%) following sclerotherapy, if a patient had residual truncal 
incompetence even in the absence of clinical symptoms. No surgeons reported they would offer 
additional intervention in the absence of clinical symptoms following traditional surgery. 
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2.3.7 Restrictions in the Availability of Varicose Vein Treatment 
 
Local restrictions in the provision of varicose vein treatment were reported by 48/108 (48%) of 
respondents. Restrictions were imposed on 28/108 (25.9%) of surgeons offering open surgery and 
23/80 (28.8%) of those offering foam sclerotherapy, however, 48/80 (60.0%), and 48/61 (78.7%) of 
surgeons reported restrictions regarding the use of EVLT and RFA respectively. The lack of funding 
for endovenous equipment was stated by many surgeons 28/80 (35%) as the reason for not 
performing endovenous procedures, although a lack of theatre time or space, the lack of a laser 
approved room and the fact that traditional surgery was cheaper than laser or radiofrequency were 
also given as reasons why endovenous procedures were not offered. Further details of reasons given 
by surgeons for not offering treatments are reported in (Table 4). When asked about the treatment 
of private patients, 33/108 (30.6%) of surgeons stated that they would advise venous treatments 
that they were unable to offer in their NHS practice.  
 
 
Figure 16. Reported rationing of different varicose vein therapies 
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Table 4. Reasons given by surgeons for restrictions in varicose vein treatments offered. 
 
2.4 Discussion 
 
This online survey of Consultant Vascular Surgeons in the UK conducted in 2008 showed that 
traditional surgery was still the most widely offered treatment for varicose veins, despite the 
apparent increasing popularity of endovenous procedures. These findings mirrored the results from 
a recent postal survey of Consultants and vascular trainees published in 2008, which reported the 
majority (96%) of surgeons were performing conventional surgery, 27% were offering foam 
sclerotherapy, 19% were offering EVLT and 3% were offering RFA to NHS patients (Winterborn et al. 
2008) and indeed showed that the most popular treatment has not changed since 1999 (Lees et al. 
1999). However, these data did show an increase in the use of endovenous therapies, compared 
with previous surveys (Lindsey et al. 2006; O'Hare et al. 2007), suggesting a slow movement towards 
newer techniques. Many surgeons who performed endovenous treatments favoured local 
anaesthetic and a significant number performed treatments on an outpatient basis, which is likely to 
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be more cost effective than performing traditional surgery under general anaesthesia (Gohel et al. 
2008).  The lack of uptake of endovenous procedures may be due to the high initial costs of 
endovenous equipment and training in endovenous techniques, at a time when varicose vein 
surgery is subject to increasing scrutiny and significant funding restrictions by a large number of 
healthcare providers (Nasr et al. 2008; Winterborn et al. 2008). At present, both laser and 
radiofrequency equipment are readily available, but the cost of the generator and catheters vary. 
Undoubtedly, the cost effectiveness of new therapies will be under great scrutiny prior to 
widespread use. 
At present consensus is lacking regarding the nature and duration of post-operative compression 
that should be applied following surgical or endovenous procedures. Evidence suggests that TEDS 
are adequate following foam Sclerotherapy (Partsch et al. 2008), and indeed, results from a recent 
randomised trial found no differences in outcomes or complications in the presence or absence of 
compression following foam Sclerotherapy (Hamel-Desnos et al. 2010).  A randomised trial 
investigating the use of compression stockings for 4 weeks following the application of compression 
bandaging after varicose vein stripping found no advantage to continued compression after 72 hours 
versus no compression (Houtermans-Auckel et al. 2009).  However, the most appropriate use of 
compression following endovenous thermal ablation has not been fully investigated and despite 
recently published evidence regarding traditional surgery and foam sclerotherapy, post-procedural 
compression varies widely throughout the country (Partsch et al. 2008). This study highlighted the 
wide variations in practices in terms of thromboprophylaxis and the use of duplex imaging. This was 
also reported in 1999, when only 27% of surgeons prescribed routine thromboprophylaxis (Lees et 
al. 1999) in comparison to 84% in this survey. Interestingly, post-operative duplex use and treatment 
of residual truncal reflux varied noticeably between traditional and endovenous treatments, with 
many surgeons performing routine post-operative duplex scans and treating asymptomatic truncal 
reflux. This may, in part be due to the need to establish the efficacy of these new treatments, 
however, with evidence to suggest that truncal reflux may not correlate with symptoms (Bradbury et 
al. 1999; Theivacumar et al. 2008b), this practice may become less widespread in the future. As the 
prevalence of varicose veins is high, it is likely that patient demand for treatment will remain high for 
years to come. Each treatment modality has advantages and disadvantages, but long term outcomes 
are unclear. This confusion is demonstrated by the huge variability in treatment modality, type of 
anaesthetic, location of therapy and post-operative management in this survey. With patient choice 
regarding treatment becoming ever more important, further evaluation of patient preferences 
regarding treatment strategy is required. Despite the introduction of minimally invasive treatments 
for varicose veins, traditional surgery remains the most frequently performed treatment for varicose 
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veins in the United Kingdom, and in Europe (Perrin et al. 2003; www.e-dendrite.com. 2009). Of the 
surgeons performing endovenous treatments, peri-operative management varies greatly. It is clear 
that further clinical trials are needed to clarify some of these issues and guide clinical practice. 
Despite reminder e-mails, the response rate in this survey was disappointingly low. Response rates 
from postal surveys in the UK are extremely variable. Postal surveys sent to both consultants and 
vascular trainees had  significantly higher response rates (Lindsey et al. 2006; Winterborn et al. 
2008), but other postal surveys achieved similarly poor responses (Jones et al. 2006). Our response 
rate may be due to inaccurate or unavailable e-mail addresses, but may also reflect a reluctance to 
engage with online surveys by Consultant Vascular Surgeons. Indeed, responses to previous email 
surveys appear to have had a poorer response rate compared with postal surveys amongst vascular 
surgeons (Nasr et al. 2008). Research into response rates comparing postal surveys with email/ web 
surveys sent to medical professionals confirms that response rates are frequently lower from 
electronic surveys, however, they have been shown to result in a more rapid response time and at a 
lower cost compared with postal surveys (Raziano et al. 2001; McMahon et al. 2003; Beebe et al. 
2007). The author acknowledges that these limitations may mean that the findings are not truly 
representative of the entire United Kingdom practice, with enthusiastic advocates for endovenous 
therapies, or more computer literate surgeons potentially being more likely to respond.  
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3 Chapter 3. The Patient’s Perception of Venous 
Disease and Patient Preferences in the 
Management of Varicose Veins. 
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3.1 Introduction 
 
The allocation of NHS resources for the treatment of varicose veins is controversial, with many 
healthcare trusts refusing to fund treatment for uncomplicated varicose veins (see chapter 2). In 
2008-2009 36,000 procedures were performed in the UK for varicose veins 
(http://www.hesonline.nhs.uk), with the majority of patients treated with traditional surgery 
(Lindsey et al. 2006; O'Hare et al. 2007; Winterborn et al. 2008). However, traditional surgery may 
be associated with significant complications, high recurrence rates (Winterborn et al. 2004) and 
considerable patient dissatisfaction (Davies et al. 1995; Campbell et al. 2003). Patients seek 
treatment for a number of reasons some of which are purely cosmetic, but most report a wide 
variety of physical symptoms and some patients may be concerned about venous complications or 
general concerns about their future (Campbell et al. 2006). Due to the high prevalence of varicose 
veins and the variety of symptoms reported, proving a causal relationship between symptoms and 
varicose veins remains difficult (Lee et al. 2003; Campbell et al. 2007). It has been suggested that 
symptoms are likely to relate to the presence of venous disease rather than actual varicosities (Kurz 
et al. 2001). The unequivocal clinical benefits and cost effectiveness of treating both complicated and 
uncomplicated varicose veins have been well documented (Barwell et al. 2004; Ratcliffe et al. 2006; 
Gohel et al. 2007b). The introduction of minimally invasive endovenous techniques offers the 
prospect of treatment under local anaesthetic, as an outpatient or office based procedure with 
quicker treatment times and rapid return to normal activities. Early outcomes following endovenous 
ablation are promising, meaning that choosing between different treatment modalities has become 
increasingly difficult. Consideration of patient preferences may help decide which treatments are 
best for individual patients. In the last decade patient preference has become an increasingly 
important consideration in all areas of medicine and surgery. The views of the patient are now 
considered essential to achieve high quality healthcare (Black et al. 2009), and national surveys of 
patients’ views of NHS healthcare have been introduced in recent years. Patient preference in the 
management of cardiovascular disease has been evaluated for over a decade. Early surveys explored 
patient preference regarding coronary re-vascularisation (Hornberger et al. 1999) and more recently 
with the introduction of endovascular aneurysm repair (EVAR), the patient’s perspective of 
minimally invasive versus open surgery has been investigated (Winterborn et al. 2009; Reise et al. 
2010). With so many different therapies to choose from, the importance of patient preference in the 
management of varicose veins cannot be underestimated. It has been shown that most patients 
wish to have an active role in their care and that patient involvement is important in order to ensure  
sustainable, effective and efficient healthcare (Coulter 2007).  
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The aim of this study was to evaluate patient knowledge of varicose vein treatments and assess the 
factors that patients considered to be important when contemplating therapy.  
 
3.2 Methods 
 
General practitioner referral letters sent to one consultant surgeon at a tertiary referral centre were 
scrutinised to identify patients who had been referred with symptomatic varicose veins. Consecutive 
patients with primary symptomatic varicose veins were invited to complete an anonymous 
questionnaire prior to their consultation with the Vascular Surgeon. Questions related to 
occupation, physical symptoms, patient knowledge of existing treatments, concerns about 
complications and recurrence, preferred treatment options and factors that might influence 
decisions regarding treatment (Appendix 2). No information was given to patients prior to 
completing the survey. Where questions were not completed by every participant, the number of 
complete responses is shown as the denominator. 
 
3.3 Results 
 
Over a 6 month period, 111 patients were invited to complete the questionnaire. A total of 83 (75%) 
complete and 28 partially complete responses were received. A total of 80/109 (73%) of patients 
were female, 2 patients did not state their gender. 43/108 (40%) were full time employees, 19/108 
(17%) were part time employees and 46/108 (43%) were not employed. Ages ranged between 18 
and 83 years, with the majority of patients 79/111 (72%) aged between 18 and 60 years. Reported 
co-morbidities included: hypertension 18/111 (16%); previous DVT 8/111 (7%); asthma (5%); 
diabetes 4/111 (4%), epilepsy 2/111(2%); chronic obstructive pulmonary disease (COPD) 2/111(2%); 
ischemic heart disease 2/111(2%) and transient ischemic attack (TIAs) 1/111 (1%). The remaining 
61% reported no co-morbidities.  
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3.3.1 Reasons for Seeking Treatment 
 
Moderate or severe pain/ discomfort was reported by 77/103 (75%) (Figure 17) and the appearance 
of varicosities moderately or severely affected 75/97 (77%) of patients.  
 
Figure 17. Pre-operative concerns of patients presenting with varicose veins 
 
When asked “Which outcome following treatment is most important to you”, answers varied greatly 
between improvement of physical symptoms, reduction in complications, improved cosmesis and a 
combination of the above (Figure 18). 
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There was no apparent trend in the symptoms reported and employment status. The majority of 
patients 54/96 (56%) were not concerned about taking time off work for treatment. Of these 35/54 
(65%) were not employed, 11/54 (20%) were employed full time and 8/54 (15%) were employed 
part time. However, discomfort after treatment and recurrence of varicose veins were of great 
concern to many patients (Figure 19). 
 
Figure 19. Patient concerns regarding varicose vein treatment 
 
3.3.2 Treatment Awareness 
 
The majority of patients were aware of surgery (89/103, 89%), although far fewer were aware of 
endovenous techniques. Of those who were aware of additional treatments, the most frequently 
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Figure 20. Patient awareness of different treatment modalities 
 
3.3.3 Treatment Preferences 
 
Most patients 74/103 (72%) stated that they did not know enough about the different treatments to 
express a preference. However, 24/103 (23%) expressed a preference for endovenous treatments 
over surgery, (either EVLA, RFA or Sclerotherapy) and of the endovenous treatments, laser was the 
most popular (Figure 21). There were no apparent trends in treatment preference according to 
occupational status, as 10/43 (23%) of patients employed full time, 4/18(22%) of those employed 
part time and 10/41(24%) of those not employed expressed a preference for endovenous 
treatments respectively. 
 
Values in parentheses are raw data 
Figure 21. Preferred treatment modalities of surveyed patients  
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3.3.4 Location and Anaesthesia 
 
Although 23/102 (22%) of patients expressed a preference for office based/outpatient treatment, 
65/102 (64%) had no location preference. In response to the statements “I would prefer my 
treatment to be carried out in a single visit rather than several separate visits” and “I would prefer 
my treatment to be carried out under local anaesthetic rather than general anaesthetic”, the 
majority expressed a preference for a single visit and for local anaesthetic (Table 5). A third 30/90 
stated that the type of anaesthetic would have no influence on their choice of treatment. 
 Agree 
Strongly 
Agree 
Moderately 
I don’t 
mind 
Disagree 
Moderately 
Disagree 
Strongly 
Patients preferring a single visit for 
treatment (n= 93) 
46% 25% 27% 2% 0% 
Patients preferring treatment under  
local anaesthetic (n=92) 
37% 26% 31% 4% 2% 
 
Table 5. Patient preference regarding treatment strategy and anaesthesia 
 
3.3.5 Factors Affecting the Patient’s Decision 
 
Some 74/92 (80%) stated that their treatment decision would be influenced by the opinion of their 
Vascular Surgeon.  Regarding the number of visits required for treatment, 30/88 (34%) of patients 
stated that it would have no effect on their choice of treatment, 29/88 (33%) said that it may 
influence their choice of treatment and only 9/88 (10%) said it would definitely affect their choice of 
treatment. Similarly 30/90 (33%) patients stated that the type of anaesthesia would have no effect 
on their choice of treatment, with only 13/90 (14%) stating that it would definitely affect their choice 
of treatment.  
Although some patients expressed preferences about anaesthesia and the number of visits required, 
these were far less likely to influence decisions about treatments. Interestingly, previous experience 
of varicose vein treatment was reported to have no influence on decisions regarding future therapy 
by nearly half of patients 38/83 (46%). Furthermore, most patients stated that what they had read in 
magazines or on the internet would have no influence on their treatment decision (Figure 22). 
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 Figure 22. Factors influencing a patient’s decision regarding treatment 
 
3.4 Discussion 
 
This study demonstrated that most patients referred with varicose veins have little knowledge of the 
available treatment options. Most were aware of surgery, but far fewer were aware of minimally 
invasive procedures. The findings indicated that the majority of patients rely strongly on advice and 
opinions of the Vascular Surgeon at the initial consultation. Interestingly, the majority of patients 
stated that information in magazines, internet or in the media would have no influence on their 
decision regarding treatment. Most respondents expressed some preference towards having 
treatment under local anaesthetic, but also would prefer treatment to be completed in a single visit. 
Although performing phlebectomy or foam sclerotherapy under local anaesthetic at the time of 
treating the truncal vein is feasible in many patients (Almeida et al. 2008), for those with bilateral 
disease and large numbers of varicosities it may be severely uncomfortable or impossible. Patients 
appeared to be divided as to which factors were more important to them. Some patients do have 
specific treatment preferences, which may be related to their occupation, concerns regarding 
cosmesis or previous experience. Understandably, the prospect of minimal discomfort and rapid 
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return to normal activities is attractive to all patients. Previous surveys of patient preferences in the 
United Kingdom published in 1998 were also conducted in patients with varicose veins prior to their 
initial consultation. Results suggested that 38% of patients would be in favour of foam sclerotherapy 
because of not having to take time off work and 31% were in favour of avoiding a general 
anaesthetic. Paradoxically 80% were in favour of surgery due to a lower recurrence rate and overall 
63% preferred surgery over sclerotherapy for the reasons above. The majority of patients also 
expressed a preference for a single procedure (Campbell et al. 1998). Similarly, patient preference 
surveys in patients with abdominal aortic aneurysm also found that prior to being provided with 
information, only 23% of patients were willing to express a treatment preference, however, 
following a comprehensive information pack, almost half in one study (Reise et al. 2010) and 84% in 
another (Winterborn et al. 2009) were in favour of minimally invasive treatment options. 
Interestingly, significant variation amongst patients was observed and many (20%) still felt unable to 
express a preference after reading the information. Nearly all felt that the provision of the 
information pack would facilitate future discussions with clinicians (Reise et al. 2010). 
As the majority of patients in this study had little or no knowledge of varicose vein treatments, the 
importance of providing suitable verbal and written information at the initial consultation is clear 
(Reise et al. 2010). Despite this, a survey of ordinary members of the Vascular Society conducted in 
2006, suggested that 70% of surgeons would give verbal information about potential treatment 
options for varicose veins to patients at an outpatient consultation and only 53% would also give 
some form of written information. Of the written information given, only 62% and 65% gave specific 
treatment details or details about complications respectively, and less than 10% of patients would 
be referred to online information resources (Edwards et al. 2009). A recent investigation of the 
information available to patients with varicose veins on the internet found that less than 50% of 
websites discussed all treatment options and many failed to warn of potential complications (Scurr 
et al. 2008). Ideally, patients should be provided with information about all potential treatment 
options, including the advantages and disadvantages, even if they are not available at that particular 
hospital, and should be allowed to express a preference as to where they are treated.  
Recommendations published by NICE in 2001 stated that varicose vein surgery should not be 
provided solely for cosmetic reasons. However, in 2006, 20% of surgeons reported that they were 
still permitted by their primary care trust to offer treatment for cosmetic varicose veins (Edwards et 
al. 2009). With recurrence of varicosities stated as being one of the most concerning issues for many 
patients in addition to cosmetic concerns, and with many preferring a single visit for treatment, 
foam sclerotherapy is unlikely to be the patient’s preferred treatment modality. Up to a third of 
patients receiving foam sclerotherapy require additional treatments in the first 3 months (Barrett et 
The Role of Endovenous Thermal Ablation in the Treatment of Varicose Veins 
 
84 
 
al. 2004) and cosmetic results and recurrence rates are often thought to be poorer than those 
achieved with traditional stripping or endovenous thermal ablation (Rigby et al. 2004; Van den Bos 
et al. 2009a).  
This small non-validated questionnaire study provided interesting information about patient opinion 
regarding varicose veins in West London. However, in our group of patients, more than a quarter 
were over the age of 60 years, suggesting that the study population may not be representative of 
the entire varicose vein population. More detailed questionnaires of larger populations may provide 
more robust information on preferences than this small study.  
 Patient’s perspective is becoming increasingly important and healthcare professionals are 
encouraged to involve patients in their treatment decisions in order to improve healthcare (Coulter 
2007). Varicose veins procedures are recognised as highly litigious (Tennant et al. 1996; Campbell et 
al. 2002), frequently as a result of poor outcomes experienced by the patient. As only patients can 
report the symptoms they experience and the impact on their quality of life, adequate assessment of 
the patient’s concerns, preferences and expectations, along with adequate verbal and written 
information is essential in order that patients have realistic expectations from their treatment. 
Further studies investigating the patients’ preferences regarding the treatment of varicose veins are 
likely to be helpful to plan for future service provision.  
This study investigated the knowledge and opinions of patients prior to consultation before they had 
been provided with any formal information, an area that is rarely studied. The findings suggest the 
majority of patients with varicose veins are unaware of potential treatment options, highlighting the 
need for clear communication and the provision of sufficient information for patients prior to 
varicose vein treatment in order to ensure informed consent. With so many potential modalities 
currently available for the treatment of varicose veins, patient’s concerns and preferences are 
clearly extremely important and should be evaluated in all patients prior to deciding on treatment 
options.
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4 Chapter 4. Prospective Study of Endovenous 
Thermal Ablation at Charing Cross Hospital 
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4.1 Introduction 
 
The introduction of novel, minimally invasive treatment modalities has revolutionised the 
management of superficial venous reflux over the last decade. Specifically, endothermal treatments 
including endovenous laser ablation (EVLA) and radiofrequency ablation (RFA) have been shown to 
be highly effective techniques to close refluxing venous channels (Luebke et al. 2008; Van den Bos et 
al. 2009a). One year occlusion rates over 90% have been reported consistently in prospective clinical 
studies (Darwood et al. 2008; Proebstle et al. 2008). Other potential advantages include minimal 
post-operative discomfort, rapid return to work and normal activities and potentially reduced 
neovascularisation and varicose vein recurrence (Rautio et al. 2002; Lurie et al. 2003; Kianifard et al. 
2006; Rasmussen et al. 2007). The most popular RFA system is the ClosureFast™ segmental ablation 
catheter produced by VNUS® Medical Technologies Inc., (San Jose, CA, USA). The 980nm laser 
(Biolitec) is one of the most frequently used laser devices at present and has been used at Charing 
Cross since 2002. As direct comparative studies of RFA and EVLA are scarce, choosing between 
interventions is extremely difficult, leading to huge inconsistencies in patient care between centres 
and clinicians. As anatomical measures of treatment success are excellent with both RFA and EVLA, 
other factors such as patient acceptance and post-operative pain may be important factors to help 
decide between treatments. To date, few studies have evaluated these issues. 
Prior to conducting a blinded randomised clinical trial comparing 980nm laser and VNUS 
ClosureFASTTM radiofrequency ablation a pilot study of patients undergoing endovenous thermal 
ablation procedures was conducted. This enabled us to evaluate likely differences in post-procedural 
pain and analgesia use which will provide the basis of a sample size calculation for the randomised 
trial. It also allowed us to identify important predictive factors for post-procedural pain and highlight 
potential confounding factors requiring adjustment in the statistical analysis.  
The aim of this pilot study was to evaluate post-operative pain in patients treated with endovenous 
laser and radiofrequency ablation and also to identify predictors of post-procedural pain. 
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4.2 Methods 
4.2.1 Patients and Setting 
 
Patients treated with segmental RFA or EVLA between 1st January and 31st July 2008 at Charing Cross 
Hospital vascular surgery department were studied prospectively. Patients with primary or recurrent 
great (GSV) or small (SSV) saphenous veins confirmed on colour venous duplex scanning were 
included. All patients were invited to complete the Aberdeen Varicose Vein Questionnaire 
(AVVQ)(Garratt et al. 1993) prior to intervention and their Clinical, Etiological, Anatomical, 
Pathophysiological (CEAP)(Eklof et al. 2004) grade and Venous Clinical Severity Score 
(VCSS)(Rutherford et al. 2000) was recorded by a clinician on the morning of their planned 
procedure. Demographic information and operative details were recorded prospectively.  
4.2.2 Interventions 
 
Segmental RFA was performed using the VNUS® ClosureFast™ catheter and EVLA was performed 
using a 980nm laser generator (Biolitec ELVes). The specific procedure performed was dictated by 
the availability of the equipment and the preference of the patient. Patients requiring bilateral 
treatment were offered the same treatment to both legs at the same sitting. All procedures were 
performed by surgeons with endovenous experience of at least 100 procedures and both RFA and 
EVLA were performed under general anaesthesia with concomitant phlebectomies (Appendix 9). 
In brief, the technique involved cannulation of the refluxing truncal vein under ultrasound guidance 
at the distal point of reflux or as close to this site as possible. The laser or radiofrequency catheter 
was then passed into the vein to be ablated and positioned 2cm from the saphenofemoral or 
saphenopopliteal junctions. With the patient in the Trendelenberg position, tumescent anaesthesia 
was then infiltrated around the vein (under ultrasound guidance) prior to ablation. Tumescent 
anaesthesia was composed of 50ml 1% lidocaine + 1:200,000 adrenaline in 1000mls of normal saline, 
and was standardised for all patients. Segmental RFA involved a double treatment of the most 
proximal venous segment to be ablated, followed by single treatments of the remaining venous 
segments as per manufacturer’s guidance. All procedures were performed on a day case basis. 
Concomitant phlebectomies were performed in all patients using a standard technique with an 
Oesch hook and closed with 6.0 prolene sutures. Initially legs were bandaged with crepe bandaging 
which was removed after 2-3 hours and patients were discharged with TED stockings and advised to 
wear them day and night for 1 week. 
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4.2.3 Assessment of Pain 
 
Following treatment, patients were asked to complete a diary card for 10 days to record the level of 
pain using a 100mm visual analogue scale (Darwood et al. 2008) (see Appendix 3). They were also 
asked to specify the day on which they were able to return to normal activities and recommence 
work duties. They were given stamped addressed envelopes to return completed diary cards.  
4.2.4 Statistical Analysis 
 
Average pain scores over 3 and 10 days were calculated and compared between treatment groups 
using the Mann Whitney U test. Demographic and anatomical factors were compared between the 
two treatment groups using Mann Whitney U and Chi Squared tests. In order to identify 
independent risk factors for post-operative pain after EVLA and RFA, the relevant factors were 
tested using a multivariate linear regression model. Specific correlations were tested using 
Spearman Rank correlation for non-parametric data. All statistical tests were performed using SPSS 
V17.0 (SPSS Inc, Chicago, Ill) and p values <0.05 were considered significant. 
 
4.3 Results 
 
4.3.1 Study Population 
 
Over the study period, 81 patients completed pain score assessments, of which 46/81 (57%) 
underwent segmental RFA and 35/81 (43%) were treated with EVLA. The majority of patients were 
female 62/81 (77%), the median age was 47 years (range 24-77) and 31/81 patients (38%) 
underwent bilateral procedures. CEAP scores were C2 (n=19), C3 (n=12), C4 (n=13), C5 (n=1) and C6( 
n=1) in the RFA group and C2 (n=17), C3 (n=13), C4 (n=1), C5 (n=3) and C6(n=1) in the EVLA group. 
Patient age, sex, AVVQ score, VCSS and number of bilateral procedures were comparable between 
the groups treated with RFA and EVLA (Table 6). However, the overall length of vein ablated was 
greater in the group treated with RFA (p=0.005, Mann Whitney U test). All patients were discharged 
from hospital on the same day as surgery and no immediate complications or incidences of DVT 
were encountered. 
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Factor assessed RFA (n=46) EVLA (n=35) P Value 
    
Patient Age (years) 46 (26-74) 47 (24-77) 0.614* 
Sex (M:F) 11:35 8:27 1.000
†
 
Initial AVVQ score 15.2 (2.5-71.5) 19.3 (2.7-42.3) 0.119* 
VCSS 4 (1-8) 5 (2-13) 0.062* 
Bilateral surgery 18/46 13/35 1.000
†
 
Length of vein ablated (cm) 37 (14-133) 31 (10-75) 0.005* 
    
Results presented as median (IQR) unless stated otherwise * Mann Whitney U test, 
† 
Chi Squared test 
 
Table 6. Comparison of assessed risk factors between studied groups 
 
4.3.2 Pain Scores 
 
Average reported post-procedure pain scores were highest for the first 3 days in both treatment 
groups (Figure 23). Median pain scores at 3 days were 14.5mm (range 1-81) following RFA compared 
with 25.8mm (range 0-80) after EVLA (p=0.053, Mann Whitney U test). Over 10 days, average pain 
scores were significantly lower after RFA (median 13mm, range 0-68) in comparison to EVLA (median 
23.3mm, range 0-85) (p=0.014 Mann Whitney U test) (Figure 23).  
4.3.3 Use of Analgesia 
 
Information regarding analgesia use was available for 73/81 (90%) patients. Patients were prescribed 
paracetamol and ibuprofen and instructed to take them only if required. Sixteen patients (n=11 in 
EVLA group, n=5 in RFA group) chose to take their own analgesia including codeine phosphate 30 mg 
or tramadol 50 mg. Analgesia use was greatest over the first 3 days. Median (range) total tablets 
taken over 3 days was 6(0-21) in the EVLA group compared with 5(0-26) in the RFA group (p=0.903 
Mann Whitney U).  Median (range) number of pain killers taken over 10 days were 11(0-58) in the 
EVLA group and 8(0-59) in the RFA group (p=0.474 Mann Whitney U).  After 10 days patients in the 
RFA group were also more likely to have stopped using any analgesia (60% no analgesia vs 53% no 
analgesia in the EVLA group). 
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Figure 23. Box plots showing average pain scores at 3 and 10 days post procedure 
 
4.3.4 Return to Work and Normal Activities 
 
The time to return to normal activities was similar after RFA (median 3 days, range 0-11) and EVLA 
(median 5 days, range 0-11, p=0.358, Mann Whitney U test). However, patients in employment 
(n=56), returned to work sooner after RFA (median 5, range 1-11 days) than EVLA (median 9, range 
1-11 days, p=0.022 Mann Whitney U test). 
4.3.5 Energy Delivered for EVLA 
 
The mean (SD) energy delivered was 75.0 (10.3) joules per cm of vein, with only 1 vein receiving less 
than 60 joules/cm (54.3 J/cm) and 7 veins receiving >80 joules/cm. No correlation was observed 
between the energy delivered per cm and post-procedural pain. (Spearman Coefficient 0.038, 
p=0.837 and Spearman Coefficient -0.004, p=0.987 at day 3 and 10 respectively.) 
4.3.6 Predictors of Post-Procedure Pain 
 
A multivariate linear regression model was used to test the predictive value of the independent 
variables listed in Table 6. However, for both 3 day and 10 day average pain scores, the regression 
model was found to be non-significant (p=0.402, R2=0.123 and p=0.197, R2=0.163 respectively). This 
is likely to be because the small number of patients recruited to the study was insufficient to allow 
the use of the regression model. Therefore, the relationship of individual factors to post-procedural 
p=0.053* 
*Mann Whitney U test 
p=0.014* 
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pain was evaluated. No factors including bilateral disease or the total length of vein correlated with 
average 3 or 10 day pain scores following RFA (Spearman Coefficient 0.006, p=0.97; 0.086, p=0.572 
respectively) or EVLA (Spearman Coefficient 0.234, p=0.183; 0.103, p=0.562 respectively). 
 
4.4 Discussion 
 
This prospective observational study demonstrated that segmental RFA is likely to be less painful 
than EVLA in the early post-procedure period in this cohort of symptomatic patients. A quicker 
return to work was also seen in employed patients treated with RFA, although the time to return to 
normal activities was similar when considering the entire population. Interestingly, a wide range of 
pain scores were seen in both treatment groups, although no significant risk predictors of post-
procedure pain could be identified in this cohort.  
The pain scores seen in this study mirror those obtained from previous studies using similar visual 
analogue pain diaries, where 3 day average pain scores of 7 +/- 16mm after RFA (Proebstle et al. 
2008) and 7 day average scores of 11mm (range 4-31) after EVLA have been reported (Darwood et 
al. 2008). Observed differences in post-procedure pain scores may be explained by differences in the 
mechanism of action of the ablation devices. Segmental RFA using the VNUS ClosureFAST™ 
catheter causes venous closure by venous wall denaturing at 120oC, whereas laser ablation causes 
coagulative necrosis with temperatures of 1200-1400oC recorded at the tip of the fibre. EVLA is 
thought to be associated with more vein wall perforations and, therefore, more pain and bruising 
(Fan et al. 2008). It would, therefore, seem logical that the length of vein ablated would correlate 
with post-operative pain, particularly after EVLA, although this was not supported by the results of 
this study. The relatively small sample sizes in this study may partly explain these findings.  
Interestingly, employed patients undergoing RFA did appear to return to work earlier than those 
undergoing EVLA. The potential implications are significant in terms of patient and societal costs, but 
it should be noted that the incidence of self-employment or non-physical occupations was not 
recorded and may have contributed to these findings. We recognise that other factors may have 
contributed significantly to post-procedure pain, which were not assessed in this study. These 
include the number and location of phlebectomies, volume of tumescent anaesthesia used, depth of 
the vein from skin and other factors. Indeed, the low R2 values in the multivariate regression models 
suggest that the factors assessed in this study may only contribute a small amount to post-
procedure pain in these patients. At a time when many efficacious endovenous interventions are 
available and patients are becoming increasingly involved in decisions about their healthcare, 
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comparative studies are urgently needed. Occlusion rates alone are likely to be insufficient to 
distinguish between treatment modalities as many studies have reported excellent anatomical 
results following traditional and endovenous therapies (Merchant et al. 2005; Darwood et al. 2008; 
Luebke et al. 2008; Proebstle et al. 2008; Van den Bos et al. 2009a). Assessments of patient 
acceptance and early outcomes are likely to be more discerning.  
In conclusion, this prospective study demonstrated that pain scores were low following both EVLA 
and segmental RFA. However, the results strongly suggested that segmental RFA using the VNUS 
ClosureFAST™ catheter was associated with significantly less post-operative pain and may be 
associated with a quicker return to work. These results highlight the need for high quality 
randomised clinical trials comparing endovenous procedures.  The limitations highlighted in this 
study including the number of phlebectomies performed, diameters of veins and tumescent 
anaesthesia will be considered and taken into account as part of the study design of the randomised 
trial and are discussed in detail in Chapter 5.   
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5 Chapter 5. VNUS ClosureFastTM 
Radiofrequency Ablation versus Laser for 
Varicose Veins (VALVV): A Randomised 
Clinical Trial 
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5.1 Introduction 
 
Published clinical series and randomised trials with radiofrequency ablation have demonstrated less 
post-procedural discomfort in comparison with traditional surgery (Rautio et al. 2002; Luebke et al. 
2008; Proebstle et al. 2008; Subramonia et al. 2009b), however, results following laser ablation have 
been less conclusive. Rasmussen et al 2007 reported that although post-procedural pain was higher 
in patients randomised to receive surgery in comparison with EVLA, this did not translate into 
quicker recovery times, and safety and efficacy in terms of clinical improvements (VCSS) and Quality 
of life scores (AVVQ) were similar (Rasmussen et al. 2007). In contrast the RCT published by Darwood 
et al 2008 did not demonstrate a significant difference in post-procedural discomfort, clinical 
improvement or quality of life, but did find that patients were able to return to work and normal 
activities significantly earlier following EVLA in comparison to surgery(Darwood et al. 2008). 
Although a number of studies have compared RFA or EVLA with traditional superficial venous 
surgery, (Lurie et al. 2003; Hinchliffe et al. 2006; Mekako et al. 2006; Rasmussen et al. 2007; 
Darwood et al. 2008), studies comparing EVLA with RFA are scarce and findings have been 
inconclusive(Morrison 2005; Puggioni et al. 2005; Almeida et al. 2006). At the time this RCT was 
designed and when recruitment commenced, there were no published randomised trials comparing 
EVLA and RFA. To date, one small randomised trial (Radiofrequency Endovenous ClosureFAST versus 
LAser Ablation for the Treatment of Great Saphenous Reflux: A Multicentre Single-blinded study 
(RECOVERY Study) comparing VNUS ClosureFASTTM and 980nm bare fibre EVLA has been published 
in June 2009(Almeida et al. 2009b). Data from the RECOVERY Study of 69 patients from 5 treatment 
centres suggest that RFA is likely to be less painful than EVLA and may result in quicker recovery 
times and that it would be cost effective and preferable to patients. It has been suggested that RFA 
may result in less post-procedural pain and quicker recovery times than EVLA as the lower 
temperatures and the pull back method used lead to fewer vein wall perforations and subsequently 
less pain and bruising (Roth 2007; Van den Bos et al. 2008). In ex- vivo and in animal models it has 
been shown  that Laser ablation results in more vein wall perforations and bruising than 
radiofrequency ablation (Schmedt et al. 2006; Schmedt et al. 2007) (Weiss 2002). Vein wall 
perforations have also been observed in human models following endovenous laser ablation 
(Proebstle et al. 2002b). Data from a departmental cohort study of 81 patients has also suggested 
that RFA is significantly less painful than EVLA and has formed the basis for the proposed 
randomised trial (Chapter 4). 
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5.1.1 Ongoing Clinical Trials 
 
The CLASS Trial (Comparison of LAser, Surgery and foam Sclerotherapy) is an ongoing multicentre 
randomised trial comparing foam sclerotherapy, alone or in combination with endovenous laser 
therapy, with conventional surgery as a treatment for varicose veins (ISRCTN51995477) and is 
funded by the HTA. This study aims to compare the cost-effectiveness in incremental cost per quality 
adjusted life year of foam sclerotherapy compared with surgery or laser therapy, using the AVVQ 
and EQ-5D as primary outcome measures. This trial does not seek to evaluate the use of 
radiofrequency ablation which is becoming increasingly popular in the UK.  
We proposed that a randomised trial directly comparing the EVLA and RFA would be of value to 
surgeons and healthcare trusts when making decisions regarding patient treatment, the purchasing 
of equipment and would also be complementary to the results of the CLASS Trial.  
5.1.2 Study Aim 
 
The aim of the study was to conduct a randomised clinical trial to compare early outcomes following 
segmental radiofrequency ablation and 980nm endovenous laser. 
5.1.3 Study Hypothesis 
 
Radiofrequency ablation using VNUS ClosureFASTTM (RFA) will result in significantly less post-
procedural pain and greater improvements in quality of life in comparison to 980nm bare fibre 
endovenous laser (EVLA) 
5.1.4 Study Objectives 
 
This study aimed to investigate the effectiveness of EVLA and RFA, the study objectives were as 
discussed below.  
5.1.4.1 Post-Procedural Pain and the Use of Analgesia 
 
Endovenous thermal ablation procedures are associated with mild to moderate pain for many 
patients, however, data from our departmental study (chapters 3 and 4) and previous patient 
surveys suggest that post-procedural discomfort is extremely important to patients. In a survey of 
patients undergoing day surgery, post-procedural pain was ranked as the post-operative outcome 
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patients would most want to avoid (Jenkins et al. 2001). Significant post-procedural pain also impairs 
recovery and discourages mobilisation and is, therefore, a highly important outcome measure 
(Hutchison 2007). Reduced post-procedural pain allows patients to use less analgesia, reducing costs 
and the likely hood of side effects and may also allow an earlier return to work, making therapies 
more cost effective.  
5.1.4.2 Quality of Life 
 
The patient’s perspective of healthcare has become increasingly important and a large emphasis is 
now placed on patient reported outcome measures (PROMs) in order to improve the patient’s 
experience and the quality of healthcare provided (Black et al. 2009). Validated PROMs are likely to 
be used as the primary outcome measure for elective surgical procedures in the UK, and will be used 
to evaluate the efficacy, cost effectiveness and the quality of services delivered by healthcare 
providers (Patient-Reported-Outcome-Measures. 2010). The international consensus on 
recommended reporting standards for endovenous ablation for the treatment of venous 
insufficiency advises the use of a generic and a system specific questionnaire in clinical trials (Kundu 
et al. 2009). 
5.1.4.3 Abolition of Reflux 
 
To assess the successful occlusion of the GSV and elimination of truncal reflux colour duplex 
scanning was performed. The interpretation of patient reported outcomes in the context of 
anatomical success is important in assessing the effectiveness of the different treatments. 
5.1.5 Trial Endpoints 
 
5.1.5.1 Primary end point 
 
 Post-procedural pain after 3 days 
 
5.1.5.2 Secondary end points 
 
 Average pain scores 10 days after surgery 
 Use of analgesia  
 Return to work and normal activities 
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 Improvement in QOL scores  measured with  AVVQ and SF12  
 Clinical improvement in CEAP and VCSS scores 
 Abolition of reflux at 6 months 
 Complications 
 
5.2 Methods 
 
5.2.1 Participants 
5.2.1.1 Patient Selection 
 
The target population consisted of consecutive adult patients presenting to one Consultant with 
symptomatic primary varicose veins due to reflux in the great saphenous vein. The study was set in 
the Department of Vascular Surgery at a London Teaching Hospital (Charing Cross Hospital). All 
patients underwent colour duplex ultrasonography (Philips iU22, Andover, MA, USA). All scans were 
performed by an accredited vascular scientist and reflux was defined as retrograde flow >0.5 
seconds after compression. All patients were given a standard information leaflet explaining the 
purpose of the trial and what their involvement would require (Appendix 7). 
5.2.1.2 Eligibility Criteria 
 
The inclusion and exclusion criteria for the trial are detailed in Table 7. 
 
Table 7. Inclusion and exclusion criteria 
  
Inclusion Criteria Exclusion Criteria 
Age > 18 years Patients unfit for general anaesthesia 
Venous reflux > 0.5 seconds in the GSV Current DVT on venous duplex 
 Previous venous surgery 
 Significant peripheral vascular disease / ABPI <0.8 
 Unwillingness to take part or complete questionnaires 
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5.2.2 Randomisation 
 
Consenting patients were randomised to either VNUS ClosureFASTTM  (RFA) or 980 nm laser (EVLA) 
using a bare fibre, with an internet randomisation service (sealedenvelope.com) by the trial co-
ordinator  ACS. In patients with bilateral GSV incompetence, the leg that was the most symptomatic 
(according to the patient) was randomised and the same treatment was performed on both legs.  
5.2.3 Ethical Approval 
 
Ethical approval for the study was sought by the author and granted by Charing Cross Research 
Ethics Committee (Ref: 08/H0711/19). The trial was registered with Current Controlled Trials 
(ISRCTN66818013). Trust approval was also obtained from Imperial College NHS Foundation Trust.  
5.2.4 Blinding 
 
All patients were blinded to treatment allocation, however, for practical reasons assessors were not 
blinded to patients’ treatment allocation. 
5.2.5 Outcome Measures 
 
5.2.5.1 Primary Outcome 
 
Patients were asked to record the worst pain they experience each day following the procedure for 
10 days post-operatively in a diary that was collected at the time of the 10 day appointment. 
Although a record of post-procedural pain was recorded for 10 days, the primary end point was 
post-procedural pain at 3 days. 
5.2.5.2 Secondary Outcomes 
 
5.2.5.2.1 Analgesia Diary and Return to Work 
 
All patients were given a diary card (Appendix 3) and asked to record daily analgesia taken and 
specify the day they returned to work and the day they resumed normal activities. All patients 
received standardised post-procedural instructions and advice and were discharged with analgesia 
consisting of paracetamol 1g QDS and Ibuprofen 400mg TDS with instructions to take them only if 
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required. All patients were advised to return to work and normal activities as soon as they felt able. 
Outcome analysis was adjusted for the use of analgesia. 
5.2.5.2.2 Quality of Life 
 
Pre-operatively all patients completed two disease specific questionnaires [Aberdeen varicose vein 
questionnaire (AVVQ), and Specific Outcome Response Venous (SQOR-V) questionnaires] and the 
generic Short Form 12(SF12) all of which are validated for measuring quality of life outcomes in 
patients with varicose veins (Smith et al. 1999; Guex et al. 2007).  Questionnaires were also given to 
patients at 6 weeks and 6 months post-operatively (Appendices 5, 6 and 11). Data from the SQOR-V 
questionnaire will be reported in Chapter 6. 
5.2.5.2.3 Clinical Disease Severity 
 
Patients were assessed using the CEAP Classification and Venous Clinical Severity Score at baseline 
and post-operatively at 6 weeks and 6 months by means of an interview.  
5.2.5.2.4 Abolition of Reflux 
 
Occlusion of the vein treated was assessed with colour duplex 6 months following intervention.  
5.2.5.2.5 Complications 
 
All complications were recorded with particular reference to haematoma, infection, 
thrombophlebitis, deep vein thrombosis, pulmonary embolism, temporary and permanent 
paraesthesia, skin staining and recurrence. 
5.2.6 Sample Size Calculations 
 
5.2.6.1 Post-Procedural Pain Scores 
 
Power calculations were based on the primary outcome measure of post-procedural pain at 3 days 
using data from our departmental cohort study (Chapter 4) and the published literature (Rasmussen 
et al. 2007; Darwood et al. 2008; Proebstle et al. 2008). Power calculations were based upon 
detection of a 20mm difference in pain scores over 3 days with a standard deviation of pain score of 
20mm, which was considered to be a significant clinical difference. To attain 90% power at the 5% 
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significance level, a minimum target sample size of 47 legs per group was required.  This figure was 
increased to allow for 10% non-compliance with randomised groups and 20% dropout at 6 weeks. 
This resulted in an overall target recruitment of 170 patients.  
5.2.6.2 Disease Specific Quality of Life 
 
Based upon the published Aberdeen Varicose Vein Questionnaire (AVVQ) data (Rasmussen et al. 
2007; Darwood et al. 2008; Proebstle et al. 2008), there appears to be a difference of approximately 
10 points (Standard deviation of 5) between baseline data and that at 3 months for the laser 
group(Darwood et al. 2008). If we anticipate this improvement will increase to 15 points with 
radiofrequency treatment at 6 weeks and assume a larger standard deviation of 10 for 90% power at 
the 5% significance level, 45 patients are required per group based on analysis of Covariance 
(ANCOVA).  
To sufficiently power the study to examine post-operative pain and quality of life, allowing for 10% 
protocol violations including cross over, this required a sample size of 140 patients. Assuming 20% of 
patients will be lost to follow up at 6 weeks, the sample size increased to 168 patients.  
Therefore, in order that the study be sufficiently powered to detect a clinically significant difference 
in post-procedural pain at 3 days and the AVVQ at 6 weeks, ethical approval for the recruitment of 
up to 170 patients was obtained. A summary of the sample size calculation is displayed in Figure 24. 
 
 
Figure 24. Sample size calculation summary 
  
45 patients per group required to detect a difference in pain at 3 days and AVVQ score at 6 weeks
recruitment target n=90
Estmiated 20% loss to follow up at 6 weeks
recruitment target n=108 
Estimated 10% cross over/ protocol violations in each group
Total recruitment target 170
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5.2.7 Time Scale of Recruitment and Follow up 
 
During the three months from October to December 2007, 104 endovenous procedures were 
performed for varicose veins by the team at Charing Cross. During this study we aimed to recruit at 
least 170 patients (85 per group).  Based on these figures a recruitment of 4 patients per week was 
predicted. The total recruitment period was set at 12 months. Each patient was followed up for a 
minimum of 6 months before discharge. 
5.2.8 Measurement of Outcomes 
 
5.2.8.1 Visual Analogue Scale 
 
An un-graduated visual analogue score has been successfully validated and used in a number of 
clinical trials to quantify post-operative discomfort following varicose veins procedures (Hinchliffe et 
al. 2006; Darwood et al. 2008). Patients were asked to record the maximum discomfort they 
experienced on a 100mm line for 10 days following the procedure. (Appendix 3) 
5.2.8.2 Duplex Ultrasonography 
 
All patients underwent a pre-operative colour duplex scan performed by a qualified vascular 
scientist using a Phillips iU22 machine. All patients were scanned immediately prior to treatment by 
the surgeon performing the procedure. The diameter of the GSV at the SFJ and at the largest point 
along the course of the GSV was noted by an accredited vascular scientist with the patient in a 
standing position on the morning of treatment.  
Follow up duplex scans were performed at 6 months by a qualified vascular scientist. Reflux of 
greater than 0.5 seconds was deemed significant reflux, deep veins were assessed as patent or 
occluded and the development of any new tributary varicosities was recorded. 
Classification of Post-Procedural Reflux 
 
Post-intervention GSVs were classified into one of 3 categories: 
1) Absence of reflux: The treated segment of the GSV had been completely ablated and, 
therefore, the GSV was either occluded with no residual reflux or competent.  
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2) Above knee ablation: The intended segment of GSV was ablated above the knee, with below 
knee reflux of >0.5 seconds. This was either new or residual.  
3) Failed ablation: GSV with reflux of > 0.5 seconds present. Failed ablations were due to : 
a. Inability or failure to ablate to within 2cm of the SFJ 
b. Re-canalization  
Post-intervention SSVs were classified as: 
1) Completely ablated/ no reflux: SSV occluded with no residual reflux. 
2) Partially ablated:  Small areas of residual reflux. 
3) Failed ablation: Reflux > 0.5 seconds throughout the SSV. 
5.2.8.3 CEAP 
 
The basic CEAP classification was documented for each patient by the author according to the 
guidelines by the American Venous Forum (Kundu et al. 2009). Measurements were made at 
baseline only as the CEAP classification was not designed to be responsive to changes following 
intervention. (Details of the CEAP classification can be found in Chapter 1.3.1). 
5.2.8.4 Venous Clinical Severity Score 
 
The Venous Clinical Severity Score Developed by the American Venous Forum used clinical 
observations and symptoms reported by the patient to attribute a numerical score with a maximum 
of 30 and has been shown to be valid and reliably reproducible and responsive to change following 
intervention (Rutherford et al. 2000).  (Details of the VCSS can be found in Chapter 1.3.2) 
5.2.8.5 Short Form 12 
 
The short form 12 is a generic health-related quality of life measure derived from the longer SF36 by 
Ware in 1988. It is recommended that clinical trials include both generic and disease specific quality 
of life assessments in order that patients with additional co-morbidities can be compared. A physical 
and mental component score for each patient is given and can be compared with normal values for 
the population (Appendix 6). 
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5.2.8.6 Aberdeen Varicose Vein Questionnaire 
 
The Aberdeen Varicose Vein Questionnaire designed by Garratt et al (Garratt et al. 1993) is a disease 
specific questionnaire consisting of 13 domains (Appendix 5). It has been shown to correlate well 
with clinical scoring systems and is responsive to changes following treatment (Garratt et al. 1996). 
5.2.8.7 Demographic Data 
 
Pre-operatively demographic data were recorded including: age; sex; medications; BMI; race; 
previous DVT and previous surgery. 
5.2.8.8 Operative Details and Procedures 
 
Surgical procedures were performed under general anaesthesia. Operative details  were recorded by 
the operating surgeon at the time of surgery and included: length of vein ablated, vein diameter, 
watts used, total number of cycles (RFA) or total joules used (EVLA), time taken for the vein ablation,  
volume of tumescence used and the number of stab avulsions. For details of the procedure 
protocols and operative detail recording see Appendices 8 & 9.  
5.2.8.9 Statistical Analysis 
 
All analyses were performed according to a pre-defined analysis plan, designed with the help of Dr 
Louise Brown, Medical Statistician, who performed the analysis of post-procedural pain, quality of 
life and occlusion rates using Stata software v10.0 (Stata Corporation, Texas, USA). All analyses were 
performed on an intention-to-treat basis. Student’s t-tests and Chi-squared tests were used to 
compare baseline characteristics between groups to check whether any differences had occurred by 
chance. The distributions of continuous variables were checked using normal plots with 
transformation of any skewed variables. Post-procedural pain scores were analysed using linear 
regression with two levels of adjustment. Primary adjustment was made for age, sex, BMI, clinical 
disease severity, the number of truncal veins ablated on the trial leg, the total length of vein ablated 
on the trial leg and the number of phlebectomies on the trial leg as primary adjustment. Secondary 
adjustment was made for all covariates in the primary analysis as well as for the use of analgesia.  
Secondary outcomes including quality of life and clinical improvements were analysed using Analysis 
of Co-Variance (ANCOVA) which adjusted changes in outcome from baseline values. In addition, 
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primary adjustment was made using the same variables as those used for the pain score analysis and 
also for the presence of bilateral disease and presence of deep venous incompetence. 
 
5.2.9 Summary of the Trial Design 
 
A summary of the trial design is shown in the flow diagram Figure 25. 
 
Figure 25. Flow diagram summarising trial methodology  
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5.3 Results 
5.3.1 Patient Recruitment 
 
Over 12 months from July 2008-2009, 313 patients were screened for inclusion in the study. A total 
of 171 met the eligibility criteria and were invited to participate and 131 patients consented to 
randomisation. After 12 months of recruitment, patient attendance for follow up had been more 
successful than expected and the minimum target recruitment of 47 patients per group, followed up 
at 6 weeks had already been met. This provided sufficient numbers for analysis of the primary and 
secondary outcomes and it was decided that recruitment should be stopped at 12 months as initially 
planned. 
128 patients were treated within 24 hours of randomisation and overall patients were treated at a 
median (range) of 0 (0-48) days following randomisation. One patient was cancelled due to problems 
with theatre equipment, and therefore 130 patients were treated as part of this study (see Consort 
flow diagram Figure 26). One patient who was randomised to RFA received EVLA due to non-
availability of RFA equipment. For patients treated with EVLA, the mean (S.D) energy density 
delivered to the GSV was 71.71 (12.98) joules/cm.  
5.3.2 Reasons for Patients Declining Entry to the Trial 
 
40 patients declined to be included in the trial, patients were not required to give reasons for 
refusal, however, some were happy to give their reasons which are detailed in Figure 27. Patients for 
whom English was not a first language or who had difficulties with reading and comprehension were 
offered the services of a translator, however, many of them stated that this was why they were 
unwilling to participate and unfortunately the questionnaires used were only available in English. 
Unwillingness to complete questionnaires, attend follow up and preferences for a particular 
treatment allocation were other reasons cited.  
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Figure 26. Consort diagram illustrating patient flow and follow up 
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Figures in parentheses are raw data 
Figure 27. Reasons for declining entry to the trial 
  
27% (11)
27% (11)10% (4)
5% (2)
5% (2)
3% (1)
20% (8)
3% (1)
Poor English
No Reason given
Preference for EVLA
Preference for RFA
Preference for LA
Unwilling to attend for follow up
Unwilling to answer 
questionnaires
Wanted to know treatment 
allocation
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5.3.3 Baseline Characteristics 
 
The patient group consisted of 89 female and 42 male patients with a mean (S.D) age of 49 (16) 
years. The baseline characteristics were comparable between the randomised groups and are 
summarised in  Table 8. 
 RFA EVLA 
 (n = 67) (n = 64) p 
Sex ratio (F : M) 47 : 20 42 : 22 0.579‡ 
Age (years)* 49(15) 48(16) 0.540† 
Body mass index (kg/m
2
)   0.334‡ 
< 30 61 (91) 61 (95) 
> 30 6 (9) 3 (5) 
VCSS* 5.1(2.1) 4.7(2.1) 0.278† 
AVVQ* 20.6(9.4) 19.2(9.5) 0.412† 
CEAP class   0.467‡ 
C1–C2 23 (34) 26 (41) 
C3–C4 39 (58) 46 (56) 
C5–C6 5 (8) 2 (3) 
Deep vein disease   0.178‡ 
Yes 13 (19) 7 (11) 
No 54 (81) 57 (89) 
Pattern of disease   0.727‡ 
GSV 54 (81) 50 (78) 
GSV and small saphenous vein 13 (19) 14 (22) 
Unilateral or bilateral disease   0.433‡ 
Unilateral 31 (46) 34 (53) 
Bilateral 36 (54) 30 (47) 
Procedural parameters 
Length ablated (cm)* 49(16) 46(14) 0.177† 
Total no. of phlebectomies above or below knee* 6.2(4.0) 6.2(3.6) 0.945† 
Values in parentheses are percentages unless indicated otherwise; *values are mean(S.D.). RFA, radiofrequency ablation; 
EVLA, endovenous laser ablation; VCSS, Venous Clinical Severity Score; AVVQ, Aberdeen Varicose Vein Questionnaire; CEAP, 
Clinical Etiologic Anatomic Pathophysiologic; GSV, great saphenous vein. †Student’s t test; ‡χ
2
 test 
Table 8  Baseline characteristics by randomised group
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5.3.4 Primary Outcome: Post-Procedural Pain at 3 Days 
 
Diary cards were available for 127 patients; unadjusted post-procedure pain scores after EVLA (61 
patients) and RFA (66) are shown in Figure 28. Patients receiving RFA reported less pain over the first 
3 days, with a mean (S.D.) pain score of 26.4 (22.1) for RFA and 36.8 (22.5) for EVLA (primary 
adjusted difference = −10.2; p=0.012) (Table 9). 
 
Figure 28. Reported pain scores for 10 days following intervention- unadjusted data.  
 
5.3.5 10 Day Pain Scores 
 
Patients in the RFA group also reported less pain over the first 10 days, with mean (S.D) scores of 
22.0 (19.8) for RFA and 34.3 (21.1) for EVLA (primary adjusted difference = −12.8; p=0.001)(Figure 28 
and Table 9).  
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 RFA (n=66) EVLA 
(n=61) 
Crude 
unadjusted 
difference* 
p Primary 
adjusted 
difference*† 
p Secondary 
adjusted 
difference*‡ 
p 
Mean(S.D) pain score 
First 3 days 
26.4(22.1) 36.8(22.5) −10.4 
(−18.2, −2.6) 
0.010 −10.2 
(−18.1, −2.3) 
0.012 −6.4 
(−14.3, 1.6) 
0.115 
Mean(S.D.) pain score 
First 10 days 
22.0(19.8) 34.3(21.1) −12.3 
(−19.5, −5.1) 
0.001 −12.8 
(−20.2, −5.5) 
0.001 −6.3 
(−13.3, 0.7) 
0.079 
 
*Values in parentheses are 95 per cent confidence intervals. †Primary adjustment for age, sex, body mass index of 30 
kg/m
2
or above, Venous Clinical Severity Score in the randomized leg (as a measure of varicose vein disease severity), 
pattern of disease (great saphenous vein (GSV) versus GSV and small saphenous vein), length of vein ablated, number of 
phlebectomies (above or below knee). ‡Secondary adjustment: adjusted primary model for use of analgesia. RFA, 
radiofrequency ablation; EVLA, endovenous laser ablation. 
 
Table 9. Linear regression analysis of pain scores after RFA and EVLA 
 
5.3.6 Analgesia Use 
 
Patients in the RFA group took fewer analgesic tablets than those in the EVLA group: mean (S.D.) 
over 3 days 8.8 (9.5) tablets after RFA versus 14.2 (10.7) tablets after EVLA (p=0.003) and over 10 
days 20.4 (22.6) and 35.9 (29.4) tablets respectively (p=0.001) (Figure 29).
 
Figure 29. Analgesia use for 10 days following intervention 
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Analgesia use was considered when performing a secondary analysis, so as to compare reported 
pain scores in patients who took the same number of analgesia tablets in both groups. This was to 
ensure that analgesic tablets were being taken in proportion to the pain experienced (patients were 
advised to take them only if necessary), and not taken prophylactically or under used for any reason. 
When pain scores were adjusted for the number of analgesic tablets taken, differences between the 
groups were reduced and of borderline significance only at 10 days. This strongly suggested that the 
behaviour of patients in both groups regarding the use of analgesia was similar and, therefore, 
confirmed that recorded differences in pain and analgesia use were highly likely to be due to true 
differences in discomfort experienced and not as a result of differences in patient behaviour 
between the two groups (Figure 30).  
 
 
 
Figure 30. Crude and adjusted pain scores at 3 and 10 days following EVLA and RFA 
 
5.3.7 Phlebectomies Performed 
 
Two patients included in the analysis did not require concomitant phlebectomy, although primary 
and secondary analyses were adjusted for the number of phlebectomy incisions. Interestingly, no 
correlation was observed between pain and the number of avulsions in the EVLA or RFA group at 3 
days (p=0.54 and p=0.93) or at 10 days (p=0.54 and p=0.90). 
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5.3.8 Disease Specific Quality of Life and Clinical Disease Severity 
Quality of life was assessed at a median (IQR) of 48 (43-54) days following intervention, data were 
available for 115 patients (RFA n=60, EVLA n=55). Improvements in quality of life at 6 weeks were 
seen in both groups and were significantly improved compared with baseline scores (AVVQ, VCSS 
and SF12 PCS p<0.001 and SF12 MCS p=0.001 Wilcoxon Signed Ranks). However, no significant 
differences in AVVQ, SF12, or VCSS were observed between the two groups. Improvements in scores 
at 6 weeks were maintained at 6 months with no significant differences from those observed at 6 
weeks and no significant difference between the RFA and EVLA groups. 
5.3.8.1 Aberdeen Varicose Vein Questionnaire 
 
 
Figure 31. AVVQ unadjusted baseline 6 week and 6 month scores 
 
Patients in both RFA and EVLA groups experienced approximately a 10 point improvement in their 
scores from baseline. No significant differences were observed between the groups with unadjusted 
data (Figure 31) or adjusted data (p=0.828 and p=0.308 at 6 weeks and 6 months ANOVA) (Raw data 
are reported in Appendix 10). 
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5.3.8.2 Venous Clinical Severity Score 
 
 
Figure 32. VCSS unadjusted  baseline, 6 week and 6 month scores 
 
Patients in both RFA and EVLA groups experienced approximately a 3 point improvement in their 
scores from baseline. No significant differences were observed between the groups with unadjusted 
data (Figure 32) or adjusted data (p=0.969 and p=0.332 at 6 weeks and 6 months ANOVA) (Raw data 
are reported in Appendix 10). 
 
5.3.8.3 Short Form 12 
 
Patients experienced approximately a 3 point improvement in the physical component of the SF12 
and a 2.5- 4 point improvement in the mental component scores. Differences in unadjusted data 
were not significant between the 2 groups (Figure 33 and Figure 34) and no significant difference 
was observed in adjusted data (p=0.580 and 0.380 PCS 6 weeks and 6 months and p=0.476 and 
p=0.080 MCS 6 weeks and 6 months ANOVA)(Raw data is reported in Appendix 10). 
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5.3.8.3.1 Short Form 12- Physical Component Score 
 
 
Figure 33. SF12 PCS unadjusted baseline 6 week and 6 month scores 
 
5.3.8.3.2 Short Form 12- Mental Component Score 
 
Figure 34. SF12 MCS unadjusted baseline 6 week and 6 month scores 
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5.3.9 Return to Work and Normal activities 
 
Data detailing return to normal activities were available for 62 patients after RFA and for 50 patients 
after EVLA. The majority of patients returned to normal activities within 3 days, this was 60% (37/62) 
in the RFA group and 50% (25/50) in the EVLA group.  77 % (48/62) and 74% (37/50) of patients had 
resumed normal activities within 7 days in the RFA and EVLA groups respectively. There was, 
however, a trend towards earlier return to normal activities on days 1 and 2 in the RFA group in 
comparison with the EVLA group.  Return to work data were available for 41 patients in the RFA and 
34 in the EVLA group. Results were similar, with 15/41 (37%) and 14/34 (41%) patients returning to 
work within 3 days, and 29/41 (71%) and 24/34 (71%) returning to work within 7 days in RFA and 
EVLA groups respectively. Overall there was no significant difference in return to normal activities or 
to work between the two groups (p=0.158 and p=0.975 respectively Mann Whitney U test). 
The days on which patients returned to normal activities are displayed below (Figure 35 and Figure 
36).  
  
 
Figure 35. Day on which patients were able to resume normal activities 
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Figure 36. Day on which patients were able to return to work 
 
5.3.10 Duplex Results: Assessment of Occlusion Rates at 6 Months 
 
Duplex scans were available for 109 patients (84%) at a median (IQR) of 189 (174-210) days. Follow 
up duration was comparable between the RFA and EVLA groups being 189 (179-205) and 186 (174-
232) days respectively p=0.266 (t test). 
5.3.10.1 Ablation of Great Saphenous Veins 
 
In both groups the majority of patients had a successful ablation of their GSV and in a further 29% 
(RFA) and 28% (EVLA) the above knee segment of the GSV was successfully ablated, leaving only 
below knee incompetence (Figure 37). These were judged as anatomical treatment successes. In 
total, 10 patients were classed as anatomical failures either due to re-canalization (RFA n=5, EVLA 
n=1) or failure to ablate to within 2cm below the SFJ (RFA n=1, EVLA n=3), usually due to a technical 
difficulty in passing the catheter due to the presence of a thigh tributary. Overall patients in the laser 
group experienced fewer failures, however, due to the small numbers of patients this was not 
significant. Overall anatomical success rates at 6 months were 89% in the RFA group and 93% in the 
EVLA group at 6 months (p=0.527 Chi square). 
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 No reflux  BK reflux  Failed ablation  Re-canalization 
 
Figures in parentheses are raw data 
Figure 37. Abolition of GSV reflux at 6 months 
 
5.3.10.2 Below Knee Reflux  
 
In 53% and 46% of the patients in the RFA and EVLA groups, persistent GSV reflux below the knee of 
>0.5 S in a vein > 3mm diameter was observed. This was either residual, due to an untreated 
segment of vein, or new, in a segment of GSV that was previously competent and, therefore, not 
ablated. Results between the RFA and EVLA groups were similar (Figure 38). 
5.3.10.3 Clinical Significance of Below Knee Reflux 
 
Patients were classified into groups according to whether they had no reflux, below knee reflux 
(either residual or de novo) or treatment failures who either had re-canalization or a segment of 
refluxing GSV above the knee. Interesting, overall patterns between 6 month AVVQ and VCSS scores 
with residual reflux were poor, particularly in the EVLA group where there was no apparent trend. 
Due to the small numbers of patients, statistical analysis of these sub-groups was not performed. 
(Figure 39 and Figure 40). 
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Values in parentheses are raw data 
Figure 38. Distribution of below knee reflux 
 
 
 
Figure 39. Relationship between the AVVQ and residual reflux 
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Figure 40. Relationship between the VCSS and residual reflux 
 
5.3.10.4  Anatomical Failures 
 
The aim was to deliver >60 j/cm LEED to the vein in the EVLA group. The one patient who 
experienced a re-canalization only received 40.6 j/cm. Despite this, he was very pleased with the 
results of his phlebectomies, and had no residual varicosities or symptoms at the 6 month follow up. 
Treatment options were discussed with him and he chose to return in 18 months time for further 
duplex imaging and clinical assessment. 
5.3.10.5  Small Saphenous and Anterior Thigh Veins 
 
27 patients underwent additional endovenous thermal ablation procedures for a refluxing short 
(n=21) or anterior thigh vein (n=6) on the randomised leg. Veins were classified as re-canalized, 
partially occluded or occluded. The results are shown in Figure 41. 
Further endovenous ablation was required by 1 patient in the EVLA group for persistent 
symptomatic SSV reflux following re-canalization, however, the remaining patients were 
asymptomatic or declined further treatment. 3 patients did not attend for a duplex scan (RFA n=2 
EVLA n=1). 
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Figure 41. Duplex outcomes following endovenous thermal ablation of short and anterior thigh veins. 
 
5.3.11 Further Treatments Required 
 
At 6 months following randomisation, a total of 15 patients (12%) required further intervention for 
residual varicosities or truncal reflux Table 10. 
Treatment required RFA (n=55) EVLA (n=54) 
GSV ablation + phlebectomies 3 3 
SSV ablation 0 1 
ATV ablation 1 1 
Phlebectomies 1 2 
Foam Sclerotherapy 1 2 
 
Table 10. Further treatments required 
 
 In the RFA group, further ablation to the GSV was required due to re-canalization (n=2) and 
persistent symptomatic GSV reflux (n=1). In the EVLA group further GSV ablation was due to 
technical failures (n=2) and persistent symptomatic below knee GSV reflux (n=1). In the EVLA group, 
one patient presented at 9 months with symptomatic recurrent varicosities originating from groin 
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tributaries which appeared to be neovascular tissue on duplex imaging (Figure 42). Of the patients 
who underwent further treatments, the majority were performed after the duplex scan at 6 months. 
1 patient in the RFA group underwent further ablation after his 6 week appointment due to 
immediate re-canalization and 1 patient in the EVLA group underwent further phlebectomies. All 
other treatments were performed after 6 months and were successful with the exception of one 
patient in the EVLA group who had a large tributary arising from the GSV and had a second failed 
ablation procedure complicated by an abscess at the cannulation site that required drainage and 
several weeks of antibiotics.  
 
 
Figure 42. Recurrence following endovenous laser ablation  
 
5.3.12 Complications 
 
At 6 months, two major complications were observed. One patient randomized to RFA suffered a 
pulmonary embolus 2 weeks after intervention (the patient was treated with warfarin, although no 
evidence of DVT or clot extension in the leg veins was found on duplex imaging). One patient in the 
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EVLA group developed a lymphatic leak from the cannulation site, and lymphoscintigraphy 
confirmed increased lymphatic collateral flow consistent with trauma at the site. In this particular 
case, cannulation of the vein below the knee was difficult and the operating surgeon performed a 
cut down onto the GSV. It was from this site that copious amount of clear, colourless fluid began to 
drain several days following surgery which then became infected. The patient was treated with 
antibiotics and has been referred to specialist lymphatic services and is currently treated with Daflon 
and graduated compression. 
Overall minor complications included wound infection (5%), haematoma (2%), thrombophlebitis 
(6%), saphenous nerve paraesthesia (10%) and skin staining (6%) (Table 11). Two patients in the 
EVLA group reported an increase in spider veins, and despite the intention to perform procedures as 
a day case, four patients (3%) required overnight admission after the procedure because of nausea 
(RFA, 1; EVLA, 1), hypotension secondary to general anaesthesia (RFA, 1) or pain requiring opioid 
analgesia (RFA, 1). 
 RFA (n=67) EVLA (n=64) 
Wound infection 4 (6) 2 (3) 
Haematoma 0 (0) 2 (3) 
Thrombophlebitis 5 (7) 3 (5) 
Paraesthesia 8 (12) 5 (8) 
Staining to skin 6 (9) 2 (3) 
Seroma 2 (3) 1 (2) 
Pulmonary embolus 1 (1) 0 (0) 
Values in parentheses are percentages. 
Table 11. Complications at 6 weeks following EVLA and RFA by randomised groups 
 
At 12 months, one further patient in the EVLA group reported a DVT which was diagnosed after 5 
months and treated at his local hospital. He has declined to attend for further follow up 
appointments. 
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5.4 Discussion 
 
The results of this randomised clinical trial confirmed that VNUS ClosureFASTTM resulted in 
significantly less pain than 980nm endovenous laser ablation. However, reported pain and analgesia 
usage was very variable in both groups. Because of the small sample size we are unable to conclude 
whether the apparent trend of an earlier return to normal activities seen in the radiofrequency 
group was significant, however, differences in the time to return to work were very small.  Despite 
earlier advantages of RFA as regards post-procedural pain, at 6 weeks there was no significant 
difference in clinical disease severity or quality of life scores and the degree of improvement in the 
AVVQ and VCSS was similar to that reported in other randomised trials (MacKenzie et al. 2004; Lurie 
et al. 2005; Darwood et al. 2008). The results of this study support the findings of other studies 
which have shown less post-procedural pain with RFA (Morrison 2005; Almeida et al. 2009b). The 
exact heating mechanism occurring during endovenous thermal ablation is incompletely understood. 
Temperatures of up to 1334oC have been recorded at the laser tip in animal models (Weiss 2002) 
which is much higher than that of the RFA probe, heated to 120oC. However, in human subjects, 
maximum temperatures of 43oC, 42oC and 36oC were recorded at 3, 5 and 10mm from the GSV using 
an 810nm diode laser with tumescent anaesthesia (Beale et al. 2006), which is likely to be similar to 
that experienced with RFA. In animal models, vein wall perforations have been shown to occur in 
100% of the 122 cases treated with the 810nm laser, but did not occur in the 3 cases treated with 
the older VNUS ClosurePLUS RFA device (Schmedt et al. 2007). Vein wall perforations have also 
been shown to occur in humans, and one explanation for the reduced pain scores following RFA may 
be that the controlled heating and segmental ablation technique of VNUS ClosureFASTTM reduces 
the number of vein wall perforations and the extravasation of blood into the tissues (Schmedt et al. 
2007; Fan et al. 2008). There are no published studies to date which have looked at the number of 
vein wall perforations following segmental RFA in humans in comparison with laser, however, it 
remains a popular theory.  
The rate of paraesthesia at 6 weeks of 12% and 8% in the RFA and EVLA groups respectively is similar 
to that reported in some studies, although rates recorded in the published literature vary widely 
between studies from 0-22% for EVLA (Van den Bos et al. 2009b). Minimal data regarding rates of 
paraesthesia are available following segmental ablation below the knee, however, Creton et al have 
reported rates of 3.4% at 1 year (Creton et al. 2010). Irreversible neuronal injury in animal models 
has been found to occur at temperature of >47oC and should theoretically be a rare occurrence if 
adequate tumescent anaesthesia is used, although the temperatures required to produce temporary 
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paraesthesia are unknown. In addition, all but 2 patients underwent phlebectomies, which were 
below the knee in the majority of cases and may have significantly contributed to the rates of 
paraesthesia observed.  
The only other published randomised trial found greater improvements in VCSS scores at 1 month 
but did not show differences in disease specific quality of life in the RFA group, compared with EVLA 
(Almeida et al. 2009b). Interestingly, predicted differences in quality of life and VCSS scores were not 
observed in VALVV trial patients at 6 weeks.  Discrepancies between the studies may be explained by 
variations in procedure technique and follow up times. In contrast to the Recovery trial (Almeida et 
al. 2009b), minor complications including paraesthesia, thrombophlebitis and skin infections were 
not more prevalent in the EVLA group at any time point. Rates of deep venous thrombosis in 
patients following EVLA and RFA are reported to be <1% overall, however, rates as high as 5.7% have 
been reported (Van den Bos et al. 2009b).  The overall rate of venous thromboembolism in patients 
in this trial at 6 months was 1.5%. One patient in the RFA group experienced a pulmonary embolus 
on day 10 post intervention, which was diagnosed and treated at a different hospital and no deep 
venous thrombosis in the leg veins was found on duplex scanning at his 6 week follow up 
appointment. The cause of this pulmonary embolus remains unknown, the patient had no known 
risk factors for thromboembolic disease at the time of surgery and remains on warfarin. In addition a 
patient in the EVLA group experienced a deep vein thrombosis in the treated limb 5 months 
following intervention.  This presented as a rapid onset pain and swelling of the leg and he attended 
his local GP and subsequently his local emergency department where a DVT was diagnosed. He was 
warfarinised as an outpatient and has declined to attend further follow up for the trial. He was not 
known to have any risk factors for venous thromboembolism and it is unknown whether this DVT 
was related to his endovenous thermal ablation procedure. Interestingly, both patients had had 
recurrent episodes of thrombophlebitis in superficial veins prior to their interventions.  
One patient experienced a lymphatic leak as a result of damage to lymphatic vessels at the site of 
cannulation. Although lymphatic injuries at puncture sites have been reported following traditional 
surgery (Disselhoff et al. 2008) there are no reports in the published literature of confirmed 
lymphatic injury following endovenous laser ablation to date(Van den Bos et al. 2009b), although 
fluid collections, likely to have been seromas, following EVLA have been reported (Janne D'Othee et 
al. 2008).  
This trial was sufficiently powered to evaluate post-procedural pain and both procedures were 
performed under identical conditions. Post-procedural ecchymosis was not evaluated due to 
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difficulties in accurately quantifying bruising, and because previous studies have shown that it does 
not necessarily correlate with post-procedural pain (Min et al. 2005) or time taken to resume normal 
activities (Rasmussen et al. 2007). Patients were blinded to treatment allocation, which significantly 
reduced the potential for bias and allowed a direct comparison of the outcomes of the two 
procedures. Although the assessors were not blinded, the primary outcomes were patient reported 
and, therefore, very unlikely to have been affected by the assessors. Patients also underwent 
concomitant phlebectomies if necessary, with the aim of completing all treatments in a single visit. 
This approach has been shown to be preferable for many patients, and associated with 
improvements in clinical and quality of life outcomes and a reduced need for further procedures 
(Carradice et al. 2009). Limitations include the fact that all procedures were performed under 
general anaesthesia, meaning that the assessment of the adequacy of the tumescence during the 
procedure was not possible. However, the technique of tumescent anaesthesia infiltration under 
ultrasound guidance was standardised for both procedures and volumes of tumescent anaesthesia 
used were recorded. The authors accept that a significant proportion of endovenous thermal 
ablation procedures are performed as outpatient or ‘office based’ procedures (Chapter 2), and that 
performing concomitant phlebectomy is feasible as an office based procedure (Almeida et al. 2008). 
However, in patients with bilateral disease or in those with large numbers of varicosities this may be 
difficult. As the aim was to complete all treatments in one visit, all patients were offered general 
anaesthesia. Patients with SSV incompetence were also included to ensure the study population 
were representative of the population presenting with primary varicose veins. Moreover, the groups 
in this randomised study were well matched in terms of disease pattern and analyses were adjusted 
for numerous variables including number of phlebectomies performed and the length of vein 
ablated to ensure that detected differences were truly due to the ablation technique.  
Results confirm that the improvements in quality of life seen in both groups at 6 weeks were 
maintained at 6 months with no difference in outcomes between the groups in terms of generic, 
disease specific quality of life or the VCSS. At 6 months, successful anatomical and functional 
outcomes were observed in both groups. Although true re-canalization rates were higher in the 
radiofrequency group than in the EVLA group, technical failures and the subsequent need for re- 
intervention were higher in the EVLA group, but these differences were not significant. 
In both treatment groups the average maximum vein diameter of the GSV measured with the 
patient standing on the morning of surgery was 8.7 and 8.8 mm in the RFA and EVLA groups 
respectively. The reasons for the 5 re-canalizations in the RFA group are unclear. However, reported 
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occlusion rates following VNUS ClosureFASTTM at 12 months have been excellent in one study, but 
data from other sources is scarce (Creton et al. 2010; Perrin 2010). All veins were of diameter 8mm 
or greater (8mm, 10mm, 12mm,12mm and 13mm) and may have re-canalized as insufficient energy 
was transferred to the vein wall. Proebstle et al  suggested that the Endovenous Fluence Equivalence 
(EFE) in j/cm2 is  important for successful occlusion (Proebstle et al. 2006) and threshold values for 
adequate EFE of >20 j/cm2 have been suggested (Proebstle et al. 2006; Vuylsteke et al. 2008).  It has 
also been suggested that the number of cycles should be increased in larger veins, and reduced in 
veins of small calibre to ensure optimum closure rates and minimise side effects (Proebstle UIP 
Monaco September 2009 unpublished data). At present there is no formal guidance regarding this 
and the manufacturers recommend a double treatment of the first segment closest to the SFJ, and 
single treatment cycles for each subsequent segment. They do state that additional cycles can be 
given at the discretion of the physician but advise against more that 3 treatment cycles per 
segment(www.vnus.com 2010). 
Successful abolition of reflux following EVLA is improved by ensuring the LEED is greater than 60j/cm 
(Theivacumar et al. 2008a). In the case of the patient who experienced a re-canalization in the EVLA 
group, the average energy delivered was 40.6 j/cm to his vein of 10mm in diameter, and this may 
explain the reason for the treatment failure.  Vein diameter has been shown to be an independent 
predictor of treatment success (Kim et al. 2006), however, vein diameter is variable and subject to 
change depending on posture and a variety of physiological parameters. It is likely that the thickness 
of the vein wall and the level of energy required for successful closure is more important than the 
vein diameter alone. To date, the degree of damage required to the outer layers of the vein wall in 
order to result in permanent closure remains unknown.  
Technical failures, frequently due to an inability to advance the laser catheter to within 2cm of the 
SFJ were more common in the EVLA group. This may reflect the different design of the catheter, the 
laser fibre being more flexible and less rigid than the RFA catheter, or may be relate to the small 
sample size. 
In a number of patients, de novo reflux was observed at 6 months. In the majority of cases this was 
in the GSV, below the knee, however, in a few patients new ATV branches from the groin were 
observed, which resulted in the development of symptomatic varicosities.  One patient presenting 
with new varicosities at 9 months following EVLA appeared to have neovascularisation at the groin 
similar to that observed following traditional groin dissection. He required further treatment with 
EVLA to this new branch with concomitant phlebectomies. It remains unclear whether this was true 
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neovascularisation or occurred as a result of a previously existing small tributary. Neovascularisation 
has been shown to occur following EVLA, although is significantly less common than following open 
surgery (Theivacumar et al. 2009a). The clinical significance of tributaries in the groin is not 
completely understood, although data suggest that they may not necessarily be associated with 
adverse clinical outcomes (Theivacumar et al. 2007). The development of further recurrences in this 
cohort of patients may be helpful in the understanding of the relationships between anatomical 
recurrence and functional outcomes following endovenous thermal ablation, which is poorly 
understood at present. 
Although the small numbers in this study prohibited sub-group analysis, it appeared that the 
majority of patients gained a significant improvement in their quality of life, despite some having 
residual or new below the knee reflux and even patients with almost complete re-canalizations 
reported improvements. Although we were unable to evaluate whether residual reflux was a 
significant contributor to ongoing functional or clinical impairment, the data provided further 
evidence to support the poor relationship observed between anatomical reflux and clinical signs and 
symptoms found in previous studies (Bradbury et al. 1999). Persistent below knee great saphenous 
reflux in patients who had undergone ligation and stripping has been associated with worsening 
clinical signs and symptoms between 6 month and 2 years following intervention (van Neer et al. 
2009), and treating below knee reflux where possible resulted in improvements in quality of life and 
reduced the need for further interventions following endovenous laser ablation (Theivacumar et al. 
2009b). The functional benefits reported in quality of life, despite significant segments of re-
canalization may be explained by published studies which have shown that re-canalized veins often 
remain small and that in some cases persistent reflux is limited and of no clinical significance 
(Theivacumar et al. 2008b). 
To date, the majority of studies provide data supporting the short term efficacy of EVLA and RFA, but 
long term data are scarce.  EVLA would appear to have the better occlusion rates of around 95%  
compared to 80% for the early RFA catheters at 5 years (Van den Bos et al. 2009a). Results from 
VNUS ClosureFASTTM appear promising from this study and previously published data (Proebstle et 
al. 2008) and are likely to be superior to the original RFA Closure device in the long term. Long term 
studies of venous occlusion and recurrence are required to support the durability of endovenous 
thermal ablation procedures.  
Both this study and the smaller Recovery trial (Almeida et al. 2009b) support the premise that 
VNUS ClosureFASTTM is less  painful than 980nm EVLA. However, to reduce the post-procedural 
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discomfort associated with EVLA, newer radial fibres and longer laser wavelengths have been 
developed. These newer techniques have been shown to be associated with low post-intervention 
pain scores (Almeida et al. 2009a; Kabnick 2009; Maurins et al. 2009; Pannir et al. 2009; Doganci et 
al. 2010; Schwarz et al. 2010) and are likely to replace the 980nm bare tip laser fibre. However, 
further data from randomised trials supporting the use of these newer devices are awaited.  
Recent research has shown that there has been a rapid increase in the popularity of endovenous 
thermal ablation in recent years and this trend is likely to continue (Lindsey et al. 2006; Winterborn 
et al. 2008; Edwards et al. 2009) . Patients seeking superficial venous interventions are frequently 
concerned about post-procedural discomfort, recovery times and recurrence (Chapter 3). It is, 
therefore, important to provide sufficient patient information about all the available procedures, in 
order that patients and physicians can reach evidence based decisions about treatment options.  
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6 Chapter 6. Measuring Venous Disease Severity 
and Evaluating Treatment Outcomes 
  
The Role of Endovenous Thermal Ablation in the Treatment of Varicose Veins 
 
 
130 
 
6.1 Introduction 
 
Venous disease is a significant cause of patient morbidity in the United Kingdom, particularly for 
those with venous ulceration, however, studies have shown that even patients with uncomplicated 
varicose veins have a poorer quality of life compared with the general population (Smith et al. 1999; 
MacKenzie et al. 2004) and improvements in quality of life following treatment of superficial reflux 
have been found to be comparable to those following laparoscopic cholecystectomy (Sam et al. 
2006). Assessing the severity of venous disease pre-operatively and following intervention is 
important to establish the efficacy of the intervention and assess the need for further procedures. 
The measurement of outcomes following treatment of superficial venous reflux is a contentious 
issue and there are a wide range of investigations, from surrogate end points (anatomical occlusion 
rates and haemodynamic improvement), to clinical and functional improvements. Numerous generic 
and disease specific quality of life questionnaires are available to choose from, each with their own 
advantages and disadvantages (Vasquez et al. 2008).  
Early studies into the efficacy of endovenous ablation techniques and traditional surgery had 
concentrated primarily on occlusion rates and haemodynamic function (Goldman 2000; Min et al. 
2001; Navarro et al. 2001) as outcomes that could be objectively measured. Although the 
importance of establishing the efficacy of these new treatments is clear, surrogate end points do not 
necessarily reflect the patients’ experiences of treatment with regards to clinical or functional 
outcomes (Kulkarni et al. 2007). There are few studies directly comparing quality of life with 
anatomical, haemodynamic and clinical outcomes.   
 
Measurement of Outcomes for Endovenous Thermal Ablation Therapies: Recommended 
Reporting Standards for Clinical Trials 
 
The publication of an international consensus on reporting standards in Chronic Venous Disease 
(CVD) in 1996 included a recommendation for assessments following surgery, which would record 
clinical outcomes at 6 months as: +3 Asymptomatic, +2 Moderate Improvement, +1 Mild 
improvement 0 Unchanged, -1 Mild worsening, -2 Significant worsening and-3 severe worsening. 
Incorporated into this was the CEAP Classification for CVD which was revised in 2004. The 
introduction of minimally invasive endovenous ablation procedures has lead to the publication of 
further recommendations in reporting standards for post-operative outcomes. In 2007 the American 
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Venous Forum (AVF) published recommended reporting standards advocating the use of disease 
specific patient reported outcome measures, in combination with a measurement of generic quality 
of life and clinical assessment in all clinical trials evaluating the use of endovenous therapies (Kundu 
et al. 2007). These guidelines were revised in 2009 (Kundu et al. 2009). The use of the venous clinical 
severity score in addition to CEAP classification and an assessment of quality of life was 
recommended. The venous clinical severity score correlates well with the CEAP classification and has 
the advantage of allowing the evaluation of changes in reported clinical signs and symptoms 
following intervention. The use of a generic QOL assessment tools such as the SF36 to assess overall 
morbidity in conjunction with a disease specific questionnaire was recommended. Acceptable 
validated disease specific questionnaires included the Aberdeen Varicose Vein Questionnaire 
(Garratt et al. 1993) the VEINES-QOL (Lamping et al. 2003; Kahn et al. 2006) and the CIVIQ-2 (Launois 
et al. 1996). In those with mild to moderate disease (frequently classed as C0-C4), it has been 
suggested that patient reported outcomes may be more useful than physician reported outcomes 
for assessing improvement (Guex 2008). The use of follow up imaging, usually colour duplex, in the 
context of clinical trials is also required, but may not be done routinely in clinical practice. 
Because of the wide variety of outcome measures currently in use, it is important to consider the 
relationship between these outcome measures, if comparisons between studies are to be made. At 
present these relationships are poorly understood.  
 
The aim of this study was to compare anatomical, haemodynamic and clinical outcomes with disease 
specific quality of life tools, including the newest SQOR-V questionnaire and the original AVVQ in 
patients undergoing treatment for varicose veins. 
 
6.2 Methods 
 
Patients referred with symptomatic varicose veins and deemed suitable for intervention over an 18 
month period were invited to complete the (AVVQ)(Garratt et al. 1993), the SQOR-V questionnaire 
and the Short Form 12 (SF12). In addition, the CEAP grade (Eklof et al. 2004), VCSS (Rutherford et al. 
2000) and demographic details were recorded prospectively. All patients had previously undergone 
duplex ultrasonography (Philips iU22) by an accredited vascular scientist and all patients with truncal 
venous reflux of >0.5 seconds with a vein diameter of >3mm were considered candidates for thermal 
ablation. Those who were unsuitable were offered open surgery. Patients with recurrent disease and 
deep venous reflux were included in the study.  
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All patients underwent endothermal ablation using VNUS ClosureFASTTM or EVLT according to the 
technique described in appendix 9. Some of the patients included were participants on the VNUS 
ClosureFASTTM Radiofrequency ablation versus Laser for Varicose Veins (VALVV) Trial (Chapter 5) and 
were, therefore, randomised to their treatment allocation. Patients who were not on the trial were 
treated according to the patient’s preference of treatment modality or equipment. All patients were 
assessed at 6 weeks where all measurements except colour duplex were repeated.  
6.2.1 Measurement of Outcomes 
 
Outcomes were grouped into 4 categories according to: Venous anatomy, haemodynamic function, 
clinical disease severity and functional assessment. Outcomes were recorded as a score per patient 
(AVVQ, SQOR-V and SF12) or as a score per leg (VRT, VSDS). VCSS and CEAP scores were noted per 
leg and for comparisons with quality of life outcomes, the score of the worst leg was used. Where 
disease specific quality of life was compared with haemodynamic function (VRT) or anatomical reflux 
(VSDS) patients with bilateral disease were excluded from the analysis. 
6.2.1.1 Anatomical 
 
Based on the findings of the duplex ultrasonography, patients were categorised as having either 
unilateral or bilateral disease, and also according to the number of refluxing veins per leg. This was 
defined as either GSV reflux, SSV reflux, ATV reflux or a combination of 2 of the above. Each leg was 
also scored according to the reflux component of the venous segmental disease score 
(VSDS)(Rutherford et al. 2000). The presence or absence of deep vein incompetence was also 
recorded. The proforma used is shown in Figure 43. 
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Figure 43. Lower limb venous duplex proforma 
 
6.2.1.2 Haemodynamic 
 
Clinical venous refill times (VRTs) were assessed using digital photoplethysmography with the 
patient in a seated position on the morning of treatment. An average of 2 reading were taken, and a 
third was taken if the first 2 readings varied by more than 10%. VRTs of greater than 30 seconds 
were considered normal. Details of the protocol are presented in Appendix 4.  
6.2.1.3 Clinical 
 
The CEAP grade and VCSS were recorded by a clinician on the morning of treatment. 
6.2.1.4 Functional/ Quality of Life 
 
Prior to procedures all patients were asked to complete the AVVQ (Garratt et al. 1993), the SQOR-V 
(Guex et al. 2007) and the generic short form 12 (SF12) questionnaire (Quality Metric TM). Further 
details of the questionnaires can be found in chapter 1.4 and copies of the questionnaires in 
Appendices 6, 7 and 11.  
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All questionnaires were scored with reference to the recommendations from the authors. The SF12 
was scored with software from Quality Metric TM.  
6.2.2 Follow up 
 
All patients were invited for follow up at 6 weeks post-procedure, when they were invited to 
complete the questionnaires again. In addition clinical assessments of disease severity and venous 
refill times were recorded by the reviewing clinician. Duplex scanning was not performed unless 
patients presented with symptoms suspicious of deep venous thrombosis. 
6.2.3 Statistical Analysis 
 
All statistical analyses were performed using SPSS version 17.0 (SPSS, Inc, Chicago, Illinois). 
Correlations between outcomes were assessed using Spearman’s correlation for non-parametric 
data. Groups were compared using Mann Whitney U and Kruskal Wallace tests for non-parametric 
data as appropriate. The responsiveness of outcome measures was assessed using the standardized 
response mean (SRM), calculated by dividing the mean change in score by the standard deviation of 
the change. The higher the SRM, the more sensitive the tool to clinical change, with SRMs of 0.2, 0.5 
and 0.8 representing small, moderate or large changes respectively (Garratt et al. 1996). To avoid 
potential errors introduced by multiple testing, p values of 0.01 or less were considered significant. 
  
The Role of Endovenous Thermal Ablation in the Treatment of Varicose Veins 
 
 
135 
 
6.3 Results 
6.3.1 Study Population and Demographics 
 
Over a period of 18 months between January 2008 and July 2009 pre-operative data were collected 
from 317 adult patients (female n=227 male n= 90), of mean (S.D) age  48.87 (14.49) years 
(minimum age 18 years , maximum age 87 years). The recruitment and follow up of patients in the 
study is summarised in (Figure 44). 
 
Figure 44. Flow diagram of patient recruitment and follow up 
 
A total of 252 patients had primary varicose veins and 65 had recurrent varicose veins. Colour duplex 
scanning confirmed that 191 patients had unilateral disease, 126 had bilateral disease and 45 also 
had deep venous incompetence.  Of the 443 legs studied 322 (73%) had GSV incompetence alone, 31 
(7%) had SSV incompetence alone, and 90 (20%) had more than 1 refluxing vein (either GSV+SSV or 
GSV + ATV or ATV+ SSV). 
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Baseline CEAP clinical scores for the group are illustrated in Figure 45 and ranged from C2 to C6, 
there were no patients classified as C0 or C1. 
No significant differences were observed in any baseline scores between patients with primary and 
recurrent disease [AVVQ (p=0.163) SQOR-V (p=0.171) SF12PCS (p=0.08), SF12 MCS (p=0.373), VCSS 
(p=0.038), VSDS (p=0.386) and VRT (p=0 .435) Mann Whitney U test].  
 
 
 
Values in parentheses are raw data 
Figure 45. Distribution of clinical CEAP scores in the study cohort 
 
6.3.2 Relationship Between Pre-Operative AVVQ, SQOR-V and SF12 
 
The AVVQ showed a strong positive correlation with the SQOR-V disease specific questionnaire 
(Figure 46), and a weak, but significant correlation with the physical component of the generic SF12 
questionnaire. Correlation with the mental component score was very weak and of borderline 
significance (Figure 47).  
 
 
 
 
 
 
41% (131)
28% (88)
25% (79)
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C2
C3
C4
C5
C6
The Role of Endovenous Thermal Ablation in the Treatment of Varicose Veins 
 
 
137 
 
 
 
 
Figure 46. Relationship between the AVVQ and SQOR-V 
 
 
 
Figure 47. Correlation between the AVVQ and the SF12 PCS and MCS  
Spearman coefficient 0.702, p<0.001 
Spearman coefficient -0.308, p<0.001 Spearman coefficient -0.162, p=0.007 
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The physical component of the SQOR-V (SQOR-V PCS) correlated with the SF12 PCS, however the 
mental component of the SQOR-V (SQOR-V MCS) did not correlate with the SF12 MCS (Figure 48).  
 
 
 
Figure 48.  Correlation between the SQOR-V and SF12 PCS and SF12 MCS 
 
6.3.3 Relationship Between Baseline Clinical CEAP and AVVQ, SQOR-V, VCSS and VRTs 
 
The AVVQ correlated with increasing CEAP grade (p<0.001 ANOVA) (Figure 49), patients with C5/6 
disease had significantly higher AVVQ scores [median (IQR)] [36.75 (18.42-45.15) than those with 
C3/4 disease, [17.68 (13.15-25.82)] (p<0.001 Mann Whitney U) who had significantly higher scores 
than those with C2 disease [15.20 (11.08, 22. 59)] (p<0.001Mann Whitney U).  
Spearman coefficient -0.310, p<0.001 Spearman coefficient -0.143, p=0.019 
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Figure 49. Relationship between AVVQ and clinical CEAP 
 
Interestingly SQOR-V scores did not correlate with CEAP scores as patients with C4 disease had lower 
scores than those with C3 disease (P=.093 ANOVA) (Figure 50). 
 
 
Figure 50. Relationship between SQOR-V with clinical CEAP 
 
 
p< 0.001 ANOVA 
p=0.93 ANOVA 
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Higher CEAP scores were also associated with significantly higher VCSS scores (p= <0.001 AVOVA) 
(Figure 51). 
 
Figure 51. Relationship between VCSS and clinical CEAP 
 
VRTs appeared shorter in patients with higher CEAP scores although variability in measurements was 
high and the trend was not significant (Figure 52).  
 
 
Figure 52.  Relationship between VRTs and clinical CEAP 
p<0.001 ANOVA 
p=0.020 ANOVA 
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6.3.4 Relationship Between VCSS and Quality of Life 
 
The VCSS correlated positively with AVVQ scores and weakly but significantly with SQOR-V scores 
(Figure 53). However, correlations were not as strong as those observed between disease specific 
quality of life tools.  
 
 
 
Figure 53. Correlation between the VCSS and the AVVQ and SQOR-V 
 
The VCSS correlated with the physical (Spearman correlation -0.206, p=0.001) but not the mental 
component score (Spearman correlation -0.0492, p=0.483) of the SF12. 
 
6.3.5 Relationship Between Anatomical Reflux and Quality of Life 
 
The AVVQ showed a weak correlation with VSDS scores when scores for both legs were added 
(Spearman Coefficient 0.230 P<.001), but did not correlate with AVVQ scores when patients with 
unilateral disease alone were evaluated (p=0.328). The SQOR-V did not correlate with VSDS scores 
when scores for both legs were added in patients with bilateral disease (Spearman Coefficient 0.124, 
p=0.036), or when patients with unilateral disease alone were analysed (Spearman Coefficient 0.014, 
p=0.856), nor did the VSDS correlate with the SF12 (p=0.983). 
Spearman coefficient 0.439, p=<0.001 Spearman coefficient 0.197, p=0.001 
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Patients with deep venous incompetence appeared to have a worse quality of life according to the 
AVVQ (p=0.042 Mann Whitney U), however, this was not reflected in the SF12 PCS or SQOR-V 
questionnaires (p=0.064 and p=0.640 respectively Mann Whitney U). 
6.3.6 Relationship of Anatomical Reflux to VCSS 
 
The VCSS showed a weak correlation with the VSDS which was of borderline significance (Spearman  
Coefficient 0.147, p=0.012) 
6.3.7 Relationship of VRT to Anatomical Reflux 
 
Patients with multiple refluxing veins did not have significantly lower VRTs than those with GSV 
reflux. Those with SSV reflux did have worse VRTS compared with those with GSV reflux alone, but 
this was not significant (p=0.263 Kruscal-Wallis). The average refill times according to patterns of 
venous reflux are summarised in Table 12. 
 
 GSV SSV 2 Refluxing veins 
VRT median(IQR) 
In seconds 
19.50 
(11.50-29.58) 
24.50 
(13.50-34.50) 
18.67 
(13.50-27.00) 
 
Table 12.  Venous refill times according to the pattern of truncal reflux 
 
A weak correlation was observed between VSDS scores and pre-operative VRTs (Spearman 
Coefficient -0.257 p<0.001).  
6.3.8 Relationship of VRTs to Functional Outcomes 
 
Venous refill times (worst leg) did not correlate with the functional outcome measures of AVVQ 
(p=1.09); SQOR (p=0.575); SF12 PCS(p=0.779); SF12MCS(p=0.209) or VCSS (p=0.11).  
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6.3.9 Assessment of Relationship Between Outcome Measures Following Intervention 
 
At 6 weeks data from 225/317 (71%) patients was available. Quality of life questionnaires were 
complete for 214 (68%) patients. No significant difference in disease severity or pattern of reflux was 
observed in patients who did not attend follow up compared with those who did, evaluated using 
the baseline VCSS(P=.591) and VSDS(p=.137) Mann Whitney U test. Overall patient’s quality of life, 
clinical and haemodynamic scores improved at 6 weeks in comparison with baseline scores. 
Improvements in scores are shown in Table 13.  
 
 
 AVVQ SQOR-V SF12 PCS SF12 MCS VCSS VRT 
Baseline 
 
17.01 
(12.14-24.64) 
45.60 
(36.54-57.17) 
49.64  
(42.48-55.24) 
50.97 
(41.60-56.47) 
4 
(4-6) 
19.33 
(11.00-25.50) 
6 week 9.69 
(5.50-16.68) 
33.53 
(25.64-42.11) 
53.73 
(46.70-56.93) 
53.81 
(645.90-57.16) 
1 
(0-2) 
25.73 
(17.00-33.00) 
p  value* p<0.001 p<0.001 p=0.001 p=0.004 p<0.001 p<0.001 
Values are given as median (IQR) * Wilcoxon Rank test 
Table 13.  Pre and post-intervention AVVQ, SQOR-V, SF12 and VCSS Scores 
 
6.3.10 Relationship Between the Changes in AVVQ, SQOR-V and SF12 
 
The relationship between improvements in quality of life post-procedure was evaluated as the 
percentage change in the post-procedure scores in comparison with those at baseline.  AVVQ scores 
post-procedure showed a positive correlation with percentage change in post-procedural SQOR-V 
scores at 6 weeks (Figure 54). 
Patients who experienced large improvements in AVVQ scores generally experienced similar 
improvements in SQOR-V scores, while those who experienced a worsening of AVVQ scores reported 
worse SQOR-V scores. However, a small number of patients had worse AVVQ scores with 
improvements in the SQOR-V and vice versa. 
 Very weak were correlations observed between changes in AVVQ scores and changes in the SF12 
MCS scores at 6 weeks were of borderline significance (0.196, p=0.008), but no correlation was seen 
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between the PCS and the AVVQ (Spearman Coefficients 0.159 p=.032 ) or between the SQOR-V and 
the SF12 (Spearman Coefficient 0.079, p=0.296). 
 
 
 
 
Figure 54. Relationship between changes in the AVVQ and SQOR-V 
 
6.3.11 Relationship Between Changes in AVVQ, SQOR-V, and VCSS 
 
Percentage changes in the AVVQ showed a weak correlation with the percentage changes in the 
VCSS (Spearman Coefficient 0.299, p<0.001), however, no correlation was observed between the 
percentage changes in the SQOR-V and the VCSS. (Spearman Coefficient 0.062, p=0.401). 
 
6.3.12 Relationship  Between the Changes in VRT  and AVVQ, SQOR-V, SF12 and VCSS 
 
Changes in venous refill times at 6 weeks did not correspond to changes in the AVVQ or the SQOR-V 
overall (Spearman Coefficient -0.021, p=0.826 and Spearman Coefficient 0.073, p=0.567 
Spearman Coefficient 0.492, p<0.001 
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respectively) or in patients with unilateral disease only (Spearman Coefficient -0.067, p=0.587 and 
Spearman Coefficient-0.069 p=0.574 for the AVVQ and SQOR-V respectively). Percentage changes in 
the VRTs did not correlate with changes in the SF12 PCS (p=0.996) or MCS (p=0.790). 
Patients with higher CEAP scores had lower VRTs at baseline and post-procedure (Table 14), 
however, post-procedure VRTs did not correlate with post-procedure VCSS scores (Spearman 
coefficient=-0.041, p=0.636). 
 
 C2 C3 C4 C5 C6 
 
VRT Baseline 
(seconds) 
 
23.5 
(13.66-34.52) 
 
21.00 
(12.25-31.00) 
 
16.00 
(10.12-25.63) 
 
3.33 
(10.50-23.00) 
 
12.00 
(6.63-13.30) 
 
VRT Post 
Procedure 
(seconds) 
 
27.67 
(19.50-32.50) 
 
27.75 
(19.37-36.00) 
 
27.50 
(18.33-34.00) 
 
17.00 
(10.63-26.38) 
 
8.50 
(6.50-14.25) 
 Figures are presented as median (IQR) 
Table 14. Venous refill times according to clinical CEAP pre and post-procedure 
 
6.3.13 Relationship of Outcome Measures in Patients with Deep Venous Incompetence 
 
Pre-operatively, the adjustment for the presence of deep venous incompetence did not affect the 
significance of the correlations reported. Post-procedure correlations between outcomes when all 
patients were included in the analysis were similar to those in patients with superficial 
incompetence alone. However, no correlation was observed between the percentage change in 
AVVQ scores with changes in the SOQR-V (p=.502), VCSS (p=.010) or VRT (p=.580) when patients 
with deep and superficial venous incompetence were analysed separately (Spearman Rank test), 
although post-procedural data from only 27 patients were available for analysis. 
6.3.14 Responsiveness of the AVVQ and SQOR-V Questionnaires 
 
AVVQ scores pre and post-intervention correlated with pre-operative CEAP scores (p<0.001 ANOVA) 
and patients across all degrees of clinical severity appeared to gain significant improvement in their 
scores (P<.001 for C2/3/4 patients and p=0.002 C5/6 patients Wilcoxon Rank). However, percentage 
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changes in AVVQ did not correlate with pre-operative CEAP as improvements were similar in all 
classes (p=0.965 ANOVA).  Results show that the SQOR-V questionnaire also appears to show 
significant improvements in scores after intervention for all degrees of severity (p=0.001 C2/3/4 and 
p=0.004 C5/6 Wilcoxon Rank). However, pre-operative SQOR-V scores did not correlate with C4-C6 
CEAP scores (p=0.093 AVOVA) or the percentage of improvement post-intervention (p=0.602 
ANOVA). The responsiveness of the AVVQ and SQOR-V questionnaires has been evaluated using the 
standardized response mean. SRMs confirmed the AVVQ and the SQOR-V were highly responsive to 
changes at 6 weeks (SRMs 0. 897 and 0.870 for the AVVQ and SQOR-V respectively). SRMs have been 
calculated for patients according to baseline clinical CEAP for the AVVQ (Figure 55) and SQOR-V 
(Figure 56). When evaluating the degree of change post-procedure, both questionnaires appear to 
show similar degrees of improvement according to the SRM. We were not able to demonstrate an 
increased sensitivity for the SQOR-V in patients with C2 and C3 disease, although data for patients 
with C1 disease was not available in this cohort. 
 
AVVQ C2 C3 C4 C5 C6 
Baseline score* 
 
17.396 
(9.675) 
19.621 
(9.520) 
20.355 
(9.876) 
27.638 
(11.601) 
39.358 
(19.278) 
6 week score* 10.319 
(8.124) 
13.032 (10.035) 11.759 
(8.617) 
13.187 
(3.923) 
26.640 
(18.298) 
Change in score* 6.706 
(8.536) 
7.802 
(8.730) 
8.523 
(8.225) 
12.027 
(11.866) 
17.574 
(12.691) 
SRM 
 
0.712 0.894 1.036 1.014 1.385 
*Values are mean (S.D) SRM- standardised response mean= change in score divided by the change in S.D 
Figure 55. Responsiveness of the AVVQ  
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SQOR-V C2 C3 C4 C5 C6 
Baseline score 
 
46.496 
(13.319) 
50.270 
(16.048) 
45.934 
(13.334) 
42.789 
(12.822) 
55.014 
(12.116) 
6 week score 35.821 
(12.128) 
39.191 
(15.994) 
34.180 
(13.017) 
34.027 
(8.336) 
39.247 
(8.631) 
Change in score 10.892 
(12.532) 
11.982 
(16.598) 
12.715 
(12.476) 
7.005 
(6.492) 
17.048  
(5.193) 
SRM 
 
0.869 0.722 1.019 1.079 3.283 
*Values are mean (S.D) SRM- standardised response mean= change in score divided by the change in S.D  
Figure 56. Responsiveness of the SQOR-V 
 
6.3.15 Responsiveness of Outcome Measures 
 
Standardised response means for the questionnaires overall, confirmed that both the AVVQ and 
SQOR-V and VCSS are highly responsive at detecting change following intervention, however, the 
SF12 showed only small changes (Table 15). 
 
 
Line denotes minimum possible score 
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 AVVQ SQOR-V VCSS SF12 PCS SF12 MCS 
 
SRM 0.897 0.870 1.756 0.234 0.225 
 
 
Table 15. Standardised response means for outcome measures  
 
6.3.16 Predictive Value of the AVVQ 
 
It has been suggested that from baseline AVVQ scores it may be possible to predict patients likely to 
achieve better outcomes post-procedure, and if so, could be used as a rationing tool.  Although 
baseline CEAP scores correlated with AVVQ scores, they were not predictive of changes in AVVQ 
scores (p=0.956 ANOVA). Baseline AVVQ scores did not correlate with changes in AVVQ scores post-
intervention (Figure 57). 
 
 
Figure 57. Predictive value of the AVVQ based on percentage change in scores 
 
Patients were divided into quartiles based on baseline AVVQ point score, (quartile 1 from 0-12, 
quartile 2 from 12.1-17.0, quartile 3 for 17.1-25 and quartile 4 >25.1).  All patient groups gained 
Spearman Coefficient 0.074 p=0.303  
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significant improvements in the post-procedural scores at 6 weeks. No cut off point for baseline 
AVVQ scores was found to be predictive of treatment success and, therefore, no evidence for the 
use of the AVVQ as a pre-operative screening tool was found (Figure 58).  
 
Figure 58. Predictive value of the AVVQ 
 
6.4 Discussion 
 
This study demonstrated that there is poor correlation between disease specific quality of life and 
other outcome measures used to evaluate varicose veins. As demonstrated previously, AVVQ scores 
did correlate with clinical CEAP scores (Mackenzie et al. 2002; MacKenzie et al. 2004), but only weak 
correlations were observed between AVVQ and pre-operative generic quality of life (SF12) or VCSS 
scores. Correlations between the SF12, CEAP and VCSS were very weak and of borderline 
significance only both pre and post-operatively, and no correlations were observed between the 
SF12 and VRTs. Results observed with the AVVQ and VCSS scores in this study were similar to those 
reported in other series and in recent randomized clinical trials assessing endovenous thermal 
ablation modalities, with improvements in scores comparable with other studies (Rasmussen et al. 
2007; Darwood et al. 2008). No correlations were observed between AVVQ scores and venous refill 
p<0.001
* 
p<0.001
* 
p<0.001
* 
p<0.001
* 
Wilcoxon Rank test 
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times, either pre-operatively or following intervention.  Although some smaller studies have shown 
correlations between VRTs and pre-operative quality of life, they have found no correlation between 
changes in VRT and either generic or disease specific quality of life following intervention (Darvall et 
al. 2010a),  suggesting that haemodynamic measurement is a poor outcome assessment tool in 
patients with uncomplicated venous disease.  Weak correlations were seen between AVVQ scores 
and anatomical reflux according to VSDS scores, further supporting the theory that the presence of 
anatomical reflux does not necessarily correlate with functional impairment or clinical disease 
(Bradbury et al. 1999; Theivacumar et al. 2008b). These findings suggest that anatomical reflux 
should not be relied upon in isolation as an outcome measure in routine practice. In addition studies 
validating the venous severity scoring system found that the VSDS did not correlate with the CEAP 
classification. However, a weak association was found pre-operatively between the VSDS and the 
VCSS, with patients with increasing numbers of refluxing segments reporting higher symptomatic 
scores. No  association was found between the VSDS and post-operative score changes following 
traditional surgery in a small group of patients (Kakkos et al. 2003).  Similarly haemodynamic success 
has been shown to be useful in the prediction of venous ulcer recurrence in patients with venous 
ulceration (Gohel et al. 2005a), although its application is of questionable use in patients with 
uncomplicated disease.  
The explanation for the correlations observed may, in part, be due to the relatively small number of 
patients studied, and also, that some haemodynamic factors were beyond the scope of this study 
and not assessed. Indeed previous studies have suggested that higher venous reflux velocities are 
associated with a worse clinical outcome following saphenous vein ablation (Marston et al. 2008), 
which were not recorded in this study. They may also represent patients in whom symptoms 
reported were unrelated to an underlying venous cause. However, due to the difficulties in 
correlating venous reflux with symptomatology (Bradbury et al. 1999; Campbell et al. 2007), this is 
extremely difficult to assess.  
  
The Role of Endovenous Thermal Ablation in the Treatment of Varicose Veins 
 
 
151 
 
6.4.1 Comparison of the AVVQ and SQOR-V 
 
A strong correlation was observed between the two disease specific quality of life questionnaires 
evaluated, which was stronger than those observed between the AVVQ or SQOR-V the SF12, 
supporting the use of the SQOR-V as a valid and responsive disease specific questionnaire. The 
results of the use of the SQOR-V questionnaire in this patient group showed strong similarities to 
those of the original authors. Average scores for C2 and C3 patients were 43.83 and 48.84 in our 
patient group in comparison to 42.24 and 48.71 reported in the original publication (Guex et al. 
2009).   
Interestingly, in the majority of patients, changes in post-procedure AVVQ scores correlated with the 
SQOR-V, but a number of patients experienced improvement in one score, with worsening of the 
other. It is possible that this may reflect different sensitivities of the questionnaires applied to 
different patient groups, or represent random errors in question responses. Because of the very 
small number of cases this applied to, the authors were unable to evaluate this further. The SQOR-V 
questionnaire was specifically designed to allow more sensitive evaluation of the functional impact 
of venous disease in patients in CEAP classes C1-C3. The results from this study were able to support 
the use of the SQOR-V in this patient group, although were unable to demonstrate any superiority 
over the AVVQ.  However, the study did not make a full assessment of the effectiveness of the 
SQOR-V questionnaire due the absence of patients with C1 disease alone, for whom referrals to 
secondary care are restricted by the UK state healthcare system.  
In patients with skin changes and ulceration (C4-C6) the SQOR-V questionnaire did not correlate with 
clinical CEAP scores, a trend also reported in the original publication (Guex et al. 2007). Differences 
in scores are likely to be due to the differences in the design of the questionnaires. The SQOR-V is 
based on patient reported symptoms and not clinical signs, where as the AVVQ attributes a heavier 
weighting to the presence of skin changes and ulceration. Despite this the SQOR-V remained highly 
responsive in all patient groups, with responsiveness scores similar to the AVVQ. Both disease 
specific questionnaires were highly responsive to changes following intervention with standardised 
response means of >0.8 (Garratt et al. 1996). Consequently no superiority of either questionnaire 
over the other was demonstrated.  
The VCSS was also highly responsive to changes following intervention. However, as described in 
other studies, generic quality of life was far less responsive to change following intervention than 
disease specific tools (Garratt et al. 1996). 
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6.4.2 Predicting Treatment Outcomes 
 
Data from this study were unable to support the use of baseline AVVQ scores as a predictor of 
treatment outcomes. Improvement in post-intervention scores were significant for patients in all 
categories of disease severity and no cut off point could be established, below which intervention 
was unlikely to result in significant improvements. Baseline SQOR-V scores did not correlate with 
clinical CEAP scores and, therefore, its use as a predictive tool was not evaluated as baseline scores 
in isolation are not predictive of disease severity. 
 
The choice of outcome measure in venous disease is difficult and has been of great interest in recent 
years(Guex 2008). The VCSS is undoubtedly easy and quick to use and provides a good assessment of 
disease severity, but offers no evaluation of the impact of the disease state on the quality of life of 
the patient, which is of paramount importance. Quality of life questionnaires provide a more 
complete assessment of the disease state, and Patient Reported Outcome Measures (PROMs) have 
recently been introduced in the United Kingdom for the assessment of outcomes following a number 
of elective procedures, including varicose veins. However, questionnaires are time consuming and 
costly to use and a number of patients are reluctant to complete them for a variety of reasons 
including difficulties with language, reading, comprehension and lack time or motivation to complete 
lengthy questionnaires.  
Current recommended reporting standards advise the use of both generic, disease specific and 
clinical evaluation tools for a comprehensive assessment (Kundu et al. 2009). Duplex 
ultrasonography has been an important tool in establishing the efficacy of endovenous ablation 
techniques, although not all patients underwent duplex scanning post-operatively in this study. The 
weak correlations observed between anatomical and functional outcomes suggest that residual 
anatomical reflux in the absence of symptoms is unlikely to justify intervention, and consequently, 
routine duplex scanning is of questionable value and may not be a cost effective use of scarce 
healthcare resources. The use of PROMs could potentially negate the need for post-operative 
haemodynamic and anatomical evaluation in routine practice. 
This study comprised of a combination of randomised and non-randomised patients and, therefore, 
differences in treatment allocation. However, no significant differences in outcomes were observed 
between the treatment groups at 6 weeks. As the aim of the study was to evaluate the relationship 
between outcome assessment tools and not the comparison of outcomes, this should not have 
affected the results. This study was also unable to evaluate disease specific quality of life 
questionnaires in patients who did not undergo intervention, as these patients are usually managed 
The Role of Endovenous Thermal Ablation in the Treatment of Varicose Veins 
 
 
153 
 
in primary care.  The follow up rate of 68% of patients at 6 weeks despite reminder letters and 
telephone calls was disappointing, and a larger dropout rate was seen in the non-randomised 
patients. 
 In this study the evaluation of digital photoplethysmography as an outcome measure was difficult to 
correlate with quality of life. However, patients with bilateral disease were excluded from the 
analysis, which may have affected the results. Overall, this is an important assessment of the 
reliability and use of different outcome measures in the assessment of venous disease, although in 
order to recommend specific tools in preference to others, larger studies will undoubtedly be 
required. 
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In the introduction, the development of endovenous thermal ablation treatments, the measurement 
of venous disease severity and treatment outcomes were discussed and further questions regarding 
the role of endovenous thermal ablation were proposed.  
Despite the fact that endovenous thermal ablation therapies were developed over 10 years ago, 
evidence from the questionnaire survey conducted (Chapter2) confirmed that their prevalence still 
remain low in the United Kingdom and traditional surgery still appeared to be the most frequently 
performed procedure. Results suggested that high initial costs and rationing by NHS healthcare 
providers were likely to be the commonest reasons behind the apparent slow uptake of these new 
procedures. However, data from previously conducted surveys of varicose veins treatments amongst 
vascular surgeons, and from venous registries confirmed that thermal ablation devices are becoming 
increasingly popular (Lindsey et al. 2006; Winterborn et al. 2008; Edwards et al. 2009). Another 
factor contributing to the lack of uptake of endovenous thermal ablation is perhaps the limited 
knowledge of their existence by the majority of the general public. When patient preferences 
regarding the nature of treatment provision for varicose veins were explored (Chapter 3), the 
majority would prefer a minimally invasive treatment performed in a single sitting. Patient 
preferences were similar to those reported in previous surveys with the majority expressing 
willingness to undergo a more invasive treatment if they felt that it would provide more durable 
results (Campbell et al. 1998). Based on the patient’s opinions expressed, endovenous ablation 
therapies are likely to be  preferable treatment modalities based on their low complication rates, 
minimal discomfort and excellent medium term success rates in comparison with other therapies 
(Van den Bos et al. 2009a). However, the majority of patients are unaware of their existence and 
reported that they would be most likely to make a decision based on the opinion of the surgeon they 
visit.  
Few studies have evaluated differences between laser and radiofrequency ablation. Data from 
earlier studies focused primarily on the efficacy of the techniques at eliminating truncal reflux, but 
occlusion rates are likely to be similar between the two techniques. Patient preferences explored in 
Chapter 3 suggest that post-procedural discomfort and recovery times were of high importance and 
further evaluation of early treatment outcomes may aid clinicians in making evidence based 
recommendations to patients. The pilot study conducted provided valuable post-procedural 
discomfort scores, in order to allow accurate sample size calculation for the randomised trial, 
although it was unable to identify any predictive factors of post-procedural pain.   
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Recruitment to the randomised study was more successful than expected, with 77% of those eligible 
agreeing to participate. Follow up for the primary end point of the study was also better than 
expected with 97% at 3 days and 88% at 6 weeks, which enabled recruitment to be completed on 
time. The number of patients recruited to the trial highlighted a disadvantage of RCTs, as only 45% 
of patients screened were eligible for inclusion, and, therefore, a large proportion of the presenting 
population were not investigated. Although generally considered the “gold standard” in clinical 
research, RCTs are only applicable to the population studied, meaning that the results of treatment 
in patients not included are often poorly understood. Results from this RCT were applicable only to 
patients with primary superficial GSV reflux as patients with recurrent varicose veins, SSV and non 
truncal reflux were not included.  Addressing these issues is difficult, although encouraging surgeons 
to enter patient data into registries may allow the investigation of uncommon disease processes and 
the evaluation of the results of treatments performed in complicated patients, frequently excluded 
from randomised trials. Unfortunately, data from  registries are often of poor quality (www.e-
dendrite.com. 2009) which may be due to the fact that data entry is very time consuming, with 
minimal benefit to the individual clinician. Similarly, results of the nationally collected PROM data 
are initially disappointing (http://www.hesonline.nhs.uk). These problems will need to be addressed 
if useful data are to be collected. Ensuring the data entered are of use to individual centres, 
clinicians and patients may help to improve the quality of the data.  
Results from the pilot study and the randomised trial confirmed that radiofrequency ablation with 
VNUS ClosureFASTTM was significantly less painful than laser ablation with the 980nm bare laser 
fibre, but no significant differences in return to work or normal activities were observed. 
Improvements in quality of life and clinical severity measures with the AVVQ, SF12 and VCSS were 
highly significant at 6 weeks and 6 months, with no significant differences between the groups. The 
study was sufficiently powered to investigate post-procedural pain, but did not have adequate 
numbers to compare anatomical success rates at 6 months, which would have required a much 
larger study. Despite the fact that there were more anatomical treatment successes in the EVLA 
group, this was not significant, and both treatments yielded good success rates at 6 months, in 
keeping with the published literature (Van den Bos et al. 2009a). Decisions regarding the choice of 
endovenous treatment modality are likely to be more complex than the evaluation of post-
procedural discomfort alone. In the light of NHS restrictions and rationing of varicose vein 
treatments (Lindsey et al. 2006; Nasr et al. 2008) the cost effectiveness of these procedures is likely 
to be scrutinised. In order to allow objective comparison between treatment modalities, the 
evaluation of treatment success must be carefully considered. Outcome measures following 
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superficial venous surgery have been highlighted as being crucial to the investigation of endovenous 
therapies. Consensus supports the movement away from surrogate outcome measures, towards 
patient reported outcome measures of success, in the hope that this will allow improvement of the 
patient’s experience and the quality of healthcare provided (Black et al. 2009; 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/D
H_092647 2010).   
Patient preferences are likely to become increasingly important factors in treatment provision and 
larger studies of patient preference are undoubtedly required. Importantly patient reported 
outcomes allow calculation of the cost effectiveness of an intervention, related to the relative 
improvement in quality of life experienced in QALYs, and are used in the allocation of healthcare 
resources. At present, calculations of cost effectiveness of therapies are based on generic 
assessment tools, in order to allow a comparison between different treatments and the relative 
importance of different disease processes. However, system specific tools are undoubtedly more 
responsive following interventions (Garratt et al. 1996). The increase in popularity of PROMs in 
research and routine practice may allow for the evaluation of more subtle differences and highlight 
advantages or disadvantages of a particular endovenous therapy. However, difficulties in comparing 
results of studies arise due to the numerous different outcome measures available. Investigation of 
the relationship between these outcome measures suggested that they correlate weakly, and, 
therefore, greater consensus regarding which to use would facilitate comparisons between studies. 
The cost effectiveness of the treatment of venous disease is difficult to calculate, as evidence of the 
rate of progression from uncomplicated disease to venous ulceration is scarce. The use of PROMs to 
calculate the disease burden to society may provide justification for the allocation of resources. It 
has been suggested that PROMs may be predictive of treatment success and that baseline scores 
could be used to ration resources. Evidence from this study suggests that patients with mild, 
moderate and severe disease benefit significantly from intervention, and unless this can be 
translated into justification of cost effectiveness, PROMs appear to be an inappropriate rationing 
tool at present. 
Due to the rapidly developing technology, endovenous therapies are under constant evaluation and 
improvement with the introduction of new laser fibres and different wavelengths. In addition, 
alternative endothermal ablation devices using steam are also being introduced. In order to 
investigate subtle differences in outcomes, well designed large randomised trials are required. 
However, these are time consuming and extremely costly to conduct, and the speed at which the 
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technology is evolving frequently means that the device under investigation has been superseded by 
a superior device before the results of the study can be published. For this reason, funding for 
clinical trials is difficult to obtain. It is likely that in the absence of large randomised studies, data 
combined from smaller studies and venous registries will be important.  However, if data from 
smaller studies is to be collated in order to draw any meaningful conclusions, consensus regarding 
the use of outcome measures will have to be reached. 
 
Conclusions 
Endovenous thermal ablation therapies have become increasingly popular over the last decade, 
however, they are not the “gold standard” treatment of varicose veins in the UK at the present time. 
Endovenous ablation is likely to be preferable to patients due to minimal post-procedural discomfort 
local anaesthetic treatment options and superior cosmetic results, although patients are generally 
poorly informed about the treatment options currently available.  
Treatment with RFA is significantly less painful than treatment with the 980nm bare fibre laser, but 
does not necessarily allow more rapid return to work. No differences were observed in clinical and 
functional outcomes at 6 weeks and functional and anatomical outcomes were also similar at 6 
months. Current laser devices are likely to be replaced with newer devices with longer wavelengths 
and coated or radial fibres. However, the evaluation of these newer devices and novel technologies 
such as steam was beyond the scope of this thesis.  
Evaluation of the severity of venous disease and the optimal outcome measure remains 
controversial. Adequate assessment of outcomes is essential in order to establish optimal treatment 
provision, which at present is highly variable. A combination of clinical and patient reported 
outcomes is likely to be effective, and may replace surrogate outcome measures in the future. 
International consensus on the most appropriate questionnaire to use for a particular patient group 
would aid comparison between clinical studies, although at present no such consensus exists. 
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9.1 Appendix 1. Web-based Questionnaire Sent to Surgeons 
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Online Surveys 
Develop, launch and analyse Web-based surveys 
 
 
 
1.  Which of the following procedures do you routinely perform for the treatment of varicose veins?  
    (select all that apply)  
   
Surgery    
Endovenous laser ablation    
Radiofrequency ablation    
Sclerotherapy    
2.  If a patient is suitable for all 4 treatment modalities please rank them in order of preference (1 being 
most popular, 4 being least popular)  
   
      
   1    2    3    4   
 a. Surgery  
    
 b. Endovenous laser ablation  
    
 c. Radiofrequency ablation  
    
 d. Sclerotherapy  
    
 
3.  Do you routinely perform venous duplex after the following procedures?    
      
   Yes    No    N/A   
 a. Surgery  
   
 b. Endovenous laser ablation  
   
 c. Radiofrequency ablation  
   
 d. Sclerotherapy  
   
 
4.  If you perform follow up venous duplex, please indicate the reasons for this (please tick all that 
apply)  
   
      
  
 Quality 
control   
 Anticipation of further 
treatment   
 Other (please 
specify)   
 a. Surgery  
   
 b. Endovenous laser ablation  
   
 c. Radiofrequency ablation  
   
The Role of Endovenous Thermal Ablation in the Treatment of Varicose Veins 
 
 
177 
 
 d. Sclerotherapy  
   
 
5.  Would you routinely intervene if you discovered truncal incompetence on duplex scanning in the 
absence of clinical recurrence after the following procedures?  
   
      
   Yes    No    N/A   
 a. Surgery  
   
 b. Endovenous laser ablation  
   
 c. Radiofrequency ablation  
   
 d. Sclerotherapy  
   
 
6.  If you routinely perform Endovenous laser ablation or Radiofrequency ablation, please indicate 
which is your usual location?  
   
N/A    
Operating theatre    
Adapted clinic room    
Other (please specify):  
   
 
  
 
a.  If you perform Endovenous laser ablation or Radiofrequency ablation, which anaesthesia do 
you routinely use?  
General anaesthesia    
Regional anaesthesia    
Local/ Tumescent anaesthesia only    
  
 
b.  What is your usual treatment plan?  
Treatment completed in a single visit    
Potential multiple visits    
Mixture of both of the above    
   
7.  Which of the following factors influence your decision regarding treatment options? (please rank: 1 
= most influential and 4 = least influential)  
   
      
   1    2    3    4   
 a. Your perception of patient preference  
    
 b. Availability of space to perform the 
procedure      
 c. Time taken to perform the procedure  
    
 d. Cost  
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8.  What is your routine method of treatment for the majority of patients with primary long saphenous 
vein incompetence and significant varicose veins?  
   
SFJ disconnection and LSV stripping with avulsions    
Endovenous laser ablation and avulsions    
Endovenous laser ablation and sclerotherapy    
Radiofrequency ablation and avulsions    
Radiofrequency ablation and sclerotherapy    
Sclerotherapy alone    
Other (please specify):  
   
9.  What is you routine method of treatment for the majority of patients with short saphenous vein 
incompetence and significant varicosities?  
   
SPJ Ligation (without stripping) and avulsions    
Stripping of the SSV with avulsions    
Endovenous laser ablation and avulsions    
Endovenous laser ablation and sclerotherapy    
Radiofrequency ablation and avulsions    
Radiofrequency ablation and sclerotherapy    
Sclerotherapy alone    
Other (please specify):  
   
10.  After treatment, what compression treatment do you routinely offer to patients?     
None    
Crepe bandage    
TEDS    
Compression stockings Grade 1    
Compression stockings Grade 2    
Other (please specify):  
   
11.  For how long do you advise patients to use compression after treatment?     
N/A    
<1 week    
1 week    
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1-2 weeks    
2-4 weeks    
up to 6 weeks    
Other (please specify):  
   
12.  Do you routinely use the CEAP classification     
Yes   No    
13.  What is your routine DVT prophylaxis regimen?  
    (select all that apply)  
   
None    
TEDS    
Subcut heparin    
Other (please specify): 
 
14.  For how long do you routinely use DVT prophylaxis?     
None    
Single dose    
The duration of in patient stay    
1 week    
1-2 weeks    
>2 weeks    
Other (please specify):  
   
15.  Do you have any local restrictions dictating which treatments you are able to offer? Please give 
brief reasons.  
   
      
    
   Yes    No   
 a. Surgery  
  
 
 b. Endovenous laser Ablation  
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 c. Radiofrequency Ablation  
  
 
 d. Sclerotherapy  
  
 
 
16.  Do you offer different treatments in the private sector where you are not restricted by NHS 
criteria?  
   
Yes   No    
  
 
If yes please indicate which treatments you are able to offer patients privately that you do not 
offer to those under the NHS  
(select all that apply) 
 
Traditional surgery    
Endovenous laser ablation    
Radiofrequency ablation    
Sclerotherapy    
Other (please specify): 
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9.2 Appendix 2. Patient Perspective Questionnaire 
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9.3 Appendix 3. Visual Analogue Pain Score and Diary Card 
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9.4 Appendix 4. Protocol for Digital Photoplethysmography 
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Measurement of venous function can be made based on the haemodymanics of blood flow in the 
leg, and has been shown to correlate with the severity of venous disease. This can be measured 
using digital photoplethysmography, which uses light rheography to measure the venous refill time.  
1) The patient is seated at rest with hips and knees at an angle of 90o. 
2) The probe is placed on the patient’s leg 10 cm above the medial malleolus and not over any 
varicosities. 
3) The machine is calibrated whilst the patient remains still. 
4) The patient performs 8 ankle dorsi flexions keeping the heel on the floor. 
5) The patient remains still with the foot flat on the floor whilst the measurement of venous 
refill time is taken. 
6) Steps 1 -5 are repeated. If the values are not within 10% of each other, a third reading is 
taken and the mean of the 3 calculated. 
The inflation of a tourniquet to 80 mmHg below the knee can simulate the effects of superficial 
venous surgery and can be use to predict which patients will benefit from treatment. 
7) A tourniquet is placed just below the patients’ knee and inflated to 80 mmHg. 
8) Steps 1-6 are repeated. 
 
 In this study venous refill time will be assessed using digital photoplethysmography pre-operatively 
with and without a tourniquet to mimic the effect of surgery, and at 6 weeks, 6 months and 12 
months. 2 consecutive readings with a coefficient of variation below 10% will be used in the study, 
with an additional reading taken if required. The mean will be calculated. 
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9.5 Appendix 5. Aberdeen Varicose Vein Questionnaire and Scoring Algorithm 
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9.6 Appendix 6.  Short Form 12 Questionnaire 
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9.7 Appendix 7. Patient Information Leaflet for VALVV Trial 
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9.8 Appendix 8. Operation Note Proforma used for Operative Data Collection 
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Vein Site 
GSV or 
SSV 
Side 
R/L 
Diameter 
(mm) 
Cycles  
(RFA), 
joules 
(EVLA) 
Watts Length of 
Vein 
mm 
Time 
secs 
Tumescence 
mls 
Number of 
Avulsions 
AK     BK 
1           
2           
3           
4           
 
Operative Details for VALVV Trial       Trial Number------------------------
------- 
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9.9 Appendix 9. Protocol for Endovenous Ablation Procedures 
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All interventions were carried out under general anaesthesia in an operating theatre by one of 3 
surgeons experienced in both techniques. For both techniques the GSV was cannulated at (or as 
near as possible to) the most distal point of venous reflux and the catheter tip was positioned 2 cm 
from the saphenofemoral junction under ultrasound guidance. Standardised tumescent anaesthesia 
(50ml 1% lidocaine + 1:200,000 adrenaline in 1000mls of normal saline) was infiltrated along the 
length of the vein under ultrasound guidance. In patients treated with segmental RFA, the first 
segment was treated with 2 RFA cycles as per manufacturer’s instructions and the remainder of the 
vein was treated with one RFA cycle per 7cm segment. Extrinsic pressure was applied over the vein 
during treatment cycles. In patients receiving EVLA, the laser was continually withdrawn with the 
aim of delivering >60 j/cm energy to the vein wall, with a power setting of 11W. Patients with 
additional small saphenous or anterior thigh vein incompetence were treated with the allocated 
treatment modality at the same sitting. Patients with varicosities were treated with concomitant 
phlebectomies using a standard technique with an Oesch hook and all phlebectomy sites were 
sutured with 6,0 prolene. Tumescent anaesthesia was not used for phlebectomy incisions. The 
patency of the deep veins was checked in all patients using ultrasound in the operating theatre 
immediately after the procedure by the operating surgeon. Following treatment a crepe bandage 
was applied for at least 2 hours, which was replaced with a thrombo-embolic deterrent (TED) 
stocking prior to discharge. Patients were instructed to wear the TED stocking continuously for 1 
week. On induction of anaesthesia, all patients received thromboprophylaxis consisting of 5000 units 
of subcutaneous heparin and a prophylactic antibiotic regimen of amoxicillin 1g and flucloxacillin 1g. 
All patients were discharged with a supply of paracetamol (1g up to 4 times a day) and ibuprofen 
(400mg up to 3 times a day) and instructed to take them only if required. All patients were also 
provided with a written information sheet advising them to mobilise as much as possible following 
the procedure and to return to work and normal activities as soon as they felt able. 
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9.10  Appendix 10. Raw Data of Baseline and Post-Procedure AVVQ, VCSS,  SF12 Scores 
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Results for Analysis of Covariance (ANCOVA) of change in AVVQ score between randomised groups 
AVVQ  
Mean (SD) 
RFA group 
N=67 
0 missing at baseline 
7 missing at 6 weeks 
11 missing at 6 mths 
EVLA group 
N=64 
0 missing at baseline 
9 missing at 6 weeks 
13 missing at 6 mths 
Crude difference * 
[95% CI] 
P-value 
Adjusted difference # 
[95% CI] 
P-value 
Baseline 
6 weeks 
6 months 
20.6 (9.4) 
10.9 (9.2) 
10.2 (9.4) 
18.9 (9.8) 
10.8 (8.9) 
10.9 (8.7) 
 
- 
 
- 
Change in 
Score at 6 
weeks 
 
-9.9 (9.4) 
 
-9.3 (8.7) 
-0.26 
[-3.11 to +2.58] 
0.854 
+0.33 
[-2.70 to +3.37] 
0.828 
Change in 
Score at 6 
months 
 
-10.9 (9.2) 
 
-8.5 (8.1) 
-1.55 
[-4.43 to +1.32] 
0.286 
-1.56 
[-4.59 to +1.46] 
0.308 
 
Results for Analysis of Covariance (ANCOVA) of change in VCSS score between randomised groups 
VCSS 
Mean (SD) 
RFA group 
N=67 
0 missing at baseline 
7 missing at 6 weeks 
11 missing at 6 mths 
EVLA group 
N=64 
0 missing at baseline 
8 missing at 6 weeks 
13 missing at 6 mths 
Crude difference * 
[95% CI] 
P-value 
Adjusted difference # 
[95% CI] 
P-value 
Baseline 
6 weeks 
6 months 
5.1 (2.1) 
1.7 (1.7) 
1.4 (1.8) 
4.7 (2.1) 
1.5 (1.8) 
1.4 (1.7) 
 
- 
 
- 
Change in 
Score at 6 
weeks 
 
-3.6 (2.2) 
 
-3.0 (2.1) 
-0.09 
[-0.71 to +0.53] 
0.777 
+0.01 
[-0.63 to +0.65] 
0.969 
Change in 
Score at 6 
months 
 
-3.8 (2.2) 
 
-2.9 (1.9) 
-0.37 
[-1.00 to +0.25] 
0.239 
-0.28 
[-0.86 to +0.29] 
0.332 
 
*Values are mean(S.D) unless indicated otherwise; values in parentheses are 95 per cent confidence intervals. 
†Adjusted for baseline value. ‡Adjusted for baseline value as well as age, sex, body mass index of 30 kg/m
2
 or 
above, Venous Clinical Severity Score (VCSS) in the randomized leg (as a measure of severity of varicose vein 
disease), pattern of disease (great saphenous vein (GSV) versus GSV and small saphenous vein), length of vein 
ablated, number of phlebectomies (above or below knee), presence of deep vein disease and unilateral versus 
bilateral disease. RFA, radiofrequency ablation; EVLA, endovenous laser ablation; AVVQ, Aberdeen Varicose 
Vein Questionnaire. 
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Results for Analysis of Covariance (ANCOVA) of change in SF-12 physical summary score 
SF-12 PSS 
Mean (SD) 
RFA group 
N=67 
2 missing at baseline 
8 missing at 6 weeks 
11 missing at 6 mths 
EVLA group 
N=64 
3 missing at baseline 
11 missing at 6 weeks 
13 missing at 6 mths 
Crude difference * 
[95% CI] 
P-value 
Adjusted difference # 
[95% CI] 
P-value 
Baseline 
6 weeks 
6 months 
48.9 (9.5) 
50.7 (8.7) 
51.7 (9.3) 
48.1 (10.1) 
53.1 (7.3) 
51.4 (9.6) 
 
- 
 
- 
Change in 
Score at 6 
weeks 
 
+2.9 (8.7) 
 
+3.4 (7.9) 
-0.16 
[-3.34 to +3.02] 
0.919 
-0.93 
[-4.26 to +2.40] 
0.580 
Change in 
Score at 6 
months 
 
+3.4 (13.2) 
 
+3.3 (14.4) 
+0.29 
[-3.32 to +3.89] 
0.875 
+1.60 
[-2.01 to +5.21] 
0.380 
Results for Analysis of Covariance (ANCOVA) of change in SF-12 mental summary score 
SF-12 MSS 
Mean (SD) 
RFA group 
N=67 
2 missing at baseline 
8 missing at 6 weeks 
11 missing at 6 mths 
EVLA group 
N=64 
3 missing at baseline 
12 missing at 6 weeks 
13 missing at 6 mths 
Crude difference * 
[95% CI] 
P-value 
Adjusted difference # 
[95% CI] 
P-value 
Baseline 
6 weeks 
6 months 
47.1 (11.0) 
50.4 (9.5) 
49.0 (10.8) 
48.0 (13.1) 
51.3 (9.9) 
52.4 (8.8) 
 
- 
 
- 
Change in 
Score at 6 
weeks 
 
+4.2 (13.3) 
 
+2.5 (10.1) 
+2.35 
[-2.27 to +6.97] 
0.316 
+1.84 
[-3.27 to +6.95] 
0.476 
Change in 
Score at 6 
months 
 
+0.9 (14.2) 
 
+4.7 (14.6) 
-3.41 
[-7.25 to +0.42] 
0.081 
-3.78 
[-8.03 to +0.46] 
0.080 
 
*Values are mean(S.D) unless indicated otherwise; values in parentheses are 95 per cent confidence intervals. 
†Adjusted for baseline value. ‡Adjusted for baseline value as well as age, sex, body mass index of 30 kg/m
2
 or 
above, Venous Clinical Severity Score (VCSS) in the randomized leg (as a measure of severity of varicose vein 
disease), pattern of disease (great saphenous vein (GSV) versus GSV and small saphenous vein), length of vein 
ablated, number of phlebectomies (above or below knee), presence of deep vein disease and unilateral versus 
bilateral disease. RFA, radiofrequency ablation; EVLA, endovenous laser ablation; SF-12® Short Form 12; PCS, 
physical component score; MCS, mental component score. 
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9.11 Appendix 11. SQOR-V Questionnaire and Scoring Algorithm 
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Item 
number 
Items Dimension Value Impact 
1 Overall discomfort (left leg) Discomfort 1-5 Physical 
2 Pain (left leg) Discomfort 1-5 Physical 
3 Heaviness (left leg) Discomfort 1-5 Physical 
4 Itching (left leg) Discomfort 1-5 Physical 
5 Night cramps (left leg) Discomfort 1-5 Physical 
6 Swelling (left leg) Discomfort 1-5 Physical 
7 Warm or burning sensation (left leg) Discomfort 1-5 Physical 
8 Tingling (left leg) Discomfort 1-5 Physical 
9 Stinging or stabbing sensation (left leg) Discomfort 1-5 Physical 
10 Restless legs (left leg) Discomfort 1-5 Physical 
11 Worse with heat (left leg) Discomfort 1-5 Physical 
12 Overall discomfort (right leg) Discomfort 1-5 Physical 
13 Pain (right leg) Discomfort 1-5 Physical 
14 Heaviness (right leg) Discomfort 1-5 Physical 
15 Itching (right leg) Discomfort 1-5 Physical 
16 Night cramps (right leg) Discomfort 1-5 Physical 
17 Swelling (right leg) Discomfort 1-5 Physical 
18 Warm or burning sensation (right leg) Discomfort 1-5 Physical 
19 Tingling (right leg) Discomfort 1-5 Physical 
20 Stinging or stabbing sensation (right leg) Discomfort 1-5 Physical 
21 Restless legs (right leg) Discomfort 1-5 Physical 
22 Worse with heat (right leg) Discomfort 1-5 Physical 
23 Overall appearance of your right leg affected by vein problems Appearance 1-5 Psychosomatic 
24 Overall appearance of your left leg affected by vein problems Appearance 1-5 Psychosomatic 
25 Vein problems impacting clothing choice  Appearance 1-5 Psychosomatic 
26 Vein problems impacting activities choice Restriction in movements  1-5 Physical 
27 Overall restriction  Restriction in movements  1-5 Physical 
28 At work  Restriction in movements  1-5 Physical 
29 At home  Restriction in movements  1-5 Physical 
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30 Sport or leisure activities Restriction in movements  1-5 Physical 
31 Prolonged standing  Restriction in movements  1-5 Physical 
32 Prolonged sitting  Restriction in movements  1-5 Physical 
33 When walking  Restriction in movements  1-5 Physical 
34 When using stairs  Restriction in movements  1-5 Physical 
35 During sleep  Restriction in movements  1-5 Physical 
36 Social activities  Restriction in movements  1-5 Physical 
37 Intimate or sexual relations  Restriction in movements  1-5 Physical 
38 Overall, do your vein problems worry you? Risk – threat to health 1-5 Physical 
39 Does the possible worsening of your vein disease worry you? Risk – threat to health 1-5 Physical 
40 Does the possibility of your condition causing complications worry you? Risk – threat to health 1-5 Physical 
41 Does it worry you that someone related to you suffers from vein disease? Risk – threat to health 1-5 Physical 
42 Overall emotional consequences Emotional problems 1-5 Psychosomatic 
43 Because of my vein problems, I am on edge Emotional problems 1-5 Psychosomatic 
44 Because of my vein problems, I am irritable Emotional problems 1-5 Psychosomatic 
45 Because of my vein problems, I feel like I am a burden to others Emotional problems 1-5 Psychosomatic 
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Original article
Endovenous treatments for varicose veins –
over-taking or over-rated?
A C Shepherd, M S Gohel, M Hamish, C S Lim and A H Davies
Imperial Vascular Unit, Charing Cross Hospital, London, UK
Abstract
Objectives: A variety of endovenous therapies for the treatment of superficial venous
incompetence are currently available. The aim of this study was to evaluate the prevalence
of endovenous techniques used by consultant vascular surgeons in the United Kingdom.
Methods: An anonymous online survey of 16 multiple choice questions relating to the nature
and provision of treatment for varicose veins was devised. Consultant members of the
Vascular Society of Great Britain and Ireland were invited to participate by email.
Results: A total of 108/352 (31%) surgeons completed the survey. The majority offered
surgery as the first-line treatment for primary great saphenous vein (GSV) and small
saphenous vein (SSV) incompetence (69% and 74%, respectively). Endovenous procedures
were offered as first-line treatment by 32/108 (29.6%) for GSV reflux, 36/51 (70.6%)
surgeons performed these under local anaesthetic and 21/51 (41.2%) were performed as
an outpatient procedure. The most important factor influencing treatment decisions was
considered to be patient preference by 77/108 (71.3%) surgeons, although 48/61 (78.7%)
respondents were restricted by primary care trusts with regard to endovenous treatments,
and 33/108 (30.6%) offered different treatments to private patients.
Conclusion: Traditional surgery remains the most commonly offered treatment for patients
with varicose veins. The provision of endovenous therapies varies greatly, and there are
significant differences in local availability regarding these treatments.
Keywords: varicose veins; endovenous ablation; traditional surgery; survey
Introduction
Varicose veins are a common clinical problem
affecting approximately 30% of the UK population.1
Patients seek treatment for a number of reasons
ranging from cosmetic concerns to chronic venous
ulceration. Traditionally, surgical treatment consists
of saphenofemoral disconnection and stripping of
the great saphenous vein (GSV). This is known to
be effective, but may be associated with wound
complications, high recurrence rates and sub-
sequently a degree of patient dissatisfaction.2–4
In recent years, minimally invasive endovenous
techniques have become increasingly popular in
the United Kingdom as an alternative to traditional
surgery. Previous postal surveys conducted in 2005
showed that endovenous treatments, including
laser and radiofrequency ablation, were used by
less than 30% of surgeons in the UK. Interestingly,
over 50% of surgeons reported local referral guide-
lines restricting the treatment of varicose veins in
2005, and in the majority of cases the use of endove-
nous techniques was restricted to private practice.5,6
Foam sclerotherapy was reported to have been used
by 20–42% of surgeons in postal surveys conducted
in 2006 and 2007.6,7
The aim of this study was to evaluate the preva-
lence of endovenous techniques used by consultant
vascular surgeons in the United Kingdom.
Methods
A questionnaire consisting of 16 multiple choice
questions was designed by members of Imperial
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Vascular Unit at Charing Cross Hospital and an
online survey was created using an academic
online survey website.8 Consultant members of the
Vascular Society of Great Britain and Ireland
(VSGBI) with published email addresses were
invited to participate by email. The questions
related to the following: routine treatments offered
to patients with varicose veins; use of venous
duplex scanning; indications for re-intervention;
anaesthesia and the location in which the treatment
was performed; factors influencing the decision
regarding treatment; the use of postoperative com-
pression and thromboprophylaxis; restrictions
imposed by primary care trusts regarding treatment
of varicose veins and the nature of treatments offered
in the private sector (see Appendix). All responses
were anonymous. Where responses were incom-
plete, the number of responses received for that
particular question was given as the denominator.
Results
A total of 352 consultant members of the VSGBI
were contacted by email and invited to complete
the survey; there were 108 responses, of which 80
were complete.
Current use of endovenous treatments
The majority of surgeons, 99/108 (91.6%), regularly
performed traditional surgery for varicose veins,
whereas sclerotherapy was routinely performed by
66/108 (61.1%) and endothermal procedures were
frequently performed by 48/101 (48%) surgeons
(endovenous laser therapy [EVLT] by 43 and radio-
frequency ablation [RFA] by 11 respondents); 23/
101 (23%) respondents did not offer any endovenous
procedures. Traditional surgery was the most fre-
quently performed treatment for GSV and small
saphenous vein reflux (see Figure 1). Of the surgeons
offering endovenous treatment, half performed
concomitant phlebectomies for varicosities and half
performed subsequent sclerotherapy of varicosities,
if required. In patients deemed suitable for all treat-
mentmodalities, 60/108 (55.6%) surgeons performed
traditional surgery, whereas 24/108 (22.2%) pre-
ferred EVLA. Radiofrequency ablation (6/108) and
foam sclerotherapy (11/108) were used relatively
less frequently (5.5% and 10.2%, respectively).
A total of 77/108 (71.3%) surgeons stated that
patient preference was the most important factor
when deciding which treatment to offer. The time
taken for the procedure, cost or space consider-
ations were considered relatively unimportant.
Anaesthesia and location of treatment provision
Endothermal treatments were performed in an
operating theatre by 30/51 (58.8%) surgeons, with
the remainder performed in an adapted outpatient
clinic or outpatient theatre. Local anaesthesia was
used by 36/51 (70.6%) surgeonsperforming endother-
mal treatments, whereas one surgeon used regional
anaesthesia and the remaining 14/51 (27.5%) pre-
ferred general anaesthesia. Almost half the endother-
mal treatments (25/51, 49.0%) were performed with
concomitant phlebectomy, with the intention of
completing treatment in a single hospital visit.
Thromboprophylaxis
In total, 66/98 (67.3%) prescribed subcutaneous
heparin or low molecular weight heparin and
42/98 (42.9%) advised TED stockings. Of those
prescribing subcutaneous heparin, 42/66 (63.6%)
would use a single dose only, 18/66 (27.3%)
would prescribe it for the duration of their inpatient
stay and two surgeons would routinely advise it for
one week. Two surgeons prescribed subcutaneous
heparin for bilateral or recurrent varicose veins
only and many commented that they may alter
thromboprophylaxis based on the individual risk
of the patient. Four surgeons stated that they
would not use pharmacoprophylaxis for patients
undergoing foam sclerotherapy; however they
would do so for endovenous or traditional
surgery. A total of 16/98 (16.3%) did not routinely
prescribe any form of thromboprophylaxis; of
these 6/16 were performing surgery and foam scler-
otherapy only, 6/16 were performing all treatments,
1/16 was performing EVLA and foam sclerother-
apy, and 3/16 were performing surgery only.
Postoperative management
Postoperative compression was most frequently rec-
ommended for 7–14 days (Figure 2). Over half of the
surgeons, 54/101 (53.4%), applied compressionbanda-
ging immediately following the procedure,whichwas
replaced with TED stockings (,18 mmHg) prior to
discharge (usually within 24 hours) whereas 6/101
(5.9%) replaced the bandaging with TED stockings
after 24 hours. Grade I (14–17 mmHg) and grade II
(18–24 mmHg) graduated compression stockings
were used by 8/101 (7.9%) and 16/101 (15.8%) sur-
geons, respectively. Some surgeons, 14/101 (13.8%),
did not use elastic compression hosiery and preferred
bandaging, usually crepe, Pannelastw (Vernon Carus,
Preston, UK) or CobanTM (3MTM, Berkshire, UK).
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There was considerable variation in regimes and
duration of compression.
Following traditional surgery, only 2/108 (1.9%)
surgeons would routinely perform colour duplex,
whereas 30/48 (62.5%) would investigate patients
with colour duplex after EVLT or RFA and 33/71
(46.5%) would do so following foam sclerotherapy.
The commonest stated reason for postoperative
duplex was to ensure successful ablation of the
treated vein (29/38 [76.3%] following EVLA, 17/21
[81.0%] following RFA and 29/44 [65.9%] following
foam sclerotherapy). Of the surgeons who per-
formed colour duplex following treatment, 10/51
(19.6%) would re-intervene following endothermal
treatments and 14/68 (20.6%) following sclerother-
apy, if a patient still had truncal incompetence
even in the absence of clinical symptoms. No sur-
geons reported that they would offer additional
intervention in the absence of clinical symptoms
following traditional surgery.
Local rationing of varicose vein treatments
Local restrictions to the provision of varicose vein
treatment were reported by 48/108 (44.4%) respon-
dents. Restrictions were imposed on 28/108 (25.9%)
surgeons offering open surgery and 23/80 (28.8%)
of those offering foam sclerotherapy; however, 48/
80 (60.0%) and 48/61 (78.7%) surgeons reported
restrictions regarding the use of EVLT and RFA,
respectively. The lack of funding for endovenous
equipment was given by many surgeons (28/80
35%) as the reason for not performing endovenous
procedures, although the lack of theatre time, space
due to pressure from other departments, the lack of
a laser approved room and the fact that traditional
surgery was cheaper than laser or radiofrequency
were also given as reasons. When asked about
the treatment of private patients, 33/108 (30.6%)
surgeons stated that they would advise venous
treatments that they were unable to offer in their
National Health Service (NHS) practice.
Discussion
This online survey of consultant vascular surgeons
in the UK conducted in 2008 showed that tra-
ditional surgery is still the most widely offered
treatment for varicose veins, despite the apparent
increasing popularity of endovenous procedures.
These findings mirror the results from a recent
postal survey of consultants and vascular trainees
published in 2008, which reported that the majority
(96%) of surgeons were performing conventional
surgery, 27% were offering foam sclerotherapy,
19% were offering EVLT and 3% were offering
RFA to NHS patients.6 However, these data
appear to show a small increase in the use of endo-
venous therapies, compared with previous
surveys,5,7 suggesting a slow movement towards
newer techniques. Many surgeons who were per-
forming endovenous treatments were favouring
procedures performed under local anaesthetic and
a significant number performed treatments on an
Figure 1 (a) First-line treatments offered to patients for great
saphenous vein incompetence (b) First-line treatments offered to
patients for small saphenous vein incompetence
Figure 2 Duration of compression prescribed by surgeons
following varicose vein treatment
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outpatient basis. Although this survey asked which
treatments surgeons were able to offer and why, it
did not investigate the patients’ perspectives.
Research has shown that patients generally have
little knowledge of treatment options prior to their
consultation and so are likely to rely strongly on
the opinion of the physician at their initial consul-
tation,9 which will undoubtedly be influenced by
the treatments they are able to offer. The lack of
uptake of endovenous procedures may be due to
the high initial costs of endovenous equipment
and training, at a time when varicose vein surgery
is subject to increasing scrutiny and significant
funding restrictions by a large number of health-
care providers.10,11 At present, both laser and radio-
frequency equipment are readily available;
however, the cost of the generator and catheters
varies significantly between the two. Undoubtedly,
the cost-effectiveness of new therapies will be
under great scrutiny prior to widespread use.
Despite reminder emails, the response rate in this
survey was disappointingly low. Response rates
from postal surveys in the UK are extremely vari-
able; recent postal surveys sent to both consultants
and vascular trainees had significantly higher
response rates5,6 but other postal surveys have
achieved similarly poor responses.12 Our response
may be due to inaccurate or unavailable email
addresses, but may also reflect a reluctance on the
part of consultant vascular surgeons to engage
with online surveys. Indeed, responses to previous
email surveys appear to have had a poorer response
rate compared with postal surveys among vascular
surgeons.11 Research into the response rates compar-
ing postal surveys with email/web surveys sent to
medical professionals confirms that the response
rate is frequently lower from electronic surveys;
however, electronic surveys have been shown to
result in a more rapid response at lower cost com-
pared with postal surveys.13–15 We acknowledge
that these limitations may mean that our findings
are not truly representative of the entire UK practice,
with enthusiastic advocates for endovenous thera-
pies or more computer-literate surgeons potentially
being more likely to respond.
At present there is no consensus regarding the
nature and duration of postoperative compression
that should be applied following surgical or
endothermal procedures. Evidence suggests that
TED stockings are adequate following foam scler-
otherapy;16 however, compression following
endothermal treatments varies widely throughout
the country.16 This study highlighted the wide vari-
ations in practices in terms of thromboprophylaxis,
postoperative compression and use of duplex
imaging. Interestingly, postoperative duplex use
and treatment of residual truncal reflux varied
between traditional and endovenous treatments. As
the prevalence of varicose veins is high, it is likely
that patient demand for treatment will remain high
for years to come. Each treatment modality has
advantages and disadvantages, but long-term out-
comes are unclear. This confusion is demonstrated
by the huge variability in treatment modality, type
of anaesthetic, location of therapy and postoperative
management in this survey. With patient choice
regarding treatment becoming ever more important,
further evaluation of patient preferences regarding
treatment strategy is required. Despite the introduc-
tion of minimally invasive treatments for varicose
veins, traditional surgery remains the most fre-
quently performed treatment for varicose veins in
the United Kingdom and in Europe.17 Of the sur-
geons performing endovenous treatments, perio-
perative management varies greatly. It is clear that
further clinical trials are needed to clarify some of
these issues and guide clinical practice.
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Appendix
Question Response options
1 Which of the following procedures do you routinely perform for the
treatment of varicose veins? (select all that apply).
Surgery, endovenous laser ablation, radiofrequency ablation,
sclerotherapy
2 If a patient is suitable for all four treatment modalities please rank them
in order of preference (1 being most popular, 4 being least
popular).
Surgery, endovenous laser ablation, radiofrequency ablation,
sclerotherapy
3 Do you routinely perform venous duplex after the following
procedures?
Surgery, endovenous laser ablation, radiofrequency ablation,
sclerotherapy
4 If you perform follow-up venous duplex, please indicate the reasons
for this (please tick all that apply).
Quality
control
Anticipation of
further treatment
Other
Surgery
EVLT
RFA
Foam
sclerotherapy
5 Would you routinely intervene if you discovered truncal incompetence
on duplex scanning in the absence of clinical recurrence after
the following procedures?
Surgery, endovenous laser ablation, radiofrequency ablation,
sclerotherapy
6 If you routinely perform endovenous laser ablation or radiofrequency
ablation, please indicate which is your usual location?
Not applicable, operating theatre, adapted clinic room, other
6a If you perform endovenous laser ablation or radiofrequency ablation,
which anaesthesia do you routinely use?
General anaesthesia, regional anaesthesia, local/tumescent
anaesthesia only
6b What is your usual treatment plan? Treatment completed in a single visit, potential multiple visits,
mixture of both of the above
7 Which of the following factors influence your decision regarding
treatment options? (Please rank: 1 ¼ most influential and 4 ¼ least
influential).
Your perception of patient preference, availability of space to
perform the procedure, time taken to perform the procedure,
cost
8 What is your routine method of treatment for the majority of patients
with primary long saphenous vein incompetence and significant
varicose veins?
SFJ disconnection and LSV stripping with avulsions, endovenous
laser ablation and avulsions, endovenous laser ablation and
sclerotherapy, radiofrequency ablation and avulsions, radio-
frequency ablation and sclerotherapy, sclerotherapy alone and
other (please specify)
9 What is you routine method of treatment for the majority of patients
with short saphenous vein incompetence and significant
varicosities?
SPJ ligation (without stripping) and avulsions, stripping of the
SSV with avulsions, endovenous laser ablation and avulsions,
endovenous laser ablation and sclerotherapy, radiofrequency
ablation and avulsions, radiofrequency ablation and
sclerotherapy, sclerotherapy alone and other (please specify)
Continued
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Appendix Continued
Question Response options
10 After treatment, what compression treatment do you routinely
offer to patients?
None, crepe bandage, TED stockings, compression stockings
Grade 1, compression stockings Grade 2, and other (please
specify)
11 For how long do you advise patients to use compression after
treatment?
N/A, ,1 week, 1 week, 1–2 weeks, 2–4 weeks, up to 6 weeks
and other (please specify).
12 Do you routinely use the CEAP classification? Yes, No.
13 What is your routine DVT prophylaxis regimen? (select all that apply). None, TED stockings, subcut heparin and other (please specify)
14 For how long do you routinely use DVT prophylaxis? None, single dose, the duration of inpatient stay, 1 week, 1–2
weeks, .2 weeks and other (please specify)
15 Do you have any local restrictions dictating which treatments you are
able to offer? Please give brief reasons.
Surgery, endovenous laser ablation, radiofrequency ablation,
sclerotherapy
16 Do you offer different treatments in the private sector where you are
not restricted by NHS criteria? If yes please indicate which treat-
ments you are able to offer patients privately that you do not offer to
those under the NHS (select all that apply).
Surgery, endovenous laser ablation, radiofrequency ablation,
sclerotherapy, other (please specify)
EVLT, endovenous laser therapy; RFA, radiofrequency ablation; LSV, long saphenous vein; SFJ, saphenofemoral junction; SPJ, saphenopopliteal
junction; SSV, small saphenous vein; CEAP, clinical, aetiological, anatomical and pathological elements; DVT, deep vein thrombosis; NHS,
National Health Service
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The treatment of varicose veins: an investigation
of patient preferences and expectations
A C Shepherd, M S Gohel, C S Lim, M Hamish and A H Davies
Imperial Vascular Unit, Imperial College, London
Abstract
Objectives:A number of modalities are now available for the treatment of varicose veins. The
aim of the study was to investigate the factors considered important by patients when
contemplating treatment of their varicose veins.
Methods: Consecutive new patients referred to a vascular surgery service were invited to
complete a short anonymous questionnaire prior to their consultation. The questionnaire
consisted of 13 multiple choice questions relating to symptoms, potential varicose vein
treatments and patient knowledge of existing therapies.
Results: Of 111 patients, there were 83 complete responses (75%). Symptoms of pain or
aching were reported as moderate or severe by 77/103 (75%) of patients and significantly
limited the activities of 47/101 (47%). Although the majority (89/103 [86%]) of patients
were aware of surgery, only 52/103 (51%) knew of the existence of endothermal ablation
(either laser or radiofrequency) and only 23/103 (22%) were aware of foam sclerotherapy.
Some 58/92 (63%) were in favour of local anaesthetic treatment. Most patients (74/103,
72%) felt inadequately informed to express a preference regarding treatment type prior to
their consultation, although 24/103 (23%) expressed a preference for endovenous
treatment. Interestingly, 74/92 (80%) stated that the opinion of their vascular surgeon
would be likely to or definitely influence their treatment decision and the majority of
patients stated that what they had read in magazines (54/80, 64%) or on the Internet
(51/85, 60%) would have no influence on their decision regarding treatment, respectively.
Conclusion: Only a minority of patients referred with varicose veins were aware of
endovenous treatments or felt adequately informed to express a treatment preference prior
to consultation. Over half of patients expressed a preference for local anaesthetic therapy
and a preference for a single visit treatment, although most would be strongly influenced
by the opinion of their vascular surgeon and not influenced by media advertising.
Keywords: patient perspective; varicose veins; endovenous ablation; questionnaire study
Introduction
Varicose veins are thought to affect up to 40% of the
UK population and become increasingly common
with age.1 Patients may seek treatment for a
number of reasons. Some have purely cosmetic
complaints, but most report a wide variety of
commonly experienced physical symptoms,
although proving a causal relationship between
symptoms and varicose veins remains difficult.1,2
Approximately 90,000 procedures are performed
annually in the UK for varicose veins,3 with the
majority of patients treated with traditional
surgery.4–6 However, traditional surgery may be
associated with significant complications, high
recurrence rates7 and considerable patient dissatis-
faction.8,9 The clinical benefits and cost-
effectiveness of treating both complicated and
uncomplicated varicose veins have been well
documented.10–12 However, recent surveys have
suggested that over 50% of surgeons have
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restrictions limiting who they are able to treat and
the treatments they can provide.4,6,13 Differences
in the referral guidelines in primary care trusts con-
sequently means that the management of varicose
veins varies widely throughout the country.13,14
The introduction of minimally invasive endove-
nous techniques offers the prospect of treatment
under local anaesthetic, potentially performed
as an office-based procedure in order to allow
quicker treatment times and rapid return to
normal activities. Endovenous therapies are associ-
ated with significant consumable costs, although
these may be outweighed by the perceived advan-
tages of quicker treatment and rapid return to
work. It has been suggested that endovenous treat-
ments may be no more expensive than traditional
superficial venous surgery if treatment times and
recovery periods are taken into account,15 although
studies of cost-effectiveness are scarce. Early out-
comes following endovenous ablation are promis-
ing, meaning that choosing between different
treatment modalities has become increasingly diffi-
cult. Consideration of patient preferences may help
decide which treatments are best for individual
patients.16 Indeed, it has been shown that most
patients want to have an active role in their care
and that patient involvement is important in order
to ensure sustainable, effective and efficient health
care.17
The aim of the study was to evaluate patient
knowledge of varicose vein treatments and assess
the factors that patients considered to be important
when contemplating therapy.
Methods
The study was set within a vascular surgical clinic
in a teaching hospital (Charing Cross Hospital,
London). General practitioner referral letters were
scrutinized to identify patients who would be
considered for treatment of their varicose veins.
Consecutive patients referred to one consultant
surgeon with symptomatic varicose veins were
invited to complete an anonymous questionnaire
prior to their consultation with the vascular
surgeon. Questions related to occupation, physical
symptoms and impact of the varicose veins,
patient knowledge of existing treatments, concerns
about complications and recurrence, preferred
treatment options and factors that might influence
decisions regarding treatment (Appendix 1). No
information was given to patients prior to complet-
ing the survey. Where questions were not com-
pleted by every participant, the number of
complete responses for that question is shown as
the denominator.
Results
Over a six-month period, 111 patients were invited
to complete the questionnaire. A total of 83 (75%)
complete and 28 partially complete responses
were received. The number of patients who com-
pleted each question is given as the denominator,
and therefore varies for each question. A total of
80/109 (73%) of patients were female, two patients
did not state their gender, 43/108 (40%) were
full-time employees, 19/108 (17%) were part-time
employees and 46/108 (43%) were not employed.
Ages ranged between 18 and 83, with the majority
of patients 79/111 (72%) aged between 18 and 60
years. Reported co-morbidities included hyperten-
sion 18/111 (16%); previous deep vein thrombosis
8/111 (7%); asthma 5/111 (5%); diabetes 4/111 (4%);
epilepsy 2/111 (2%); chronic obstructive pulmonary
disease 2/111 (2%); ischaemic heart disease 2/
111 (2%) and transient ischemic attacks 1/111 (1%).
The remaining 61% reported no co-morbidities.
Reasons for seeking treatment and
time of treatment
Moderate or severe symptoms of pain or discomfort
were reported by 77/103 (75%) (Figure 1). The
appearance of varicosities moderately or severely
affected 75/97 (77%) patients and was the
outcome of most concern in 19/95 (20%) patients
(Figure 2). There was no apparent trend in the
symptoms reported and employment status
(Figure 3). The majority of patients 54/96 (56%)
were not concerned about taking time off work for
treatment. Of these, 35/54 (65%) were not employed,
11/54 (20%) were employed full time and 8/54
(15%) were employed part-time. However, discom-
fort after treatment and recurrence of varicose veins
were greater concerns for patients (Figure 4).
Location and anaesthesia
Although 23/102 (22%) of patients expressed a pre-
ference for office-based/outpatient treatment, 65/
102 (64%) had no location preference. In response
to the statements ‘I would prefer my treatment to
be carried out in a single visit rather than several
separate visits’ and ‘I would prefer my treatment
to be carried out under local anaesthetic rather
than general anaesthetic’, the majority expressed a
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preference for a single visit and for local anaesthetic
(Table 1). Of these, 30/90 (33%) stated that the type
of anaesthetic would have no influence on their
choice of treatment.
Awareness of treatments and
patient preferences
The majority of patients were aware of surgery
(89/103, 89%), although far fewer were aware of
endovenous techniques (Figure 5a). Most patients
stated that they did not know enough about the
treatments to express a preference (74/103, 72%).
However, 24/103 (23%) expressed a preference for
endovenous treatments over surgery (either endo-
venous laser ablation, radiofrequency ablation or
sclerotherapy) and of the endovenous treatments,
laser was the most popular (Figure 5b). There
were no apparent trends in treatment preference
according to occupational status; however, 10/43
(23%) of patients employed full time, 4/18 (22%)
of those employed part-time and 10/41 (24%) of
those not employed expressed a preference for
endovenous treatments, respectively.
Factors influencing patient decisions
Some 74/92 (80%) stated that their treatment
decision would be influenced by the opinion of
their vascular surgeon. Regarding the number of
visits required for treatment, 30/88 (34%) of patients
stated that it would have no effect on their choice of
treatment, 29/88 (33%) said that it may influence
their choice of treatment and only 9/88 (10%) said
it would definitely affect their choice of treatment.
Similarly 30/90 (33%) patients stated that the type
of anaesthesia would have no effect on their
choice of treatment, with only 13/90 (14%) stating
that it would definitely affect their choice of
treatment.
Although some patients expressed preferences
about anaesthesia and the number of visits required,
thesewere far less likely to influence decisions about
treatments. Interestingly, previous experience of
Figure 1 Patient reported symptoms of varicose veins
Figure 2 Treatment outcomes considered most important by patients
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varicose vein treatment was reported to have no
influence on decisions regarding future therapy by
nearly half of patients 38/83 (46%). Furthermore,
most patients stated that what they had read in
magazines or the Internet would have no influence
on their treatment decision (Figure 6).
Discussion
This study demonstrated that most patients referred
with varicose veins have little knowledge of the
available treatment options. Most were aware of
surgery, but far fewer were aware of minimally
invasive procedures. The findings in this study
indicate that the majority of patients rely strongly
on advice and opinions given by the vascular
surgeon at the initial consultation. Interestingly,
the majority of patients stated that information in
magazines, Internet or in the media would have
no influence on their decision regarding treatment.
Most respondents expressed some preference
towards having treatment under local anaesthetic,
but also would prefer treatment to be completed
in a single visit, which is often impossible, particu-
larly for patients with bilateral disease or large
numbers of varicosities. Patients appeared to be
divided as to which factors were more important
to them. Some patients do have specific treatment
preferences, which may be related to their occu-
pation, concerns regarding cosmesis or previous
experience; however, the prospect of minimal dis-
comfort and rapid return to normal activities is
understandably attractive to all patients.
As the majority of patients in this study had little
or no knowledge of varicose vein treatments, the
importance of providing suitable verbal and non-
verbal information at the initial consultation is
clear, in order that informed consent be gained for
Figure 4 Patient concerns regarding varicose vein treatment
Figure 3 Symptoms reported according to employment status
(a) Patients in full time employment (b) Patients in part-time
employment (c) Patients not in employment
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procedures. Despite this, a survey of ordinary
members of the vascular society conducted in
2006 suggested that 70% of surgeons would give
verbal information about potential treatment
options for varicose veins to patients at an outpati-
ent consultation and only 53% would also give
some form of written information. Of the written
information given, only 62% and 65% gave specific
treatment details or details about complications,
respectively, and less than 10% of patients would
be referred to online information resources.13 A
recent investigation of the information available to
patients with varicose veins on the Internet found
that less than 50% of websites discussed all treat-
ment options and many failed to warn of potential
complications.18 Ideally, patients should be
provided with information about all potential treat-
ment options, including the advantages and disad-
vantages, even if they are not available at that
particular hospital, and should be allowed to
express a preference as to where they are treated.
Recommendations published by NICE in 2001
stated that varicose vein surgery should not be pro-
vided solely for cosmetic reasons.19 However, in
2006, 20% of surgeons reported that they were still
permitted by their primary care trust to offer treat-
ment for cosmetic varicose veins.13 In terms of treat-
ing varicose veins, the most cost-effective procedure
is likely to be foam sclerotherapy.20 However, with
recurrence of varicosities stated as being one of
the most concerning issues for many patients, in
addition to cosmetic concerns, and with many
Table 1 Patient preferences regarding anaesthesia and number of visits
Agree
strongly (%)
Agree
moderately (%)
I do not
mind (%)
Disagree
moderately (%)
Disagree
strongly (%)
Patients preferring a single visit for
treatment (n ¼ 93)
46 25 27 2 0
Patients preferring treatment under
local anaesthetic (n ¼ 92)
37 26 31 4 2
Figure 5 (a) Patients’ awareness of different treatment modalities; (b) Preferred treatment modalities
of surveyed patients
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preferring a single visit for treatment, foam scler-
otherapy is unlikely to be the patients’ preferred
treatment modality. A third of patients receiving
foam sclerotherapy are likely to require more than
one treatment in the first three months21 and cos-
metic results and recurrence rates at present are
often thought to be poorer than those achieved
with traditional stripping or endovenous ablation.22
This small non-validated questionnaire study
provides interesting information about patient
opinion regarding varicose veins in West London.
However, in our group of patients, more than a
quarter were over the age of 60 years, suggesting
that the study population may not be representative
of the rest of the United Kingdom population.
Moreover, we recognize that more detailed ques-
tionnaires of larger populations may provide more
robust information on preferences than this small
study.
The patients perspective is becoming increasingly
important and health-care professionals are encour-
aged to involve patients in their treatment decisions
in order to improve health care.17 Varicose veins
procedures are recognized as a highly litigious
medical field23,24 and therefore adequate assess-
ment of the patients concerns, preferences and
expectations, along with adequate verbal and
written information, is extremely important in
order that patients have realistic expectations from
their treatment. Further studies investigating
the patients’ preference regarding the treatment of
varicose veins are likely to be helpful in order
to plan for future service provision.
This study investigated the knowledge and
opinions of patients prior to consultation before
they had been provided with any formal infor-
mation – an area that is rarely studied. The findings
suggest the majority of patients with varicose veins
are unaware of potential treatment options,
highlighting the need for clear communication
and the provision of sufficient information for
patients prior to varicose vein treatment in order
to ensure informed consent. With so many potential
modalities currently available for the treatment of
varicose veins, patients’ concerns and preferences
are clearly extremely important. Clinicians should
attempt to evaluate preferences and expectations
from all patients in order to ensure that the most
appropriate treatment option, delivered in the
correct manner, can be offered.
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Randomized clinical trial of VNUS ClosureFAST
TM
radiofrequency ablation versus laser for varicose veins
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Background: Endovenous laser ablation (EVLA) and radiofrequency ablation (RFA) are both associated
with excellent technical, clinical and patient-reported outcomes for the treatment of varicose veins. The
aim of this study was to compare the techniques in a randomized clinical trial.
Methods: Consecutive patients with primary great saphenous vein reflux were randomized to EVLA
(980 nm) or RFA (VNUS ClosureFASTTM) at a single centre. The primary outcome measure was
postprocedural pain after 3 days. Secondary outcomemeasures were quality of life at 6 weeks, determined
by the Aberdeen Varicose Vein Questionnaire (AVVQ) and Short Form 12 (SF-12), and clinical
improvement assessed by the Venous Clinical Severity Score (VCSS). Analyses were performed on the
basis of intention to treat using multivariable linear regression.
Results: Some 131 patients were randomized to EVLA (64 patients) or RFA (67). Mean(s.d.) pain
scores over 3 days were 26·4(22·1) mm for RFA and 36·8(22·5) mm for EVLA (P = 0·010). Over 10 days,
mean(s.d.) pain scores were 22·0(19·8) mm versus 34·3(21·1) mm for RFA and EVLA respectively
(P = 0·001). The mean(s.d.) number of analgesic tablets used was lower for RFA than for EVLA
over 3 days (8·8(9·5) versus 14·2(10·7); P = 0·003) and 10 days (20·4(22·6) versus 35·9(29·4) respectively;
P = 0·001). Changes in AVVQ, SF-12 andVCSS scores at 6 weeks were similar in the two groups: AVVQ
(P = 0·887), VCSS (P = 0·993), SF-12 physical component score (P = 0·276) and mental component
score (P = 0·449).
Conclusion: RFA using VNUS ClosureFASTTM was associated with less postprocedural pain than
EVLA. However, clinical and quality-of-life improvements were similar after 6 weeks for the two
treatments. Registration number: ISRCTN66818013 (http://www.controlled-trials.com).
Based on an abstract presented to the Annual Meeting of the Vascular Society of Great Britain and Ireland, Liverpool,
UK, November 2009, that was awarded the Venous Forum Prize and published as Br J Surg 2010; 97(Suppl 1): 13
Paper accepted 24 February 2010
Published online in Wiley InterScience (www.bjs.co.uk). DOI: 10.1002/bjs.7091
Introduction
In the past decade the introduction of minimally invasive
endovenous ablation therapy has revolutionized the
treatment of varicose veins. In 2001, endovenous laser
ablation (EVLA) and radiofrequency ablation (RFA) were
approved for use by the National Institute for Health
and Clinical Excellence in the UK. Since then surveys
and venous registries have shown that their use has
been increasing steadily1–5. Perceived advantages over
traditional surgery include fewer complications, minimal
postprocedural pain6–8 and faster recovery times9,10.
Theoretically, the reduced incidence of neovascularization
in the groin may also result in lower recurrence rates
in years to come11. The majority of patients with
primary varicose veins have great saphenous vein (GSV)
incompetence that is amenable to endovenous thermal
ablation12. With evidence to suggest that patients are
concerned about recovery times and recurrence rates13,
the appeal of endovenous interventions is understandable.
A wide range of endovenous laser wavelengths and ﬁbres
are now available, although the 980-nm wavelength and
bare ﬁbre are used most widely in the UK at present4. The
most popular RFA system is the VNUS ClosureFAST
TM
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(VNUS Medical Technologies, San Jose, California, USA)
segmental ablation catheter, which has superseded ear-
lier continuous-withdrawal catheters. Although a number
of studies have compared RFA or EVLA with tradi-
tional superﬁcial venous surgery8–9,14, studies comparing
EVLA with RFA are scarce and ﬁndings have been
inconclusive15–17. To date, only one small randomized
trial comparing VNUS ClosureFAST
TM
and EVLA has
been published18. The aim of the present study was to
compare early outcomes following EVLA 980 nm and
segmental RFA in a randomized study.
Methods
Consecutive adults presenting to one vascular specialist
were screened for suitability for the trial. All patients
underwent colour duplex ultrasonography (Philips iU22,
Andover, Massachusetts, USA) and patients over 18 years
of age with primary GSV incompetence were invited to
participate. All scans were performed by an accredited
vascular scientist and reﬂux was deﬁned as retrograde ﬂow
of more than 0·5 s after calf compression. Patients with
current deep vein thrombosis (DVT), signiﬁcant arterial
disease (ankle : brachial pressure index below 0·8) or who
were unsuitable for general anaesthesia were excluded.
Treatment allocation
Consenting patients were randomized to either VNUS
ClosureFAST
TM
(RFA) or 980-nm laser (EVLA) using
a bare ﬁbre, using an internet randomization service19.
In patients with bilateral GSV incompetence, the leg
that was more symptomatic according to the patient
was randomized and the same treatment was performed
on both legs. All patients were blinded to treatment
allocation; however, for practical reasons, assessors were
not blinded. Ethical approval for the study was granted
by Charing Cross Research Ethics Committee (reference
08/H0711/19) and the trial was registered with Current
Controlled Trials (ISRCTN66818013).
Interventions
All interventions were carried out under general anaes-
thesia in an operating theatre by one of three surgeons
experienced in both techniques. For both techniques,
the GSV was cannulated at, or as near as possible to,
the most distal point of venous reﬂux, and the catheter
tip was positioned 2 cm from the saphenofemoral junc-
tion under ultrasonographic guidance. Standard tumes-
cent local anaesthesia (50 ml 1 per cent lidocaine with
1 : 200 000 adrenaline (epinephrine) in 1000 ml normal
saline) was inﬁltrated along the length of the vein under
ultrasonographic guidance. In patients treated with seg-
mental RFA, the ﬁrst segment was treated with two RFA
cycles according to themanufacturer’s instructions, and the
remainder of the vein was treated with one RFA cycle per
7-cm segment. Extrinsic pressure was applied over the vein
during treatment cycles. In patients who had EVLA, the
laser was continually withdrawn with the aim of delivering
energy greater than 60 J/cm to the vein wall, with a power
setting of 11 W. Patients with additional small saphenous
or anterior thigh vein incompetence were treated with the
allocated treatment modality at the same sitting. Patients
with varicosities were treated with concomitant phlebec-
tomies using a standard technique with an Oesch hook and
all phlebectomy sites were sutured with 6/0 polypropy-
lene. Tumescent anaesthesia was not used for phlebectomy
incisions.
In all patients the patency of the deep veins was checked
by the operating surgeon using duplex ultrasonography
in the operating theatre immediately after the procedure.
After treatment, a crepe bandagewas applied for at least 2 h,
and was replaced with a thromboembolic deterrent (TED)
stocking before discharge. Patients were instructed to wear
the TED stocking continuously for 1 week. On induction
of anaesthesia, all patients received thromboprophylaxis
consisting of 5000 units subcutaneous unfractionated
heparin sodium and prophylactic antibiotics: amoxicillin
1 g and ﬂucloxacillin 1 g. All patients were discharged with
a supply of paracetamol (1 g up to four times a day) and
ibuprofen (400 mgup to three times a day) and instructed to
take them only if required. All patients were also provided
with a written information sheet advising them to mobilize
as much as possible after the procedure, and to return to
work and normal activities as soon as they felt able.
Outcomes assessed and follow-up protocol
All patients were asked to complete the Aberdeen Varicose
Vein Questionnaire (AVVQ), a validated disease-speciﬁc
quality-of-life questionnaire for varicose veins20,21, and
the Short Form 12 (SF-12; Medical Outcomes Trust,
Waltham, Massachusetts, USA) to assess generic quality
of life before the procedure, and the Clinical Etiologic
Anatomic Pathophysiologic (CEAP) class and Venous
Clinical Severity Score (VCSS) were recorded by a
clinician. Patients were assessed at 10 days and 6 weeks.
Patients were given a diary card with a 100-mm visual
analogue scale to record postprocedural pain each day for
10 days. They were also asked to record any analgesic drugs
taken, and the time taken to return to normal activities and
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work, if applicable. The primary outcome measure was
mean postprocedural pain over the ﬁrst 3 days. Patients
were invited to attend follow-up after 6 weeks, when
quality of life was assessed using the AVVQ and SF-
12. The VCSS was also assessed and any complications
at 1 and 6 weeks were recorded. Assessment of vein
occlusion rates 6 months after the intervention will be
undertaken and reported separately. Duplex imaging was
not otherwise performed unless a patient presented with
symptoms suspicious of DVT.
Sample size calculation
Power calculation was based on the primary outcome
measure of postprocedural pain after 3 days using data
from a published departmental cohort study and the
published literature6,9,22,23. The calculation was based
on detection of a 20-mm difference in pain scores over
the ﬁrst 3 days with a standard deviation of pain score
of 20 mm. To attain 90 per cent power at the 5 per cent
signiﬁcance level, a minimum target sample size of 47
legs per group was required. This number allowed for
10 per cent non-compliance in the randomized group and
20 per cent dropout at 6 weeks.
Statistical analysis
All analyses were performed according to a predeﬁned anal-
ysis plan using Stata software version 10.0 (StataCorp,
College Station, Texas, USA) on the basis of intention
to treat. As the trial was relatively small, Student’s t and
χ2 tests were used to compare baseline characteristics
between groups in order to check whether any differences
had occurred by chance. The distribution of continuous
Assessed for
eligibility
n = 313
Excluded n = 182
Did not meet randomization
   criteria n = 142
Declined to participate n = 40
Allocated to EVLA 980 nm n = 64
Received EVLA 980 nm n = 63
Did not receive any treatment n = 1
(surgery cancelled)
Completed follow-up at 3 days n = 61
Lost to follow-up n = 3
Completed follow-up at 10 days n = 51
Lost to follow-up n = 13
Completed follow-up at 6 weeks n = 55
Lost to follow-up n = 9
3-day analysis n = 61
Excluded n = 3
Lost to follow up n = 2
Surgery cancelled n = 1
10-day analysis n = 51
Excluded n = 13
Incomplete data n = 12
Surgery cancelled n = 1
6-week analysis n = 55
Excluded n = 9
Lost to follow-up n = 8
Surgery cancelled n = 1
3-day analysis n = 66
Excluded n = 1
Lost to follow-up n = 1
10-day analysis n = 59
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Incomplete data n = 7
Lost to follow-up n = 1
6-week analysis n = 60
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Lost to follow-up n = 7
Completed follow-up at 6 weeks n = 60
Lost to follow-up n = 7
Completed follow-up at 10 days n = 59
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Allocated to VNUS ClosureFAST n = 67
Received VNUS ClosureFAST n = 66
Did not receive VNUS ClosureFAST
   n = 1
Randomized
n = 131
En
ro
lm
en
t
Al
lo
ca
tio
n
Fo
llo
w
 u
p
An
al
ys
is
Fig. 1 CONSORT diagram for the trial
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Table 1 Comparison of baseline patient characteristics in a trial comparing two treatments for varicose veins
RFA (n = 67) EVLA (n = 64) P
Sex ratio (F :M) 47 : 20 42 : 22 0·579‡
Age (years)* 49(15) 48(16) 0·540†
Body mass index (kg/m2) 0·334‡
<30 61 (91) 61 (95)
≥30 6 (9) 3 (5)
VCSS* 5·1(2·1) 4·7(2·1) 0·278†
AVVQ* 20·6(9·4) 19·2(9·5) 0·412†
CEAP class 0·467‡
C1–C2 23 (34) 26 (41)
C3–C4 39 (58) 36 (56)
C5–C6 5 (7) 2 (3)
Deep vein disease 0·178‡
Yes 13 (19) 7 (11)
No 54 (81) 57 (89)
Pattern of disease 0·727‡
GSV 54 (81) 50 (78)
GSV and small saphenous vein 13 (19) 14 (22)
Unilateral or bilateral disease 0·433‡
Unilateral 31 (46) 34 (53)
Bilateral 36 (54) 30 (47)
Procedural parameters
Length ablated (cm)* 49(16) 46(14) 0·177†
Total no. of phlebectomies above or below knee* 6·2(4·0) 6·2(3·6) 0·945†
Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.). RFA, radiofrequency ablation; EVLA, endovenous laser ablation;
VCSS, Venous Clinical Severity Score; AVVQ, Aberdeen Varicose Vein Questionnaire; CEAP, Clinical Etiologic Anatomic Pathophysiologic; GSV,
great saphenous vein. †Student’s t test; ‡χ2 test.
variables was checked using normal plots, with transforma-
tion of any skewed variables. Postprocedural pain scores
were analysed using linear regression with two levels of
adjustment. Primary adjustment was made for age, sex,
body mass index, clinical disease severity, number of trun-
cal veins ablated on the trial leg, total length of vein ablated
on the trial leg and number of phlebectomies on the trial
leg as primary adjustment. Secondary adjustment was made
for all co-variables in the primary analysis as well as for the
use of analgesia.
Secondary outcomes including quality of life and clinical
improvements were analysed using analysis of co-variance
(ANCOVA), which adjusted changes in outcome for
baseline values. In addition, primary adjustment was made
using the same variables as those used for the pain score
analysis, and also for presence of bilateral disease and
presence of deep venous incompetence.
Results
Over 12 months from July 2008 to July 2009, 313 patients
were screened for inclusion in the study. A total of 171 met
the eligibility criteria and were invited to participate; 131
patients consented to randomization. Of the 40 patients
who declined inclusion, six expressed a preference for
a particular treatment (RFA, 2; EVLA, 4). Some 128
patients were treated within 24 h of randomization; overall,
patients were treated a median of 0 (range 0–48) days
after randomization. One operation was cancelled owing
to problems with theatre equipment, and therefore 130
patients were treated as part of this study (Fig. 1). One
patient who was randomized to RFA received EVLA,
owing to non-availability of RFA equipment. For patients
treatedwithEVLA, themean(s.d.) energy density delivered
to the GSV was 71·71(12·98) J/cm.
The patients included 89 women and 42 men with a
mean(s.d) age of 49(16) years. Baseline characteristics were
comparable between the randomized groups (Table 1).
Primary outcome measure: pain scores
Diary cards were available for 127 patients; postprocedural
pain scores after EVLA (61 patients) and RFA (66) are
shown in Fig. 2. Two patients included in the analysis did
not require concomitant phlebectomy, although analyses
were adjusted for the number of phlebectomy incisions.
Patients receiving RFA reported less pain over the
ﬁrst 3 days, with a mean(s.d.) pain score of 26·4(22·1)
for RFA and 36·8(22·5) for EVLA (primary adjusted
difference = −10·2; P = 0·012) (Table 2).
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Fig. 2 Daily visual analogue pain scores after endovenous treatment for varicose veins with radiofrequency ablation (RFA) or
endovenous laser ablation (EVLA)
Table 2 Linear regression analysis of pain scores after radiofrequency or endovenous laser ablation treatment for varicose veins
RFA
(n = 66)
EVLA
(n = 61)
Crude unadjusted
difference* P
Primary adjusted
difference*† P
Secondary adjusted
difference*‡ P
Mean(s.d.) pain score
First 3 days 26·4(22·1) 36·8(22·5) −10·4 (−18·2, −2·6) 0·010 −10·2 (−18·1, −2·3) 0·012 −6·4 (−14·3, 1·6) 0·115
First 10 days 22·0(19·8) 34·3(21·1) −12·3 (−19·5, −5·1) 0·001 −12·8 (−20·2, −5·5) 0·001 −6·3 (−13·3, 0·7) 0·079
*Values in parentheses are 95 per cent conﬁdence intervals. †Primary adjustment for age, sex, body mass index of 30 kg/m2 or above, Venous Clinical
Severity Score in the randomized leg (as a measure of varicose vein disease severity), pattern of disease (great saphenous vein (GSV) versus GSV and small
saphenous vein), length of vein ablated, number of phlebectomies (above or below knee). ‡Secondary adjustment: adjusted primary model for use of
analgesia. RFA, radiofrequency ablation; EVLA, endovenous laser ablation.
Postprocedural pain and analgesia use
Patients in the RFA group also reported less pain over the
ﬁrst 10 days, with mean(s.d.) scores of 22·0(19·8) for RFA
and 34·3(21·1) for EVLA (primary adjusted difference =
−12·8; P = 0·001) (Table 2). Patients in the RFA group
took fewer analgesic tablets than those in the EVLA
group: mean(s.d.) over 3 days 8·8(9·5) tablets after RFA
versus 14·2(10·7) tablets after EVLA (P = 0·003) and over
10 days 20·4(22·6) versus 35·9(29·4) tablets respectively
(P = 0·001) (Fig. 3). When pain scores were adjusted for
the number of analgesic tablets taken, differences between
the groupswere reduced and of only borderline signiﬁcance
(Table 2).
Secondary outcome measures
Quality of life and Venous Clinical Severity Score
Quality of life was assessed a median of 48 (interquartile
range 43–54) days after intervention; data were available
for 115 patients (RFA, 60; EVLA, 55). Improvements in
quality of life were seen in both groups, although there
were no signiﬁcant differences between the two groups in
AVVQ, VCSS or SF-12 in either the physical component
or mental component score (Table 3).
Return to normal activities and work
Data regarding return to normal activities were available
for 62 patients after RFA and for 50 after EVLA.
The majority of patients returned to normal activities
within 3 days: EVLA, 25 (50 per cent) of 50 patients;
RFA, 37 (60 per cent) of 62. About three-quarters of
patients resumed normal activities within 7 days: EVLA,
37 (74 per cent) of 50; RFA, 48 (77 per cent) of 62.
Regarding return to work, data were available for 41
patients in the RFA and 34 in the EVLA group.
Results were similar, with 15 (37 per cent) and 14
(41 per cent) patients returning to work within 3 days,
and 29 (71 per cent) and 24 (71 per cent) returning
to work within 7 days in RFA and EVLA groups
respectively.
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Fig. 3 Number of analgesic tablets used each day after endovenous treatment for varicose veins with radiofrequency ablation (RFA) or
endovenous laser ablation (EVLA)
Table 3 Analysis of co-variance for secondary outcomes after radiofrequency or endovenous laser ablation for varicose veins
RFA (n = 60) EVLA group (n = 55) Crude difference*† P Adjusted difference*‡ P
AVVQ
Baseline 20·6(9·4) 18·9(9·8) −0·3 (−3·1, 2·6) 0·854 0·2 (−2·8, 3·2) 0·887
6 weeks 10·9(9·2) 10·8(8·9) — —
VCSS
Baseline 5·1(2·1) 4·7(2·1) −0·1 (−0·7, 0·5) 0·777 0·0 (−0·6, 0·6) 0·993
6 weeks 1·7(1·7) 1·5(1·8) — —
SF-12 PCS
Baseline 48·9(9·5) 48·1(10·1) −2·6 (−0·6, 0·5) 0·101 −1·8 (−5·2, 1·5) 0·276
6 weeks 50·7(8·7) 53·1(7·3) — —
SF-12 MCS
Baseline 47·1(11·0) 48·0(13·1) −0·7 (−4·4, 3·0) 0·704 −1·5 (−5·4, 2·4) 0·449
6 weeks 50·4(9·5) 51·3(9·9) — —
Values are mean(s.d.) unless indicated otherwise; *values in parentheses are 95 per cent conﬁdence intervals. †Adjusted for baseline value. ‡Adjusted for
baseline value as well as age, sex, body mass index of 30 kg/m2 or above, Venous Clinical Severity Score (VCSS) in the randomized leg (as a measure of
severity of varicose vein disease), pattern of disease (great saphenous vein (GSV) versus GSV and small saphenous vein), length of vein ablated, number of
phlebectomies (above or below knee), presence of deep vein disease and unilateral versus bilateral disease. RFA, radiofrequency ablation; EVLA,
endovenous laser ablation; AVVQ, Aberdeen Varicose Vein Questionnaire, SF-12, Short Form 12; PCS, physical component score; MCS, mental
component score.
Complications
During the study, two major complications were observed.
One patient randomized to RFA suffered a pulmonary
embolus 2 weeks after intervention (the patient was treated
with warfarin, although no evidence of DVT or clot
extension in the leg veins was found on duplex imaging).
One patient in the EVLA group developed a lymphatic
leak from the cannulation site, and lymphoscintigraphy
conﬁrmed increased lymphatic collateral ﬂow consistent
with trauma at the site.
Table 4 Reported complications after radiofrequency or
endovenous laser ablation
RFA (n = 67) EVLA (n = 64)
Wound infection 4 (6) 2 (3)
Haematoma 0 (0) 2 (3)
Thrombophlebitis 5 (7) 3 (5)
Paraesthesia 8 (12) 5 (8)
Staining to skin 6 (9) 2 (3)
Seroma 2 (3) 1 (2)
Pulmonary embolus 1 (1) 0 (0)
Values in parentheses are percentages.
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Minor complications included wound infection
(4·6 per cent), haematoma (1·5 per cent), thrombophlebitis
(6·1 per cent), saphenous nerve paraesthesia (9·9 per cent)
and skin staining (6·1 per cent) (Table 4). Two patients in
the EVLA group reported an increase in spider veins and,
despite the intention to perform procedures as a day case,
four patients (3·1 per cent) required overnight admission
after the procedure because of nausea (RFA, 1; EVLA, 1),
hypotension secondary to general anaesthesia (RFA, 1) or
pain requiring opioid analgesia (RFA, 1).
Discussion
This study demonstrated that VNUS ClosureFAST
TM
resulted in signiﬁcantly less pain than 980-nm EVLA
for varicose veins. However, reported pain and analgesia
use was very variable in both groups and, interestingly,
reductions in pain did not translate into faster recovery
times. At 6 weeks there was no signiﬁcant difference in
clinical disease severity or quality-of-life scores, and the
degree of improvement in the AVVQ and VCSS was
similar to that reported in other randomized trials9,24,25.
The results of the present study support the ﬁndings of
other studies that have shown less postprocedural pain
after RFA16,18, but failed to show differences in outcomes
after 1 month18. Discrepancies between studies may be
explained by variations in procedure technique and follow-
up times. In contrast to the RECOVERY trial18, minor
complications including paraesthesia, thrombophlebitis
and skin infections were not more prevalent in the
EVLA group at any time point. One patient in the
RFA group had a pulmonary embolus 10 days after the
procedure. This was diagnosed and treated at a different
hospital and no DVT was found in the leg veins on
duplex imaging. The cause of this pulmonary embolus
remains unknown; the patient had no known risk factors
for thromboembolic disease at the time of surgery and
remained on warfarin.
One possible explanation for the reduced pain scores
following RFA may be that the controlled heating and
segmental ablation technique of VNUS ClosureFAST
TM
reduces the number of vein wall perforations and the
extravasation of blood into the tissues26,27; this has been
shown to occur after use of the 980-nm laser in animal
models26 and in humans28.
Recent research has suggested a rapid increase in
the popularity of endovenous thermal ablation and this
trend appears likely to continue1–3,5. Patients seeking
superﬁcial venous interventions are frequently concerned
about postprocedural discomfort, recovery times and
recurrence13. It is therefore important to provide sufﬁcient
information about all the available procedures, so that
patients and physicians can reach evidence-based decisions
about treatment options.
This study was sufﬁciently powered to evaluate
postprocedural pain and both procedures were performed
under identical conditions. The authors decided not
to evaluate postprocedural bruising owing to difﬁculties
in accurate quantiﬁcation, and because previous studies
have shown that it does not necessarily correlate with
postprocedural pain29 or time taken to resume normal
activities6. Patients were blinded to treatment allocation,
signiﬁcantly reducing the potential for bias and allowing a
direct comparison of the outcomes of the two procedures.
Although the assessors were not blinded, the primary
outcomes were patient reported and therefore unlikely to
have been affected by the assessors. Patients also underwent
concomitant phlebectomies if necessary, with the aim of
completing all treatment in a single visit. This approach has
been shown to be preferable formany patients13, associated
with improvements in clinical and quality-of-life outcomes
and a reduced need for further procedures30.
Limitations of the study included the fact that all pro-
cedures were performed under general anaesthesia, so that
an assessment of the adequacy of the tumescence during
the procedure was not possible. However, the technique of
tumescent anaesthesia inﬁltration under ultrasonographic
guidance was standardized for both procedures. Elsewhere,
a signiﬁcant proportion of endovenous thermal ablation
procedures are performed as outpatient procedures5, and
even performing concomitant phlebectomy is feasible as an
ofﬁce-based procedure31. However, this may be difﬁcult in
patients with bilateral disease or those with large numbers
of varicosities. As the aim was to complete all treatments in
one sitting, patients were therefore offered general anaes-
thesia.Moreover, the groups in this randomized study were
well matched in terms of disease pattern, and analyses were
adjusted for numerous variables including number of phle-
bectomies performed to ensure that detected differences
were truly due to the ablation technique.
To date, the majority of studies have provided data
supporting the short-term efﬁcacy of EVLA and RFA, and
long-term data are scarce. EVLA would appear to have
better occlusion rates, of around 95 per cent, in comparison
with 80 per cent for the early RFA catheters at 5 years32.
However, results from VNUS ClosureFAST
TM
appear
promising22 and may be superior to the original RFA in
the longer term.Long-term studies of venous occlusion and
recurrence are clearly required to support the durability of
endovenous thermal ablation procedures.
Both this study and the smaller RECOVERY trial18
support the premise that VNUS ClosureFAST
TM
is less
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painful than 980-nm EVLA. However, to reduce the post-
procedural discomfort associated with EVLA, newer radial
ﬁbres, longer wavelengths and jacketed laser ﬁbres have
been developed. These newer techniques have been shown
to be associated with low postintervention pain scores33–36
and are likely to replace the 980-nm bare-tip laser ﬁbre.
Data from randomized trials supporting the use of these
newer devices are awaited.
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Commentary
Randomized clinical trial of VNUS ClosureFAST
TM
radiofrequency ablation
versus laser for varicose veins (Br J Surg 2010; 97: 810–818)
This was a well constructed prospective randomized trial comparing the early outcomes of radiofrequency ablation
and endovenous laser ablation of the great saphenous vein. The primary outcome measure of postprocedural pain was
clearly stated and the study was adequately powered with additional numbers built in for non-compliance and dropout.
The ﬁndings were similar to those of the RECOVERY trial1. Both studies showed that radiofrequency ablation using
the VNUS ClosureFAST
TM
technique caused less postoperative pain as determined by a visual analogue scale. The
additional comparison of analgesic use strengthens the results; however, pain is subjective and the study would have been
improved by comparing some objective features such as bruising, and by ensuring that clinicians performing the follow-up
were blinded. Unlike the RECOVERY study, which compared quality of life at 2, 7, 14 and 30 days, quality of life in
this study was reassessed only at 6 weeks postprocedure, and showed no difference between the groups. Unfortunately, a
considerable proportion (12 per cent) of the patients were lost to follow-up at 6 weeks and, although this was built into
the power calculation, one has to consider why these patients did not attend.
All patients undergoing treatment for varicose veins should receive information and advice regarding analgesia
requirements and return to normal activity. Although there is no evidence that changing patient information alters
patients’ choices, it is important to standardize the information given to patients in a study of this kind in order to remove
bias2.
This study suggests that radiofrequency ablation using the VNUS ClosureFAST
TM
technique is better for patients in
the short term. The longer-term clinical results are awaited eagerly.
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